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 This dissertation focuses on the implications of social position and life course on 
the experience of Amyotrophic Lateral Sclerosis (ALS). Using a sociology in medicine 
frame, I test three theoretical perspectives (fundamental cause theory, social determinants 
of health, and life course theory) to determine the influence of social conditions on the 
development and progression of, and medical care for, people with ALS (pALS). Further, 
I use ALS as an exemplar of the need for a sociology of disease. 
Using the Amyotrophic Lateral Sclerosis National Registry, I first assess the 
association of social position with the reported onset location at the time of diagnosis of 
ALS. Second, I assess the influence of social position on the time between reported date 
of symptom development and diagnosis. The final study evaluates the odds of reporting 
several types of medical care dependent on the position in the life course.   
Results indicate that social position (race/ethnicity, gender, and education) 
influence the experience of the onset of ALS. Further, position in the life course is 
associated with the reporting of onset location, with those at older ages being more likely 
    
 
to report bulbar or global onset in contrast to limb onset. Position in the life course is also 
associated with symptoms of ALS, with older persons with ALS (pALS) experiencing 
symptoms earlier, often prior to diagnosis. Social position and position in the life course 
also influenced the adoption of life-extending medical care for pALS, with younger 
pALS adopting more of these interventions.  
Overall, the results indicate that even in a rare disease with an unknown cause, 
fundamental cause theory, the social determinants of health, and life course theory 
provide a valuable framework for understanding the experience of ALS. These theories, 
however, need refinement when used in the sociology of disease. Additionally, the results 
are evidence of a need for a sociology of disease. Finally, the results highlight the need 
for more inclusive research designs, as well as additional qualitative and quantitative 
work in understanding how social position shapes the lived experience of ALS.  
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CHAPTER ONE: INTRODUCTION 
Amyotrophic Lateral Sclerosis (ALS) is a progressive disease characterized by the 
degeneration of the motor neurons and resulting atrophy and paralysis of the muscles, 
leading to respiratory distress and eventually death two to five years after diagnosis. ALS 
is a rare diagnosis, affecting approximately five per 100,000 people in the United States 
(Mehta et al., 2016). Furthermore, the number of people diagnosed with ALS is expected 
to increase globally as the population ages, from 222,801 people with ALS in 2015 to a 
projected number of 376,674 in 2040 (Arthur et al., 2016).  
A diagnosis of ALS is a process of elimination, and the cost of simply obtaining a 
diagnosis can be in the tens of thousands of dollars prior to insurance coverage, which 
may factor into the perception of a short survival time after diagnosis (Kiernan et al., 
2011; Obermann & Lyon, 2015). Further complicating the detection of ALS is the 
presentation of the disease. The onset location of ALS symptoms, as well as the 
symptoms themselves, vary by case. Limb onset ALS often begins with weakness in the 
hand or foot, with the first symptoms presenting as drop foot or trouble grasping objects, 
bulbar onset begins as difficulty in speaking or swallowing, and global onset can be a 
combination of limb and bulbar and/or weakness in the chest and trunk muscles (Kiernan 
et al., 2011; Andersen, 2018). Further, atypical presentations can include weight loss, 
fasciculations, and frontal-temporal dementia, among others (Kiernan et al., 2011; 
Andersen, 2018).  
The variability in onset location has been implicated in the failure of clinical trials 
for promising treatments for ALS, as well as the inconsistency in the effectiveness of 
currently approved treatments (Belsh and Schiffman, 1996; Srinivasan et al., 2006). 
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Additionally, the variability of the earliest symptoms can lead to incorrect diagnoses and 
unnecessary medical procedures, culminating in a substantially delayed diagnosis which 
prevents access to medications and enrollment in clinical trials before the disease has 
progressed into later stages (Mitchell et al., 2010; Rothstein, 2017; Jaiswal, 2019). 
In the absence of a cure, understanding how social position might shape the 
experience of ALS is an important part of understanding the differences in onset location, 
symptoms, and medical care among pALS. A considerable amount of ALS research is 
biomedical. In the biomedical research, the emphasis is on how suspected risk factors1 
are associated with the development and progression of ALS (Del Agulia et al., 2003; 
Paillisse et al., 2005; Watanabe et al., 2014; Pupillo et al., 2014). Yet a sociological 
perspective highlights the potential importance of social position in the experience of 
ALS and may demonstrate that social position is more than just a control variable, but a 
signal of larger social processes which can lead to disparities in access to medical care, 
support, and altering the experience of ALS. The ability to understand ALS from a 
sociological perspective may provide insight on how social factors shape the experience 
of the disease and the health of the population effected by the disease (Link, 2008). 
Whether the biological aspects of ALS are so powerful as to supersede the effects of the 
social position remains unknown at this time, but as with other diseases (e.g. diabetes, 
cancer, Alzheimer’s), there is the potential for a greater understanding of the biological 
disease process by incorporating attention to social position, as well as the how the social 
world shapes the experience of the disease by pALS (Cassileth et al., 1985; Lyman, 1989; 
Luftey & Freese, 2005; Timmermans and Haas, 2008). 
 
1 A risk factor is any attribute, characteristic or exposure of an individual that increases the likelihood of 
developing a disease or injury (WHO, 2017). 
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Overall, the goal of this dissertation is threefold. First, the work presented here 
contributes to the understanding of the both biological disease process of ALS and the 
illness experience of pALS by using a sociological lens to understand how social position 
shapes the experience of ALS. Additionally, the research presented here tests three of the 
prominent theories in medical sociology on a rare disease with unknown causes, a 
category of conditions often overlooked by social scientists. Finally, using ALS as an 
exemplar, I turn the attention of broader theories to a specific disease, in order to 
illustrate the need for a sociology of disease, a more targeted form of medical sociology. 
Moreover, this dissertation provides an opportunity to engage not only sociologists, but 
epidemiologists, biomedical researchers, and medical providers in a conversation across 
disciplines, opening doors to a new perspective in understanding ALS as a disease 
process and as a lived experience.  
The Status of Current Research on the Onset of ALS  
The onset of ALS is heterogeneous, and without a clear understanding of the 
underlying reasons for the differences. The unknown factors in ALS onset makes 
prevention efforts and diagnosis difficult. In addition, risk factors for the development of 
ALS are largely unknown, however, researchers have identified several potential 
candidates. Several genetic mutations, such as the mutation of the SOD1 gene, have been 
suspected in the development of familial ALS and may be a risk factor for sporadic ALS 
as well (Wang et al., 2016). Exposures to heavy metals (e.g. lead), organic chemicals 
(e.g. pesticides used in farming), and occupational exposures (e.g. electrical shock), are 
considered potential risk factors that have been studied extensively, although not in 
connection to each other (Sutedja et al., 2007; Fang et al., 2009; Yu et al., 2014; Wang et 
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al., 2017). Research on ALS in Guam, where rates historically have been high, has linked 
exposure to Beta-N-methylamino-L-alanin (BMAA) to a potential gene-by-environment 
trigger. Exposure to BMAA is high in Guam due to its presence in water sources and 
marine animals, and prior research links BMAA exposure to pockets of high ALS rates in 
areas of the Atlantic seaboard due to participation in the fishing industry (Caller et al., 
2011; Stommel et al., 2013; Wang et al., 2017).  
Military service has been linked to ALS development, as veterans are twice as 
likely as civilians to develop the disease, but the link is currently unclear (Weisskopf et 
al., 2015; Wang et al., 2017). For example, previous research has indicated physical 
trauma or injury, lower BMI, lower educational attainment, and the higher levels of 
physical activity found in higher rates among service members may be particular risk 
factors for the development of ALS (Weisskopf et al., 2015; Wang et al., 2017). Findings 
on the link between ALS and physical activity, however, are unclear (Longstreth et al., 
1998; Wang et al., 2017). Previous research, for example, has suggested that professional 
sports players are more likely to develop ALS as a result of their occupation (e.g. 
American football, soccer) which includes both a high level of physical activity, but also 
the potential for head injuries both of which are linked to ALS development (Chiò et al., 
2005; Wang et al., 2017).  
Research suggests health conditions and health behaviors are potential risk factors 
for ALS development. For example, viral infections, through a mechanism of the immune 
response, may initiate the cascade of symptoms associated with ALS (Wang et al, 2017). 
In addition, researchers have posited that ALS may be an issue of energy consumption in 
the body, and metabolic conditions as a potential risk factor may be linked to the lower 
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BMI and high levels of physical activity seen in people with ALS (Ingre et al., 2015). In 
addition, individuals who smoke are at higher risk of developing ALS, however, this 
correlation has been debated as the association appears in some studies and not in others 
when other risk factors are included in the measures (Sutedija et al., 2007; Yu et al., 
2014; Wang et al., 2017). 
The Status of Current Research on the Symptoms and Progression of ALS 
ALS progression is measured using the Amyotrophic Lateral Sclerosis Functional 
Rating Scale revised scale (Cedarbaum et al., 1999) which monitors the progression of 
impairment in people with ALS from the date of their diagnosis, including both limb and 
bulbar function as well as difficulty breathing and ventilator support. Understanding the 
variability in progression, however, is difficult given that many symptoms often develop 
long before a diagnosis is reached.  
Much of the work in ALS progression has been biomedical, focusing on 
nutritional status (e.g. weight loss, vitamin D deficiencies), comorbidities (e.g. 
hyperlipidemia, diabetes), and genetics as factors in symptom development and the rate 
of progression (Dupuis et al., 2011; Wang et al., 2017). Social position, when included in 
research on the diagnosis and progression of ALS, is considered through a biomedical 
lens and are often limited to age and gender (Del Agulia et al., 2003; Paillisse et al., 
2005; Watanabe et al., 2014; Pupillo et al., 2014). Socioeconomic status does, however, 
influence both health and the ability to access to care (Adler et al., 1994), leading to the 
potential for SES to be linked through these factors to a delayed diagnosis and a 
perception of a more rapid progression of ALS. 
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The Status of Current Research on Medical Care in the Treatment of ALS 
Treatment of ALS is complex for all involved, including health professionals 
(Radunovic et al, 2007). Multidisciplinary ALS clinics (MDCs) and palliative home care 
are the most recommended options, with MDCs being the option of choice of ALS 
experts (Radunovic et al, 2007; Obermann & Lyon, 2015). Not all patients, however, 
choose to use or have access to multidisciplinary ALS clinics without a long journey 
(Stephens et al., 2015; Horton et al., 2018) and palliative care services and in-home 
respite care can be limited by financial constraints and availability (Radunovic et al, 
2007; Obermann & Lyon, 2015). For those who are not referred by a medical provider to 
an MDC or Telemedicine program, other barriers including the lack of knowledge or lack 
of time to research and consider such treatment options may prevent access (Stephens et 
al., 2015). In addition, it can take approximately five months to receive Medicare 
coverage after a diagnosis of ALS. Without these resources, people with ALS may find 
that they have needs that they are not prepared for (e.g. mobility, nutrition, speech 
assistance) and/or have limited time to research and access assistance due to disease 
progression.  
Additionally, there are concerns and confusion over what types of care are 
considered supportive (e.g. improving quality of life) versus life-sustaining (Shneerson, 
2011). People with ALS may avoid care seen as life-extending due to fears of being a 
burden to family members, the cost of life-sustaining care, and the potential of being 
locked-in and unable to express wishes to end such care (Oliver and Turner, 2010). 
Moreover, life-sustaining care can be complex and highly technical, which may deter 
older and less technologically savvy patients from accessing such care. 
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Theoretical Perspectives 
Sociology in Medicine and Social Position 
Robert Straus outlined two distinct divisions in medical sociology—sociology of 
medicine and sociology in medicine. Sociology of medicine is interested in the structure, 
role relationships, rituals, and functions of medicine as a system of behavior, while 
sociology in medicine is primarily concerned with the disease process or factors 
influencing the response to illness (Strauss, 1957; Gevitz, 1986). The dissertation is 
framed within the ideas of sociology in medicine, with its primary goal to gain a better 
understanding of the disease process of ALS as well as pALS responses to the disease in 
the form of medical care.  
In using sociology in medicine as a frame, one must carefully consider how to 
present the topic of social hierarchies and how they influence the disease process, as well 
as the response to illness. Doing so is important, as using the biomedical terminology 
(e.g. race, sex) can inadvertently give the impression that biology, rather than social 
experiences, are being described as variables of interest when discussing disease 
development and outcomes.  
Social location is more commonly used to describe how people are situated in 
history and society, specifically positioning within the matrix of domination (Crenshaw, 
1990; Collins, 1990). Social location encompasses race/ethnicity, gender, social class, 
age, ability, and other factors that can be used to describe people’s location within social 
hierarchies. Social location often suggests intersectionality; someone who identifies as 
Black, queer, and a woman will have a vastly different social location within the matrix 
of domination than a White, cisgender, heterosexual man (Crenshaw, 1990).  
8 
 
   
 
Rather than risking the implication of an intersectional approach, I have opted to 
use social position to represent dichotomous distinctions (e.g. man/woman, White/Non-
white) in the analysis presented in the dissertation. The decision to use social position is 
threefold: (1) ALS has long been described and represented as a disease predominantly 
affecting White, middle-aged men (e.g., Lou Gehrig disease) (2) the known population of 
people diagnosed with ALS is very small and often has a short time of survival after 
diagnosis, which limits data collection and restricts the ability to complete intersectional 
analysis within the confines of the dissertation, and (3) the limitations of the data used in 
the dissertation, including the admitted underrepresentation of racial/ethnic minority 
populations. The use of social position to describe a dichotomous distinction recognizes 
these limitations, while acknowledging that the ALS community represented here is more 
than a dichotomy of several different statuses. 
Sociology of Disease 
More recently, Timmermans and Haas (2008) noted the need for a ‘sociology of 
disease’, in which sociologists explore the connection between the social world and 
disease. Few sociologists make one disease, such as ALS, the focus of their work. 
Further, few have used clinical endpoints in their analysis, which is one way to determine 
how social processes affect disease outcomes (Timmermans and Haas, 2008). Overall, 
the goal of a sociology of disease is to take the themes and theories from the sociology of 
health and illness and focus attention on specific health outcomes. Although social 
epidemiology may seem like a more natural fit for this type of work, the goal is not to 
point out collective risk factors but to account for the multiple pathways in which the 
experience of the social world may influence disease directly (Pescosolido, 2006; 
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Timmermans and Haas, 2008). In fact, the success of epidemiology and biomedicine 
highlights the need to understand how the social affects the development and experience 
of disease (Pescosolido, 2006; Link, 2008; Timmermans and Haas, 2008). In this 
dissertation, I use ALS as an exemplar to illustrate the need for a sociology of disease, as 
well as testing the use of more general sociological theories—including fundamental 
cause theory, social determinants of health, and life course theory—in a specific disease 
which has already been diagnosed.  
Fundamental Cause Theory and Social Determinants of Health 
Many medical sociologists have posited that social position, such as 
socioeconomic status, race/ethnicity, and education, are fundamental causes of health 
disparities that can influence overall health, leading to differential outcomes in 
interventions and potentially altering outcomes of clinical trials (Link & Phelan, 1995; 
Williams & Collins, 2001; Phelan et al., 2004; Braveman et al., 2005; Pampel, 2009; 
Phelan et al., 2010; Freese & Luftey, 2011; Phelan & Link, 2013; Phelan & Link, 2015; 
Masters et al., 2015). Social factors, such as social position, are useful in understanding 
what factors differentially places people at ‘risk of risks’ of exposure to proximal risk 
factors (Link & Phelan, 1995).  
Fundamental cause theory posits that decreased risk reflects metamechanisms, 
which include flexible resources (e.g. education, income). Flexible resources allow 
individuals, when they have access, to take purposive action to prevent disease or 
improve prognosis after an disease is diagnosed, the ability to avoid proximal risks (e.g. 
avoiding polluted neighborhoods, avoiding smoking), and unintentional exposure to 
health enhancing norms (Link & Phelan, 1995; Williams & Collins, 2001; Mirowsky and 
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Ross, 2010; Freese & Luftey, 2011; Diez Roux, 2012; Phelan & Link, 2013). Moreover, 
the unequal distribution of flexible resources affects multiple disease outcomes through 
multiple pathways that can change over time as people with more access to the resources 
develop strategies to avoid risk (Link & Phelan, 1995; Williams & Collins, 2001; Freese 
& Luftey, 2011; Diez Roux, 2012; Phelan & Link, 2013).  
The influence of fundamental causes on the outcomes of disease are expected in 
medical sociology, however, they are too often disregarded or taken for granted in 
traditional epidemiological research (Link, 2008). Modern epidemiology, though 
beginning to consider social position as a potential contributor to health disparities, still 
largely focuses on proximal risk factors (e.g. diet, chemical exposure) (Link & Phelan, 
1995). Additionally, social factors—over and above their contributory nature to health 
outcomes—can influence how scientific progress is communicated and how treatment 
and recommendations are understood and utilized by the larger population (Link, 2008).  
The fundamental causes of health disparities, in particular socioeconomic status, 
are tied to the social determinants of health (Braveman, Egerter, and Williams, 2011). For 
example, people in a lower socioeconomic position may be exposed to higher levels of 
environmental toxins in their neighborhood, may have constrained choices and therefore 
be led to a career that increases the risk of injury or exposure to dangerous chemicals, 
and/or may have less access to healthcare resources, all of which have been implicated in 
the increased risk of developing ALS and the potential for a delayed diagnosis of the 
disease. The use of fundamental cause theory and the social determinants of health 
framework allows for a better grasp of both the upstream and downstream effects on 
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health (Link & Phelan, 1995; Glass & McAtee, 2006; Braveman, Egerter, and Williams, 
2011).  
Fundamental cause theory and the social determinants of health are often used to 
describe how inequities increase the risk of developing medical conditions in specific 
populations. I, however, have opted to use these theories in another way. In an attempt to 
understand how inequity might shape the biological disease course and the illness 
experience of a disease with an unknown cause, I use fundamental cause theory and the 
social determinants of health on a population already diagnosed with ALS. In other 
words, the fundamental causes of health disparities may not only make a difference 
between experiencing good health or disease, but also how the experience of disease is 
shaped by social position.  
Given that those in more privileged positions are able to access more flexible 
resources, they could be more apt to notice ALS symptoms and pursue diagnosis earlier 
in the disease course, with the results being illustrated by differences in onset type. 
Further, those with more flexible resources may be more likely to opt into more time 
consuming and higher cost options for care, improving the quality of life for the pALS in 
these positions. Overall, the ability to understand a disease from fundamental cause/social 
determinants perspective prior to the discovery of an eventual cause could provide insight 
on how social factors shape the experience of the disease itself, the health and wellbeing 
of the population affected, and the ability to access future treatments or cures (Link, 
2008). 
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Life Course Theory  
Timing of life transitions within the life course can also affect health outcomes 
(Elder, 1998). For example, care decisions by and for those diagnosed with ALS can be 
different based on the when the diagnosis is given in the life course. The diagnosis of 
ALS and the likelihood of a fatal outcome within a few years would be considered an off-
time transition—ALS often strikes in the years where people are in the prime of their 
careers, raising children, and caring for elderly parents (Elder & Rockwell, 1979). 
Research illustrates that people who are over the age of 70 when diagnosed with ALS 
tend to be more accepting of the disease course than those in early-to-mid adulthood 
(Foley et al., 2014). Further, it suggests the difference may be that people diagnosed with 
ALS in late adulthood are more likely to anticipate the end of their lives, and the 
diagnosis comes after important milestones such as raising children into adulthood and 
reaching other important life transitions (Foley et al., 2014). People with ALS who have a 
partner and adult children, more common in late adulthood, are likely less reliant on in-
home nursing care or respite care and potentially make different decisions regarding 
mechanical ventilation and other invasive treatments, especially if the pALS feels as 
though these options puts undue burden on others (Foley et al., 2014). Further, the timing 
of ALS development in the life course potentially influences resources available to those 
diagnosed. For example, already qualifying for Medicare coverage could allow for 
shorter time to diagnosis, allowing more intervention to take place earlier in the disease 
course, thereby influencing the rate of progression. In addition, life course theory 
includes human agency, allowing for people diagnosed with ALS to construct their life 
course in a way best suited to their needs (Elder, 1994).  
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Using life course theory, in conjunction with fundamental cause theory and the 
social determinants framework, informs the considerations of how disadvantage and 
misfortune can accumulate over the life course, increasing the potential for ALS 
development in those who are susceptible (Ferraro et al., 2009; Ferraro et al., 2016). Life 
course theory illustrates that timing of diagnosis in the life course, the lives the pALS are 
linked to, and the experience of life transitions, should matter in the decisions to pursue 
medical treatments for ALS.  
Summary 
Amyotrophic Lateral Sclerosis (ALS) is a relatively rare disease, approximately 
5,000 people in the US are diagnosed per year. At any given time, it is estimated that 
16,000 people in the US are living with ALS. Ninety to ninety-five percent of cases of 
ALS are sporadic with no known cause, and the remaining 5-10% are familial (genetic). 
Moreover, the majority of people with ALS die within 2-to-5 years. Consequently, 
longitudinal studies with sufficient baseline data that allow for comprehensive research 
on determining who will develop ALS and who will not do not currently exist. Further, 
using matched cases (e.g. American Community Survey) is difficult, as ALS may strike 
anyone at any point in the life course and there is no known test to show otherwise. 
Among those who have been diagnosed, however, there are many questions about 
patterns of onset type, the patterns of symptom development and progression, and 
medical care utilization. Therefore, this dissertation focuses on a population of people 
who have already diagnosed with ALS.  
Using fundamental cause theory, the social determinants of health, and life course 
theory as a theoretical guide (Figure 1.1 and 1.2), I look at if, and how, social position 
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shapes the experience of ALS. Currently, ALS is not well understood by either the 
biological or the social sciences. While the biological research is underway, a next step 
for medical sociologists is to understand how these theories may apply in a little 
understood, relatively rare, and deadly disease in those who are already diagnosed in 
ALS. ALS is often thought of as solely a biological disease; however, a sociological 
perspective allows for the expansion of ideas to social position in order to develop a 
better understanding of the experience of the disease (Ingre et al., 2015; Brown and Al-
Chalabi, 2017). Previous work in diseases such as diabetes (Lutfey & Freese, 2005), 
arthritis (Reisine et al., 1995), and cancer (Rubin et al., 2014) have highlighted how the 
social affects the biological, and the dissertation expands this line of research into 
understanding the experience of ALS. Further, using these theories, I turn the attention of 
theories used in the broader study of the sociology of health and illness to ALS, to 
illustrate the need for a sociology of disease. 
To accomplish the goals of the dissertation, the second chapter explores how 
social position shapes the reported onset location at the time of an ALS diagnosis. The 
third chapter investigates how social position shapes the time between reported symptom 
development and diagnosis of ALS. Chapter four examines how position in the life 
course and social position shape medical care decisions reported by people with ALS. 
Understanding the way social position and life course position shape these experiences 
will potentially inform the fruitfulness of fundamental cause, social determinants, 
sociology of disease, and life course theory for better understanding the experience of a 
rare and incurable disease plus inform clinical trial formation, access to and the 
effectiveness of ALS treatments, and advances efforts to prevent health disparities, thus 
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hopefully improving the quality of life for people with ALS. The concluding chapter of 
the dissertation discusses the contribution of the research presented in the preceding 
chapters, the limitations of the National ALS Registry, and directions for future research.  
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Figure 1.1 Using Sociological Theories to understand the Social Context of ALS2  
 
 
 
 
  
 
2 Bolded text indicates available variables in the National ALS Registry Dataset. 
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Figure 1.2 Outline of Variables connected to theories used in understanding the 
Social Context of ALS 
 
3  
 
* Veteran status may be considered a life transition, a social determinant of health, or as a potential 
indicator of flexible resources.  
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CHAPTER TWO: HOW DOES SOCIAL POSITION SHAPE ALS ONSET 
LOCATION?  
Introduction 
Amyotrophic Lateral Sclerosis (ALS) researchers often study social position in 
isolation as individual risk factors (e.g. race/ethnicity, gender, socioeconomic class) 
(Ingre et al., 2015). For example, previous epidemiological and biomedical studies have 
implicated exposures to toxic chemicals, smoking behavior, and physical activity levels 
as potential risk factors for the development of amyotrophic lateral sclerosis (ALS), 
including where symptoms first appear on the body (Swinnen and Robberecht, 2014; 
Wang et al., 2016). Without understanding these exposures and behaviors within their 
social context, however, Ingre et al. (2015) suggests that scientists are unable to 
determine if they are risk factors in and of themselves, or proxies for larger social 
processes interacting with biological factors (Ingre et al., 2015). I posit, based upon 
fundamental cause theory and the social determinants of health that social position shapes 
the onset location of ALS, and therefore shaping the earliest experiences of ALS (Link & 
Phelan, 1995; Glass & McAtee, 2006; Braveman, Egerter, and Williams, 2011). Further I 
evaluate how fundamental cause theory, social determinants of health, and life course 
theory (Elder & Rockwell, 1979; Elder, 1998) define the social dimensions of ALS, 
further indicating a need for a sociology of disease (Timmermans and Haas, 2008). 
Diagnosis of ALS and Onset Location 
A diagnosis of ALS is a process of elimination, and the cost of simply obtaining a 
diagnosis can be in the tens of thousands of dollars prior to insurance coverage (Kiernan 
et al., 2011; Obermann & Lyon, 2015). Common tests in the diagnostic pathway for ALS 
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include an electromyogram (EMG), MRIs of the brain, neck, and cervical spine, lumbar 
puncture (also known as a spinal tap), and biopsies of the muscle tissues in affected areas 
(Iwasaki, and Kinoshita, 2001). The EMG is essential for the confirmation of a diagnosis 
of ALS, and muscle biopsy is often the last step in the confirmation process (Iwasaki, and 
Kinoshita, 2001).  
The diagnostic pathway is how a physician, most of a neurologist, determines 
diagnosis of ALS and the suspected onset location of ALS symptoms. The onset location 
of ALS is heterogeneous, however, and there is not a clear understanding of the 
underlying reasons for the differences in onset location. ALS onset is classified by the 
motor neurons affected, with the resulting damage being expressed by the different 
regions of the body (Kiernan et al., 2011; Andersen, 2018). Limb onset, the most 
common onset location, begins with asymmetric, painless weakness in a limb. The person 
with ALS often presents with atrophy and weakness of the muscles, fasciculations 
(twitching), and abnormal reflexes. Bulbar onset, which affects about 20% of patients, 
affects the bulbar (neck and jaw) muscles, leading to slurred speech and difficulty 
swallowing. Trunk or global onset affects 3-5% of people with ALS (pALS), and 
symptoms are first reported in the trunk, including the back or abdominal areas, breathing 
muscles, or total body weakness. All forms of ALS, limb, bulbar, and trunk/global, 
eventually progress, leaving the person who is affected unable to speak, move, or breathe 
on their own. ALS is universally fatal with an average life expectancy of 2-5 years, 
however, with medical intervention (e.g. tracheostomy, PEG tube) people with ALS may 
potentially live for much longer (Georgoulopoulou et al., 2013).  
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The heterogeneity of ALS onset and the relative rarity of the disease may lead to 
incorrect diagnoses or a delayed diagnosis of ALS (Belsh and Schiffman, 1996; 
Srinivasan et al., 2006; Kraemer, Buerger, and Berlit, 2010; Nzwalo et al, 2014). 
Moreover, the diagnosis of ALS may be delayed until further into its progression if 
symptoms are not recognized as significant by the patient, their family members, or their 
family physicians (O’Brien et al., 2011). A delayed diagnosis of ALS may mean that the 
disease has progressed further than the original onset site, leading to a distorted clinical 
picture of where onset truly began. Further, a delay in diagnosis may give the appearance 
of shorter survival times for the patient, which may be a source of distress (Househam 
and Swash, 2000; O’Brien et al., 2011).   
Proximate Risk Factors in ALS 
Risk factors for the development of ALS are largely unclear; however, researchers 
have identified several potential candidates. These risk factors are often considered 
largely from a biomedical lens. Several genetic mutations, such as the mutation of the 
SOD1 gene, have been suspected in the development of familial ALS and may be a risk 
factor for sporadic ALS as well (Wang et al., 2016). Exposures to heavy metals (e.g. 
lead), organic chemicals (e.g. pesticides used in farming), and occupational exposures 
(e.g. electrical shock, chemical exposure), are considered potential risk factors that have 
been studied extensively, although not in connection to each other (Sutedija et al., 2007; 
Fang et al., 2009; Yu et al., 2014; Wang et al., 2016). Additionally, research suggests 
health behaviors are potential risk factors for ALS development. Individuals who smoke 
are at higher risk of developing ALS, however, this correlation has been debated as the 
association appears in some studies and not in others when other proximal risk factors are 
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included in the measures (Sutedija et al., 2007; Yu et al., 2014; Wang et al., 2016). 
Alcohol consumption has been reported as having a potential protective effect (de Jong et 
al, 2012) or no association with the development of ALS (Nelson et al., 2000).   
Social Position and ALS Onset Location 
Social position (e.g. indicated by gender, race/ethnicity, or social class), when it is 
included in ALS research, is often considered largely through a biomedical lens. The 
wide variation of potential proximate risk factors, however, indicates there may be more 
at work than simple environmental exposures. As Ingre et al. (2015) noted, different risk 
factors have been studied independently of each other, but little work has been done to 
study how they may interact and what factors may predispose a person to those 
circumstances. Further, the onset location of ALS may be, in part, due to the differences 
in the vulnerability of nerves to exposure to proximal risk factors linked to ALS 
development (Brown, Lockwood, and Sonawane, 2005; Aschbacher et al., 2013; 
D’Amico et al., 2013; Bozzo et al., 2017).  
Exposures to risks, however, is often a function of experiences in the social world. 
Extant research has considered that social position—race/ethnicity, education, and 
socioeconomic status—operate as fundamental causes of health disparities (Link and 
Phelan, 1995; Williams and Collins, 2001; Lutfey and Freese; 2005; Mirowsky and Ross, 
2010). Fundamental cause theory is useful in understanding what social factors may 
differentially place people at ‘risk of risks,’ including the proximate risk factors related to 
the development of ALS (Link & Phelan, 1995). Fewer studies explore how fundamental 
social structures shape the experience of those with a disease (Timmermans and 
Buchbinder, 2010; Umberson et al., 2016). Moreover, understanding the patterns of 
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social position in an illness may help to understand how ALS symptoms are expressed  
and experienced through differing exposures (Link & Phelan, 1995; Glass & McAtee, 
2006; Braveman, Egerter, and Williams, 2011). For example, women and people of color 
are often at higher risk of poorer health due to exposure to socio-environmental stressors 
(e.g. discrimination and  harassment). Social and environmental stressors may increase 
the level of cortisol, as well as increase oxidative stress within the cells (Fidler et al., 
2011; Goosby and Heidbrink, 2013; Aschbacher et al., 2013). In the case of ALS, the 
weathering of the body from these constant insults may leave the central nervous system 
more vulnerable to damage, leading to differences in the expression of individual 
symptoms (Geronimus et al., 2001). Differences in stressors due to social position is one 
potential explanation for variations in the experience of ALS; yet there are other potential 
connections that I detail below.  
Race and Ethnicity. ALS is often depicted as a disease that effects White men, 
however, this may be due to White men being overrepresented in many clinical and 
registry studies (Chiò et al., 2011; Mitsumoto et al., 2014; Kaye et al., 2018). Further, 
White men may be overrepresented in cases of ALS because they have fewer competing 
risks of death compared to Black men (Ferraro and Farmer, 1996; Howard et al; 2000).  
Currently, development of ALS is thought to be less frequent in minorities and is often 
hypothesized as perhaps a result of genetic differences (e.g., protective genes) (Gundogdu 
et al., 2014). Considering fundamental cause theory and the social determinants of health, 
it is more likely that racial/ethnic minority populations have differing access to resources, 
leading to this population remaining undiagnosed until the disease has advanced to later 
stages. Further, people of color have reported believing ALS is a ‘White disease’ leading 
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to the potential dismissal of symptoms or a delay of diagnostic tests, especially if the 
provider is under the same impression, due to the majority of ALS coverage in popular 
media portraying the disease as affecting only White men (Carter, 2019). In addition, 
later diagnosis of ALS may limit the ability of racial/ethnic minority populations to 
access specialty clinics and clinical trials, limiting information on this population. Based 
upon prior data and fundamental cause theory and the social determinants of health, I 
hypothesize that: 
H1: Given that racial/ethnic minorities face greater social and environmental 
risk factors which may cause widespread damage to the nervous system, as 
well as may face later diagnosis due to the perception of ALS as disease of 
White men, racial/ethnic minorities will have different patterns of onset, with 
minorities having higher odds of reporting global onset of ALS symptoms. 
 Gender. Although ALS has been presented as overwhelmingly affecting males, 
European studies have indicated the differences in rates of ALS diagnosis between men 
and women diminish in the fifth and sixth decade of life (Mehta et al., 2014; Manjaly et 
al., 2010). In addition, the onset location for women tends to be different than for men. 
For example, studies report women are much more likely to report bulbar onset of ALS 
symptoms, but posit the differences is potentially due to gonadal hormones or biological 
differences in the nervous system (McCombe and Henderson, 2010; Swinnen and 
Robberecht, 2014). Other potential behavioral and environmental factors, such as 
cigarette smoking and occupational risk exposure, have previously been shown to explain 
the increased rate of bulbar onset in women (McCombe and Henderson, 2010; Sutedja, 
2010). The differences in ALS prevalence rates between men and women, as well as the 
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differences in onset location between the genders is not well understood. Previous 
studies, however, have not accounted for race/ethnicity or socioeconomic status, as well 
as proximate risk factors, when attempting to explain the differences in onset location 
between men and women. Therefore, I posit that: 
H2: Women will have different patterns of onset than men, with women 
having higher odds of reporting bulbar onset of ALS symptoms, which will 
not be explained by proximate risk factors when including social positions of 
race/ethnicity or socioeconomic status. 
Socioeconomic Status and Education. Socioeconomic status and education are 
linked (Krieger, Williams, and Moss; 1996; Mirowsky and Ross, 2010). Further, 
education is both thought of as a fundamental cause of health disparities and as a proxy 
for socioeconomic status (Krieger, Williams, and Moss; 1996; Mirowsky and Ross, 
2010). Exposure to hazards such as pesticides or environmental toxins are influenced by 
socioeconomic status and education—people of lower socioeconomic status and 
minorities may live in areas with a greater level of environmental pollution—and lower 
educational attainment may prohibit leaving an occupation or a home where proximate 
risks occur. In addition, those with lower education levels may have constrained choices 
and therefore be led to a career that increases the risk of injury, and/or may have less 
access to healthcare resources (Link & Phelan, 1995; Williams & Collins, 2001; 
Mirowsky and Ross, 2010; Freese & Luftey, 2011; Diez Roux, 2012; Phelan & Link, 
2013). All these risks have been individually implicated in the increased risk of 
developing ALS; however, research has not connected these factors back to 
socioeconomic status or education level. Moreover, lower education may lead to a 
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difference in the type of work one engages in, as well as in how symptoms of ALS 
become salient (Krieger, Williams, and Moss; 1996; Mirowsky and Ross, 2010). For 
example, a job that requires more physical labor (e.g., mechanic) may lead to the belief 
that limb onset symptoms are due to overuse or injury rather than signs of ALS, whereas 
trouble with speech or swallowing may be more unusual and require attention. 
Considering these factors, I hypothesize:  
H3: pALS with different levels of education will have different patterns of 
onset, with those with a college degree or more having lower odds of 
reporting global or bulbar onset of ALS symptoms than those with an 
education of high school or less. 
Military service has been linked to ALS development, as veterans are twice as 
likely as civilians to develop the disease, but the link is currently unclear (Weisskopf et 
al., 2015; Wang et al., 2016). For example, previous research has indicated physical 
trauma or injury, lower BMI, lower educational attainment, and the higher levels of 
physical activity found among service members may be particular risk factors for the 
development of ALS (Weisskopf et al., 2015; Wang et al., 2016). Although military 
service is often described as a proximate risk factor, it may also operate as an indicator of 
social position. For example, military enlistment is particularly attractive to young people 
with lower socioeconomic statuses, larger family sizes, and less-educated parents 
(Kleykamp, 2006). The development of ALS is twice as common among military 
veterans, which may be in part due to the exposures during military service but may also 
be influenced by the experiences of the veteran both pre- and post-enlistment. Given the 
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potential similarities between veterans and those with lower levels of education, I 
hypothesis that: 
H4: Civilians will be more likely to report bulbar and trunk/global onset of 
ALS symptoms than Veterans. 
Life course and social resources. Position in the life course, including age and 
marital status, may influence when symptoms become salient for an individual. Having a 
partner or spouse in the home may act as another set of eyes, allowing for earlier 
detection of ALS symptoms and a clearer picture of where the symptoms started (Waite 
and Gallagher, 2001). Furthermore, younger adults who are more physically active may 
recognize limb onset symptoms as unusual for their daily activities (e.g. difficulty 
running), whereas an older adult may dismiss troubles with daily activities (e.g. dressing) 
as a sign of aging, consequently delaying diagnosis until there is greater involvement of 
the nerves. Therefore, it is reasonable to suspect that these social factors may influence 
the reported onset location of ALS via how the person affected by ALS may come to 
realize that something has changed within their body in the time leading up to diagnosis. I 
posit that: 
H5: Those who are not married (e.g. never married, divorced, or widowed) 
will have higher odds of reporting global onset of ALS symptoms, compared 
to their married counterparts. 
and 
H6: Those younger than 50 will be less likely to report bulbar or global onset, 
whereas those older than 59 will more likely to reporting bulbar or global 
onset, compared to those aged 50-59. 
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Data and Methods 
Data 
 The National ALS Registry, created in October 2010, is a voluntary web-based 
registry for people who have been diagnosed with ALS. The registry collects data on 
demographic characteristics, risk factors, current and lifetime occupational and military 
history, family history of ALS, clinical data such as phenotype, and outcome data. In 
addition, the registry collects information from the Department of Veterans Affairs and 
Medicare for people diagnosed with ALS. The risk factor survey in the ALS Registry was 
created and validated by the Stanford University School of Medicine’s ALS Consortium 
of Epidemiologic Studies and is constructed to eliminate the need for healthcare provider 
involvement in answering the survey questions (Bryan et al., 2016; Raymond et al., 
2019). Due to the potential physical, mental, and emotional limitations of pALS, the risk 
factor survey utilizes smaller modules to facilitate completion (Bryan et al., 2016). The 
National ALS Registry collects data through a secure web portal from those who have 
self-identified as having ALS. In addition, each participant completes a separate 
questionnaire developed by the U.S. Department of Veterans Affairs ALS registry to 
confirm an accurate ALS diagnosis (Bryan et al., 2016). One potential drawback to the 
online survey is the potential for self-selection bias, with the data slanted toward an urban 
dwelling, younger, better educated patient.  
The clinical symptoms survey module was created in partnership with the ALS 
Research Group to examine physical symptoms participants developed before and after a 
diagnosis of ALS (Raymond et al, 2019). The survey contains fifty-four questions on 
topics such as site of onset, time of initial symptom onset to diagnosis, and time of 
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diagnosis to hospice referral. The module launched in December 2013 to new enrollees 
and previous enrollees were prompted to return to the web portal to complete this survey. 
Therefore, this analysis covers from 19 October 2010 to 31 December 2016. In total, 
9,789 respondents are included in this study with no exclusions.  
Measures 
 Onset Location. The dependent variable is the part of the body where the patient 
first reported ALS-related weakness or symptoms. In order to create a categorical 
variable for analysis, the body was subdivided into 3 areas: 1) limb—symptoms first 
reported in the extremities, including the hand, arm, foot or leg, 2) bulbar— symptoms 
first reported in the oral and facial muscles, including issues with speech and/or 
swallowing, and 3) trunk/global—symptoms first reported in the trunk, including the 
neck, back or abdominal areas, breathing muscles, or total body weakness. Onset location 
was missing for .54% of the registry respondents.  
 Social Position. Potential factors in the development of ALS include the social 
position of the patient at the time they entered the registry. Race/ethnicity was 
constructed as a dichotomous variable due to the small number of racial/ethnic minority 
patients in the registry, with White (=0) and Minority (=1) as populations of interest. The 
gender of the patient is a dichotomous variable of men (=0) and women (=1). Education 
is a categorical variable of high school or less (=0), tech or trade school or some college 
education (=1) and a bachelor’s degree or more (=2). Race/ethnicity, sex, and education 
did not have missing data. 
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 Veteran’s Status. I include veteran status as a dichotomous variable in the model, 
with veteran (=0) and civilian (=1). Military enlistment data was missing for .07% of the 
registry respondents.  
 Proximal Risk Factors. The National ALS Registry asks for respondent’ longest 
occupation. In order to create categories which would include enough respondents, this 
variable is categorized as low risk (= 0) and high risk (= 1). Occupations were 
categorized using previous research as a guide; if exposure to risks would be considered 
low (e.g. secretarial work) or high (e.g. automotive technician) the occupation was 
included in the corresponding category. Occupational data was missing for 38.18% of the 
respondents. A dichotomous question of personal history of ever smoking (yes = 1) or 
ever drinking (yes = 1) was asked of the respondents. Smoking history was missing for 
.72% of the respondents, and drinking history was missing for .23% of the respondents.  
Life Course and resources. In order to account for a potential social relationship 
which may influence recall of diagnosis or an earlier diagnosis, I include marital status. 
Marital status is a dichotomous variable of married or cohabitating (= 0) or never 
married, separated/divorced, or widowed (= 1), with missing data for .12% of the 
respondents. As age may play a role in what symptoms are noticed first, I included age as 
a categorical variable: 18-39 (= 0), 40-49, 50-59, 60-69, 70-79, and 80+ (= 5). Age was 
missing for .02% of the respondents.  
Analysis 
 Multiple Imputation using Chained Equations was used to impute missing data 
with ten imputations completed (Bodner, 2008). Table 1.1 reports the pre- and post-
imputation proportions in each category. The similar estimates for each variable, as well 
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as between the pre-and-post imputation bivariate analyses, demonstrate reliably imputed 
data.  Bivariate tests of the association between onset location and each of the dependent 
variables were then performed. I use multinomial logistic regression to examine the 
relative risk ratio of reporting bulbar onset or global onset compared to limb onset. Model 
1 includes the distal factors of social position (race/ethnicity, gender, education). Model 2 
includes social position and veteran status. Model 3 includes social position, veteran 
status, and proximal risk factors, including occupational risk and smoking/drinking 
history. Finally, Model 4 includes the addition of marital status and age at diagnosis. 
Results for Model 4 are reported in this chapter; tables for Models 1-3 can be found in 
appendix A. All analyses were completed using STATA version 15. 
Results 
Demographics  
As indicated by Table 1.1, just over 73% of the respondents reported limb onset, 
just over 20% reported bulbar onset, and nearly 6% reported trunk/global onset. The 
sample is almost exclusively White (97.18%), and nearly 60% of the sample is male. 
Over 60% of the respondents reported having at least a bachelor’s degree. Veterans make 
up nearly 24% of the sample. Over 60% of the individuals in the registry records report 
working in a low risk occupation, while just over 45% report a history of smoking and 
81% report a history of drinking alcohol. The majority of the sample is married or 
cohabitating (82%). Most of the respondents are between the ages of 50-59 and 60-69 
(29.79% and 35.99 % respectively).  
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Bivariate Associations  
Table 1.2 displays the F tests results used to determine if there were relationships 
between the dependent variable of onset location and the independent variables. Tests of 
the bivariate associations do not show associations between onset type and race/ethnicity, 
occupational risk category, marital status, or a history of smoking. The results show there 
is an association between onset location and (1) gender, with women being more likely to 
report bulbar onset than men, (2) education, with higher levels of education less likely to 
report global onset than lower levels of education, (3) alcohol consumption, with pALS 
who consume alcohol more likely to report limb onset than pALS who do not consume 
alcohol, (4) veteran status, with veterans more likely to report limb onset than civilians 
and, (5) age at diagnosis, with younger pALS more likely to report limb onset than older 
pALS (p < .001).  
Multinomial Logistic Regression of Reporting of Onset Location  
 Table 1.3 presents the results of the multinomial logistic regression. In contrast to 
Hypothesis 1, racial/ethnic minorities are no more likely to report bulbar onset (RR = 
1.29, 95% CI [.96, 1.73]) versus limb onset, or global onset (RR = .93, 95% CI [.54, 
1.60]) versus limb onset, compared to whites. This finding is surprising, given the 
existing literature on racial/ethnic minority health disparities we would expect to see a 
potentially greater level of nerve involvement at diagnosis. Due to the small number of 
nonwhite participants in the registry, however, the lack of association may be an issue of 
power. Therefore, Hypothesis 1 is not supported. 
The results show women, in comparison to men, are more likely to report bulbar 
onset compared to limb onset of ALS symptoms, supporting Hypothesis 2 and consistent 
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with existing research in onset location. The higher risk of bulbar onset among women is 
interesting, given that many clinical studies are populated by pALS with limb onset, and 
thus there are gaps in knowledge relevant to the disease for women. Compared to men, 
women are more likely to report bulbar onset compared to limb onset (RR = 1.43, 95% 
CI [1.28, 1.61]), and less likely to report global onset compared to limb onset (RR = .93, 
95% CI [.33, .51]).  
The results of education and onset location partially support Hypothesis 3, as 
results do show that those with the highest level of educational attainment are 28% less 
likely to report global onset (RR = .72, 95% CI [.57, .90]) compared to limb onset in 
contrast to pALS with a technical or trade degree or at least some college education. With 
the addition of age at diagnosis and marital status, pALS with a high school education or 
less compared to those with pALS with a technical or trade degree or at least some 
college education do not significantly differ in their risk of bulbar onset versus limb onset 
(RR = 1.09, 95% CI [.92, 1.30]). Education level may make a difference in the perception 
of onset, as those with higher levels of education (e.g. bachelor’s degree of greater) could 
have fewer work-related explanations for symptoms in the limbs than those with less 
education. 
In comparison to veterans, civilians are 25% more likely to report bulbar onset 
versus limb onset (RR = 1.25, 95% CI [1.09, 1.44]) and 119% more likely to report 
global onset versus limb onset (RR = 2.19, 95% CI [1.73, 2.79]). These results support 
Hypothesis 4, as civilian pALS have higher odds of reporting bulbar and trunk/global 
onset of ALS symptoms than those pALS who served in the military.  
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Concerning marital status, those pALS who are not married are no more likely to 
report bulbar onset versus limb onset (RR = 1.01, 95% CI [.89, 1.16), however, they are 
47% more likely to report global onset versus limb onset (RR = 1.47, 95% CI [1.18, 
1.84]) when compared to those who are married. These results support Hypothesis 5. For 
married pALS, it may be that a spouse notices symptom earlier in the disease course and 
wives may be more insistent on their spouse obtaining medical care. Further, in support 
of Hypothesis 5, the results show that pALS under the age of 50 are less likely to report 
bulbar or global onset of symptoms compared to limb onset, and those pALS over the age 
of 59 are more likely to report bulbar onset or global onset compared to limb onset, when 
compared to those between the ages of 50 and 59. One exception to this is pALS who are 
ages 40-49 are no more or less likely to report bulbar onset over limb onset than those 
ages 50-to-59. Overall, the results indicate a pattern of younger pALS being less likely to 
report bulbar or global onset compared to limb onset (see Table 1.3 for full results), 
which may be due to the perception of the initial onset of ALS being confused with the 
normal process of aging in older adults.  
Discussion 
 In an attempt to better understand how social position may shape the reported 
onset location of ALS symptoms, I use fundamental cause theory, social determinants of 
health, and life course theory in analyzing the National ALS Registry data. The use of 
these theories in analyzing the registry data provides new insights into how social 
position may shape the onset location of ALS. Further, I use sociological theories to 
understand the social dimensions of a disease that is often conceptualized and studied as 
purely biological (Ingre et al., 2015; Brown and Al-Chalabi, 2017).  
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 Social position and position in the life course does seem to shape onset location, 
which is a new finding in research on ALS. There are several potential explanations for 
these findings. Social position and position in the life course could influence the 
perception of symptoms of ALS and where they begin. Moreover, social position could 
be an influence on the exposures that trigger a gene by environment interaction which 
influences the biological development of symptoms are where they begin. Finally, social 
position has been shown in previous work to influence access to healthcare resources, 
allowing the symptoms to spread prior to diagnosis and changing the reported onset 
location.  
 Women and people of color are often at higher risk of poorer health due to 
exposure to socio-environmental stressors (e.g. discrimination, harassment) (Schultz et 
al., 2001; Williams and Jackson, 2005). In the case of ALS, the weathering of the body 
from socio-environmental stressors leave the central nervous system more vulnerable to 
damage, leading to differences in the expression of individual symptoms. pALS of color 
in the National ALS Registry, however, were no more likely to report bulbar or global 
onset versus limb onset in comparison to white pALS. Biomedical research has posited 
this is due to a potential difference in genetics, as it appears that minorities are less likely 
overall to develop ALS. Alternatively, there is a small sample of racial/ethnic minority 
pALS in the registry and issues overall with collecting data on ALS, potentially masking 
differences. Previous work has compared the registry to other sources of data and has 
noted that the registry underreports cases of ALS among non-whites (Kaye et al., 2018). 
In addition, health disparities research has illustrated the issues with access to and the 
quality of care/diagnosis for minorities in the US healthcare system (Phillips, Meyer, and 
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Adiar, 2000; Shi, Lebrun, and Tsai, 2010; Shi et al., 2014). Cases of ALS are difficult to 
diagnosis, taking a good deal of time and resources, which may limit the number of 
accurate diagnoses in racial/ethnic minority populations. Finally, the differences in life 
expectancy between Whites and minorities could affect the reported numbers of ALS 
diagnosis in racial/ethnic minority patients. For example, it may be that Black-Americans 
develop other serious health conditions and have other social exposures (e.g. violence) 
that increase the potential they do not live long enough to develop ALS, as the average 
age of diagnosis is in the late fifties and early sixties (Geronimus et al., 2001). 
Women were more likely to report bulbar onset in comparison to limb onset when 
compared to men, consistent with previous research in this area. Previous work in gender 
differences in ALS onset have posited biomedical explanations for the increase in bulbar 
onset in women. For example, higher levels of bulbar onset reports in women may be due 
to differences in gonadal hormones (e.g. estrogen, progesterone, testosterone) or 
biological differences in the central nervous system (McCombe and Henderson, 2010; 
Swinnen and Robberecht, 2014). Other potential behavioral and environmental factors, 
such as cigarette smoking and occupational risk exposure, have previously been shown to 
explain the increased rate of bulbar onset in women (McCombe and Henderson, 2010; 
Sutedja, 2010), however, the inclusion of these proximal risk factors in these models does 
not explain away the higher likelihood of women reporting bulbar onset. 
Women, given their position in the social hierarchy, face potential differences in 
the amount and type of chronic stressors in comparison to men. Higher levels of chronic 
stress for women leads to higher levels of oxidative stress via the repeated activation of 
the HPA axis, causing damage to the cells in the body, including the nervous system 
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(Aschbacher et al., 2013). Oxidative stress has been implicated as one potential trigger 
for ALS, and may influence the onset location (Bozzo et al., 2017). Gender, however, 
does not seem to affect survival rates between women and men, meaning the oxidative 
stress may only trigger ALS, but not influence mortality (McCombe and Henderson, 
2010). Therefore, it is important to not disregard the potential of social position to shape 
ALS experience when including women in biomedical research of ALS, including the 
potential of exploring stress-related biomarkers in the development of ALS.  
 Education and socioeconomic status are often thought of as the fundamental 
causes of health disparities (Link & Phelan, 1995; Williams & Collins, 2001; Mirowsky 
and Ross, 2010; Freese & Luftey, 2011; Diez Roux, 2012; Phelan & Link, 2013). For the 
population of people with ALS in the National Registry, pALS with the highest-level of 
education were less likely to report global onset than limb onset, however, there was no 
difference in the likelihood of reporting bulbar onset compared to limb onset. pALS with 
higher levels of education (and by proxy potentially higher socioeconomic status) are 
more aware of the potential for symptoms to mean that something is going on with their 
body and are likely to seek medical care for symptoms earlier in the disease course, 
preventing the appearance of global symptoms (e.g. total body weakness). In addition, 
individuals with higher education levels may be less likely to be exposed to 
environmental and occupational hazards and have occupations that allow for less of the 
symptoms to be explained as related to activities on the job.  
 Civilians are more likely to report onset of ALS symptoms in the bulbar region or 
in the trunk/global region than limb onset, in comparison to their veteran peers. Prior 
research has hypothesized that differences in both the rate of development and onset 
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location may be due to differences between those who enlist in the military and those 
who do not, including higher rates of physical trauma or injury, lower BMI, lower 
educational attainment, and the higher levels of physical activity (Weisskopf et al., 2015; 
Wang et al., 2016). Considering prior research has shown that military enlistment is 
particularly attractive to young people with lower socioeconomic statuses, larger family 
sizes, and less-educated parents (Kleykamp, 2006), it is likely that onset location is 
influenced by the experiences of the veteran both pre-and-post enlistment, including 
higher rates of occupational and environmental exposures. It is important to future 
research to include early life experience and related exposures, in addition to military 
service, to begin to understand the differences in reported onset location between 
veterans and civilians. Additionally, veterans often have access to different healthcare 
systems (e.g. VA system) which are aware of the greater risk of ALS among veterans, 
allowing for the testing of suspicious symptoms earlier in disease development.  
 pALS who are not married are more likely to report global onset compared to 
limb onset, with no differences between bulbar and limb onset, compared to their married 
peers. Given that ALS eventually affects all areas of the body, having a partner in the 
home may help to catch the gradual onset of limb or bulbar symptoms before they begin 
to affect other areas of the body. Further, extant research has shown that marriage is 
beneficial to one’s health, by lowering the impact of stress on both physical and 
psychological health (Slatcher, 2010; Carr et al., 2014). Therefore, it might be that 
marriage and its potential for reducing stress protects the central nervous system from 
damage, leading to ALS symptoms developing in one region of the body (e.g. bulbar or 
limb) rather than in a widespread manner.  
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 It becomes apparent when considering age at diagnosis that position in the life 
course may influence the reported onset location of ALS. pALS diagnosed with ALS who 
are younger are less likely to report bulbar or global onset than limb onset compared to 
those who are diagnosed between the ages of 50-59, the average age at diagnosis. pALS 
older than 50-59 are more likely to report bulbar or global onset than limb onset. There 
are several potential reasons for these results. Previous research has postulated aging 
itself may cause damage to neurons, leading to an increase in global onset (Atsuta et al., 
2009; Yokoi et al., 2016). People diagnosed with Familial ALS (FALS), which is due to 
genetic causes, tend to be younger with limb onset being most common among these 
patients (Gaudette et al., 2000). FALS only makes up 5-10% of ALS cases, however, 
which does not fully explain the differences in onset location. It may be that symptoms of 
ALS that develop in the limbs are more salient to those who are younger and are more 
physically active. Older adults may dismiss troubles with daily activities as a sign of 
aging, which may delay diagnosis until there is further involvement of the nerves. 
Finally, in line with many of the other patterns found in the data, it may be that the effects 
of stress accumulate over the life course, causing damage to the nervous system and 
affecting onset location (Geronimus. 1992; Geronimus et al., 2001; Ferraro et al., 2009; 
Ferraro et al., 2016). 
Limitations 
There are a number of limitations to consider with this study. The first is the 
nature of the National ALS Registry. The National ALS Registry has been designed for 
biomedical and epidemiological research, and therefore limits the work of the social 
scientist. The ALS Registry is reliant on patient self-reporting data and may be subject to 
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recall bias and bias due to self-identification. Further, the registry is a large non-random 
sample that is opt-in and is therefore not generalizable to the ALS population.  
The registry is available in an online format only, which may limit access and 
cause the registry to reflect a younger, White, and educated patient sample. The registry 
sample provided by the CDC is less racially diverse than the overall registry which 
includes Medicare and Veteran’s Association claims data. There are several potential 
reasons for this, including access to computers that are required for self-registration; 
reduced awareness of the registry; and reduced participation in areas with substantial 
nonwhite populations (Kaye et al., 2018). In addition, while the sample size overall is 
robust, smaller numbers of specific populations, such as non-white patients, makes it 
difficult to detect single axis disparities and limits the ability to do intersectional analysis 
to better understand the relationship of social position and ALS. Finally, the limited 
access to data due to reidentification risks limit the analysis to a small number of survey 
modules, which prevents a fuller picture of the experience of ALS. Even with these 
limitations, the National ALS Registry is the most comprehensive, geographically diverse 
sample of people diagnosed with ALS.  
Conclusion and Implications 
 Fundamental cause theory, social determinants of health, and life course theory 
are valuable sociological theories in understanding health disparities and differences in 
disease development. These theories have helped to highlight differences in social 
position and reported onset location of ALS in patients who have registered with the 
National ALS Registry. Although fundamental cause theory, as well as the social 
determinants of health, do not fully and consistently explain the differences in onset 
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location among pALS, they do highlight areas where these theories may help clarify 
where differences are occurring in the disease course. Further, the use of these theories 
shows where potential refinements in the theories are needed to allow for their use at the 
micro-level in a rare disease with unknown causes. Additionally, the findings reinforce 
the need for a sociology of disease, in order to understand the disparities in trajectories 
and health outcomes in specific diseases rather than understanding disparities from a 
general overview (Timmermans and Haas, 2008). The goal of a sociology of disease in 
the case of ALS is to take the themes and theories from the sociology of health and 
illness and focus attention on specific health outcomes such as onset location. Although 
social epidemiology may seem like a more natural fit for this type of work, the goal here 
is not to point out collective risk factors but to account for the multiple pathways in 
which the experience of the social world may influence ALS onset directly (Pescosolido, 
2006; Timmermans and Haas, 2008). In fact, the previous successes of epidemiology and 
biomedicine in understanding ALS highlights the need to understand how the social 
affects the development and experience of ALS (Pescosolido, 2006; Link, 2008; 
Timmermans and Haas, 2008). 
Future research in ALS should consider the implications of social position and the 
position in the life course on the experience of ALS. These considerations are especially 
important as it relates to risk exposures, to not only suspected proximate risk factors, but 
to the experience of stress. Stress is known to affect health in a myriad of ways, both 
physically and psychologically. Previous research has examined the effects of stress in 
ALS through pathways related to hormones (e.g. cortisol) and damage to the nervous 
system (e.g. oxidative stress) (Fidler et al, 2011; Bozzo et al., 2017). The addition of a 
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module to the registry asking about life events and chronic stressors, in combination with 
biomarker data, could begin to clarify the connection between stress and ALS. 
 An additional implication of the work presented here is the need to rethink the 
way clinical trials are designed. The results presented illustrate concerns—reported onset 
location varies by social position—which is often not accounted for in clinical trials for 
ALS treatments. Prior research evaluating clinical trials implicated a lack of 
consideration of variations in the disease (e.g. onset location, speed of progression) in the 
widespread failure of promising trials, as the majority of trial participants are young, 
white and male, the majority of those with limb onset (Chiò et al., 2011; Mitsumoto et al., 
2014). I argue that addition to ensuring variation in onset location in clinical trials, it is 
important to take into consideration the social position of the participant, as variations in 
onset location do appear to have connections to social forces. By beginning to understand 
how social position and position in the life course are related to the reported onset 
location of ALS, researchers and health professionals can begin to incorporate the social 
factors into research on the diagnosis, treatment, and biomedical research of ALS.  
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Table 2.1. Descriptive Statistics for Pre and Post Imputation Data (N = 9789) 
 Pre-Imputation Post-Imputation 
Percentage 
Variable Frequency Percent  
Onset Location    
Limb (0) 7169 73.24 73.61 
Speech/Swallowing (1) 2003 20.46 20.59 
Trunk/Global (2) 564 5.76 5.80 
Missing 53 .54 0 
Race/Ethnicity    
White (0) 9513 97.18 97.18 
Non-White (1) 276 2.82 2.82 
Missing 0 0 0 
Gender    
Men (0) 5861 59.87 59.87 
Women (1) 3928 40.13 40.13 
Missing 0 0 0 
Education    
High School or Less (0) 1392 14.22 14.22 
Tech/Trade/Some College (1) 2034 20.78 20.78 
College Degree (2) 6363 62.00 62.00 
Missing 0  0 0 
Veteran Status    
Civilian or Other (0) 7473 76.34 76.41 
Veteran (1) 2309 23.59 23.59 
Missing 7 .07 0 
Occupational Risk Category    
Low Risk (0) 3810 38.92 62.22 
High Risk (1) 2242 22.90 37.78 
Missing 3737 38.18 0 
Ever Smoked Cigarettes    
No (0) 5288 54.02 54.40 
Yes (1) 4431 45.27 45.60 
Missing 70 .72 0 
Ever Drank Alcohol    
No (0) 1815 18.54 18.61 
Yes (0) 7951 81.22 81.39 
Missing 23 .23 0 
Marital Status    
Married or Cohabitating (0) 7998 81.70 81.80 
Never Married, Separated, Divorced, Widowed (1) 1779 18.17 18.20 
Missing 12 .12 0 
Age at Diagnosis    
18-39 (0) 427 4.36 4.36 
40-49 (1) 1382 14.12 14.12 
50-59 (2) 2916 29.79 29.79 
60-69 (3) 3522 35.99 35.99 
70-79 (4) 1406 14.37 14.36 
80+ (5) 134 1.37 1.37 
Missing 2 .02 0 
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Table 2.2.  Bivariate Associations by Reported Onset Location (N = 9789) 
 Limb 
Onset 
Bulbar 
Onset 
Trunk/Global 
Onset 
Chi-Square Test 
Pre-Imputation  
P Value  
F-Test Post-
Imputation  
P Value 
Race/Ethnicity    p = .51  p = .51  
White .74 .20 .06     
Non-White .71 .23 .05     
Gender    p < .001 *** p < .001 *** 
Men .75 .18 .07     
Women .71 .25 .04     
Education    p = .01 ** p = .01 ** 
High School or Less .71 .22 .07     
Tech/Trade/Some College  .74 .19 .07     
College Degree or More  .74 .21 .05     
Veteran Status        
Civilian or Other .73 .21 .06 p < .001 *** p < .001 *** 
Veteran .77 .18 .05     
Occupational Risk 
Category 
   p = .05  * p = .06  
Low Risk .73 .20 .06     
High Risk .74 .21 .05     
Ever Smoked Cigarettes    p = .20  p = .20  
No .74 .20 .06     
Yes .73 .21 .05     
Ever Drank Alcohol     p = .03  * p = .04 * 
No .72 .23 .05     
Yes .74 .20 .06     
Marital Status    p = .07  p = .08  
Married or Cohabitating .74 .20 .06     
Never Married, Separated, 
Divorced, Widowed 
.72 .22 .07     
Age at Diagnosis    p < .001 *** p < .001 *** 
18-39 .95 .03 .01     
40-49 .79 .17 .04     
50-59 .78 .17 .05     
60-69 .69 .25 .06     
70-79 .66 .24 .10     
80+ .60 .34 .06     
 
*p < .05, **p < .01, ***p < .001 
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Table 2.3. Model 4: Multinomial Logistic Regression Predicting Reporting of Onset Location, Risk 
Factors, Social Position, Marital Status, and Age at Diagnosis, Relative Risk Ratios (N=9789) 
 
Base Category: Limb 
 Bulbar Global 
 Relative 
Risk Ratio 
Confidence 
 Interval 
Relative 
Risk Ratio 
Confidence Interval 
Racial/Ethnic Minority 1.29 (.96, 1.73) .93 (.54, 1.60) 
Women 1.43 *** (1.28, 1.61) .41 *** (.33, .51) 
Education (ref= Tech, Trade, or Some 
College) 
    
High School or Less 1.09 (.92, 1.30) 1.02 (.77, 1.37) 
College or More 1.14 (1.00, 1.30) .72 ** (.57, .90) 
Civilian 1.25 *** (1.09, 1.44) 2.19 *** (1.73, 2.79) 
Low Occupational Risk .93 (.79, 1.08) 1.46 ** (1.10, 1.93) 
Ever Smoked Cigarettes (ref=Never) 1.02 (.91, 1.13) .78 * (.65, .95) 
Ever Drank Alcohol (ref=Never) .94 (.82, 1.08) 1.14 (.89, 1.50) 
Single/Separated/Divorced 1.01 (.89, 1.16) 1.47 *** (1.18, 1.84) 
Age at Diagnosis (ref=50-59)     
18-39 .15 *** (.09, .25) .22 *** (.10, .50) 
40-49 .98 (.83, 1.18) .71 * (.52, .97) 
60-69 1.67 *** (1.48, 1.91) 1.34 ** (1.07, 1.67) 
70-79 1.77 *** (1.50, 2.09) 2.79 *** (2.17, 3.59) 
80+ 2.72 *** (1.84, 4.00) 1.87 (.88, 4.00) 
Constant .15 *** (.11, .20) .03 *** (.02, .05) 
 
*p < .05, **p < .01, ***p < .001 
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CHAPTER THREE: DO SOCIAL FACTORS SHAPE THE TIME FROM ALS 
SYMPTOMS TO DIAGNOSIS? 
Introduction 
 
Sociologists are uniquely positioned to translate how social factors influence 
symptoms of disease progression and to inform biomedical researchers of the potential 
perils of taking social factors for granted in biomedical research. Further, there is a need 
for sociologists to understand how well existing theories, including fundamental cause 
theory, social determinants of health, and life course theory, describe the social factors 
involved in the experience of ALS. Finally, in response to Timmermans and Haas’ (2008) 
call for a sociology of disease, sociologists need to understand how well existing theories 
in the sociology of health and illness fit the experience of disease, especially one as rare 
as ALS.  
Therefore, this paper addresses the question: How does social position shape the 
time between early symptoms of ALS and diagnosis? I posit that differences in the time 
between symptoms and diagnosis for people with ALS may in part be due to differences 
in social position and position in the life course. Developing a better understanding of 
how social position can potentially reveal patterns in the time between reported symptom 
development and diagnosis may help to understand how social forces shape the 
variability of ALS symptoms among people with ALS.  
Guided by fundamental cause theory, I expect that those in less advantaged social 
positions (e.g. minorities, women, lower levels of education) will report more time 
between the development of ALS symptoms than their more advantaged peers. Guided 
by life course theory, I expect that older adults will report less time between the 
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development of symptoms and diagnosis than younger adults. Overall, I expect that the 
development of most of the early symptoms of ALS will be reported as happening before 
diagnosis by participants in the ALS registry, indicating the disease must progress to later 
stages in order to be noticed and diagnosed.  
Social Position and the Time Between ALS Symptoms and Diagnosis 
 
The order of appearance of ALS symptoms and the rate of progression are highly 
variable (Havercamp et al., 1995; Voustianiouk et al., 2008). Given that many symptoms 
of ALS develop prior to diagnosis, a delay in diagnosis may give the appearance of 
shorter survival times, as well as limit access to medications during the time when they 
would be most beneficial (Househam and Swash, 2000).  
In order to assess disease progression, ALS progression is typically measured 
using the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised Scale (ALSFR-
R) (Cedarbaum et al., 1999) or the Appel Rating Scale (Appel et al., 1987). Both scales 
monitor the progression of impairment in people with ALS from the time of diagnosis, 
including strength and function of the muscles, speech and swallowing function, as well 
as respiratory function and ventilator support. The ALSFR-R and Appel Rating Scale are 
used as predictors of progression to the terminal stage of ALS (Appel et al., 1987; 
Cedarbaum et al., 1999).  
Given that many of the early symptoms of ALS develop long before diagnosis, 
progression estimates may be influenced by the mechanisms which drive variability in 
symptom development. The potential for ALSFR-R scores to be influenced by these 
unknown mechanisms is concerning—ALSFR-R scores are used extensively in as part of 
the qualification requirements for clinical trials testing new ALS treatments—and a poor 
47 
 
   
 
initial ALSFR-R score may preventing enrollment in clinical trials (Mitchell et al., 2010; 
Rothstein, 2017; Jaiswal, 2019). 
The variability of the earliest symptoms can lead to incorrect diagnoses and 
unnecessary medical procedures, culminating in a delayed diagnosis and preventing 
access to medications when they are most effective (Belsh and Schiffman, 1996; 
Srinivasan et al., 2006). For example, two pharmaceutical drugs are thought to slow ALS 
progression - Riluzole and Edaravone; however, these medications slow progression only 
in certain subgroups of people in the initial stages of ALS (Rothstein, 2017; Jaiswal, 
2019). Without a better understanding of symptom development and progression of ALS, 
many people with ALS (pALS) may miss the window where these medications are most 
effective.  
Fundamental cause theory may be useful in understanding why there is variability 
in ALS symptom development and the timing of diagnosis. Fundamental cause theory 
posits that social factors, such as the stratification of people by social position, are 
underlying causes of health disparities leading to worse health outcomes in the form of 
disease development (Link & Phelan, 1995). ALS itself may be due in large part to 
biological factors interacting with the social, however, the discovery and treatment of the 
disease itself may be influenced by fundamental causes (e.g. the ability to react to the 
disease). 
For example, race/ethnicity, as well as socioeconomic status (SES), have been 
shown to influence both health care access and utilization for those in less advantaged 
positions (Adler et al., 1994). pALS in lower SES positions may disregard symptoms as a 
consequence of their work and of getting older. Additionally, there are many potential 
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penalties for lower SES groups needing to attend to health needs (e.g. lost wages, 
employment termination) which may delay seeing a physician until the symptoms can no 
longer be ignored, leading to longer times between symptom development and diagnosis.  
Similarly, veterans seem to have symptoms develop more quickly than civilians, 
yet this association may be spurious and simply reflect socioeconomic status or education 
levels related to military enlistment (Muddasir Qureshi et al., 2006; Kleykamp, 2006). 
Therefore, fundamental cause theory and the social determinants of health may help to 
explain the variability of time between symptom development and diagnosis. 
Life Course Theory and the Time Between ALS Symptoms and Diagnosis 
 
Position in the life course, including age and marital status, may influence when 
symptoms become salient for an individual as an indicator of a potential disease process. 
Having a partner or spouse in the home may act as another set of eyes, allowing for 
earlier detection of ALS symptoms (Waite and Gallagher, 2001). Furthermore, younger 
adults who are more physically active may react to some symptoms as unusual (e.g. 
difficulty running), whereas an older adult may dismiss these symptoms as a sign of 
aging. Therefore, it is reasonable to suspect that these social factors may influence the 
time between symptom onset and diagnosis via how the person perceives symptoms as 
they develop. 
The Current Study 
 
The role of fundamental causes (e.g. social stratification) in the progression of 
ALS symptoms is an area in need of further exploration. Existing research tests potential 
social factors such as gender and age with a biomedical lens, while disregarding the 
potential effects of  racial and class (i.e. education) stratification (Del Agulia et al., 2003; 
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Paillisse et al., 2005; Watanabe et al., 2014; Pupillo et al., 2014). The emphasis on social 
inequality in fundamental cause theory and the lack of prior emphasis on social status in 
prior research on ALS leads me to ask: How does social position shape the length of time 
between awareness of ALS symptoms an ALS diagnosis? Using the framework provided 
by fundamental cause theory, I posit that social position will shape the time between 
symptom development and diagnosis. In addition, I ask: Do fundamental cause theory, 
social determinants, and life course theory fit in the case of a rare disease? These 
sociological theories suggest the importance of examining if social stratification (e.g. 
fundamental cause theory) and age (e.g. life course theory) are associated with the time 
between the development of the symptoms of ALS and diagnosis of ALS. At this time, it 
is unclear if people with more or less privilege will have a shorter period of time between 
the development of ALS symptoms and a diagnosis of ALS. Potentially, people with 
more privilege could have more knowledge of symptoms as an issue that can be 
addressed, as well as more resources to access medical care that can lead to diagnosis. 
The access to resources for people with more privilege suggests that the time between 
symptoms and diagnosis may be shorter. People with fewer resources, however, tend to 
have more physical jobs and the physical impairments that often signal ALS (e.g. 
weakness and cramping) may be more salient when the symptoms begin to affect their 
job performance. The result of a reduction in productivity may lead to people with less 
privilege to seek medical care more quickly after recognizing symptoms. Thus, 
fundamental cause theory highlights the importance of examining how social positions 
are likely to matter for time between symptom appearance and diagnosis. Finally, I posit 
that these broader theories will be useful in a sociology of disease framework to 
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understand how social position and life course position shape the experience ALS. To 
explore the potential connection between social position, position in the life course, and 
the development of symptoms, I use data from the National ALS Registry.  
Data and Methods 
Data 
 The National ALS Registry, created in October 2010, is a voluntary web-based 
registry for people who have been diagnosed with ALS. The registry collects data on 
demographic characteristics, risk factors, current and lifetime occupational and military 
history, family history of ALS, clinical data such as phenotype, and outcome data. Due to 
the potential physical, mental, and emotional limitations of pALS, the risk factor survey 
utilizes smaller modules to facilitate completion (Bryan et al., 2016). The clinical 
symptoms survey module was created in partnership with the ALS Research Group to 
examine physical symptoms participants developed before and after a diagnosis of ALS 
(Raymond et al., 2019). The survey contains fifty-four questions on topics including the 
time between symptom onset and diagnosis. The clinical symptom module launched in 
December 2013 to new enrollees and previous enrollees were prompted to return to the 
web portal to complete this survey. Therefore, this analysis covers from 19 October 2010 
to 31 December 2016. The number of respondents who reported a symptom varies by 
category and are reported in Table 3.1.  
Measures 
 
 Dependent variable: Time between symptom development and diagnosis. 
Five symptoms, weakness, cramping, trouble swallowing, twitching (fasciculations), and 
trouble with bowels, were available in the dataset provided from the National ALS 
Registry. To calculate the time between symptom and diagnosis, only those who reported 
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developing the symptom were included in the analysis. Because the data is cross-
sectional it is not possible to do time-to-event analysis. I measure the time between 
symptom development and diagnosis in years by subtracting the reported date of 
symptom development from the date the respondent was diagnosed with ALS. Negative 
values represent symptom development before diagnosis and positive values represent 
symptom development after diagnosis. 
 Independent variables. The independent variables include: (1) social position 
(race/ethnicity, gender, education), (2) age at diagnosis, (3) onset location, (4) veteran 
status, (5) proximal risk factors, and (6) social resource of marriage, which are detailed in 
chapter 2. In addition, the analysis includes insurance coverage and multidisciplinary 
clinic usage. Insurance coverage provides a measure for access to medical care, which 
may influence the ability to receive a diagnosis in a timely manner. In the case of the 
National ALS Registry, all participants reported some form of insurance, which is not 
unusual as ALS qualifies pALS for Medicare, Veterans Administration coverage, and/or 
Medicaid. Insurance is a count variable of one (reference), two (=1), or three (=2) types 
of insurance policies. Multidisciplinary ALS clinic (MDC) attendance is a resource for 
people with ALS in recognizing symptoms. I categorize MDC use as never attended 
(reference), attended but discontinued (=1), and currently attending (=2).  
Analysis 
 
 Multiple Imputation using Chained Equations was used to impute missing data 
(Enders, 2003). Table 3.1 reports the post imputation means and proportions in each 
category. I then perform bivariate tests of association to explore potential bivariate 
patterns of the time between the development of a symptom and diagnosis and each of 
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the dependent variables. I use multivariable ordinary least squares regression to examine 
the time between the development of each symptom and diagnosis. Each regression is 
created in steps; (1) social position, (2) social position and age at diagnosis, (3) social 
position, age at diagnosis, onset location (to control for disease variability), veteran 
status, and proximate risk factors (to control for exposures and the potential relationship 
with social position), and (4) social position, age at diagnosis, onset location, veteran 
status, proximate risk factors, and social resources. Reference categories were chosen in 
order for the constant to represent the characteristics of those most commonly diagnosed 
with ALS; White males in between the ages of 50-59 with at least some college 
education, who are veterans and married, have healthy health behaviors, and report limb 
onset of ALS symptoms. The discussion of the results focuses primarily on the final 
models.  
Results 
Demographics 
 
Table 3.1 reports the proportion of people with different characteristics overall, 
the proportion in each category with a symptom, and the mean time between each 
symptom and ALS diagnosis for each category of each variable. All 9,787 members of 
the registry reported weakness, with a mean time between symptom development and 
diagnosis of 1.29 years before diagnosis.  Fewer (N = 5,675) respondents reported 
cramping, with a mean time between symptom development and diagnosis of 2.07 years 
after diagnosis. Trouble swallowing was reported 2,170 respondents, with a mean time 
between symptom development and diagnosis of .62 years before diagnosis. Twitching, 
also known as fasciculations, was reported by 5,410 members of the sample with a mean 
time between symptom and diagnosis of 1.32 years before diagnosis. The final symptom, 
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trouble with bowels, was reported by 1138 respondents, with a mean time between 
symptom and diagnosis of 2.11 years before diagnosis. Four symptoms, weakness, 
trouble swallowing, twitching, and trouble with bowels are, on average, reported as 
developing before diagnosis and cramping as developing after diagnosis. The results 
potentially indicate that ALS must progress further than the earliest symptom in order to 
be noticed and diagnosed. 
The registry sample is mostly White (97%) and nearly 60% male. The sample is 
also more educated than the US population as a whole with over 60% of the respondents 
having at least a bachelor’s degree. Veterans make up nearly 24% of the sample. Over 
60% of the sample report working in a low risk occupation, while just over 45% report a 
history of smoking and 81% report a history of drinking alcohol. The majority of the 
sample is married or cohabitating (82%). Most of the respondents are between the ages of 
50-59 and 60-69 (29.79% and 35.99 % respectively). The individual demographics for 
each symptom sample are described in Table 3.1 as not all pALS reported each symptom 
and the sample sizes vary. 
Bivariate Analysis 
 
In addition to the descriptive statistics described above, Table 3.1 also displays 
the F tests results used to determine if there were associations between the dependent 
variable of time between symptoms and diagnosis and the independent variables (Cohen 
et al., 2014). Results are reported for each symptom. Overall, there is evidence that the 
time between symptom development and diagnosis is shaped by social position and 
position in the life course, although the same patterns do not exist in the case of every 
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symptom, suggesting that a combination of fundamental cause and life course theory are 
fruitful for understanding social position patterns of the experience of ALS.  
Weakness. The only social position indicator associated with the time between 
weakness and diagnosis is education.  pALS with a high school or less education reported 
less time between weakness and diagnosis than those with at least a tech degree or some. 
pALS who were older at diagnosis report more time between weakness and diagnosis. 
pALS with bulbar onset report less time between recognizing weakness and diagnosis, as 
do civilians. pALS who are single report less time between developing weakness and 
their diagnosis date. 
 Cramping. Women report less time between cramping and the date of diagnosis. 
Civilians also report less time between the development of cramping and diagnosis. 
pALS who have a history of smoking report more time between the development of 
cramping and diagnosis, as do those who are single.   
 Trouble Swallowing. Differences in reporting trouble swallowing do seem to be 
related to more proximal risks and resources. pALS who are in the higher occupational 
risk category reported more time between trouble swallowing and diagnosis than those in 
the low occupational risk category, and those with a history of drinking reported less time 
between the development of swallowing issues and diagnosis. pALS with three types of 
insurance reported less time between trouble swallowing and diagnosis, and those who no 
longer attend an MDC reported trouble with swallowing, on average, after diagnosis, 
compared to reported developing trouble swallowing prior to diagnosis.    
 Twitching. pALS with higher education and those who are older have longer 
times between the development of twitching and diagnosis. pALS with bulbar onset 
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reported less time between twitching and diagnosis. Veterans, those in low risk 
occupations, as well as those who have a history of smoking or drinking reported 
developing twitching longer before diagnosis. 
 Trouble with Bowels. The time between reporting developing trouble with 
bowels and diagnosis is associated with the social position variables race/ethnicity, 
gender, and education. Racial/ethnic minority pALS report trouble with bowels longer 
before diagnosis, as do women. pALS with the highest levels of education report more 
time between trouble with bowels and diagnosis. In addition to social position indicators, 
several other characteristics and resources are associated with the difference between 
trouble with bowels and diagnosis. Those who are older, have limb onset, are civilians, 
have high occupational risk, and no history of smoking nor alcohol use have longer times 
between trouble with bowels and diagnosis. pALS who are currently attending an MDC 
also had more time between developing bowel trouble and diagnosis.  
Multivariate OLS Regression of Time between Symptoms and the Date of Diagnosis 
 
 Time between weakness and diagnosis. Table 3.2 reports the results of the 
regression analysis for time between weakness and diagnosis. The constant for the 
regression models represent the characteristics of those with the value “zero” on all of the 
variables – coded so that the reference categories represent those most commonly 
diagnosed with ALS (i.e. exemplar pALS); White males in between the ages of 50-59 
with at least some college education, who are veterans and married, have healthy health 
behaviors, and report limb onset of ALS symptoms. Measured by the constant, the 
average time between developing weakness and diagnosis is just over a year (b = -1.13, p 
< .001) for exemplar pALS. In what might appear to be contrary to fundamental cause 
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theory and the social determinants of health, those with a high school education or less 
report less time between the development of weakness and the diagnosis of ALS than 
those with at least a tech or trade degree or some college, meaning they may be more 
likely to think of weakness as related to a disease, rather than as a sign of aging or work-
related (b = .31, p < .001; therefore for this group the time is -1.13 + .31 = -.82). It is also 
possible that due to limited resources, those with less education may be concerned about 
the costs of seeing a doctor (e.g. losing a physical job or taking time off of work) and 
therefore they may wait until the symptoms of ALS have advanced to a point they can no 
longer be ignored, thus resulting in a quicker time to diagnosis. There were no differences 
between pALS with a college education or more and those with a tech or trade degree or 
some college. Age at diagnosis further shapes when weakness is experienced, with pALS 
who are 60-69 (b = -.46, p < .001), 70-79 (b = -.32, p < .001), and 80+ (b = -.96, p < 
.001), report more time between developing weakness and diagnosis than those at 
younger ages, with results consistent with life course theory. pALS with bulbar onset 
report less time between the onset of weakness and diagnosis than other onset types, 
perhaps due to the nature of bulbar onset having more involvement of the muscles in the 
tongue, mouth, and neck (b = .53, p < .001). In contrast to the idea that resources should 
shorten the time between symptoms and diagnosis, those pALS who report having two 
types of insurance report more time between weakness and diagnosis than those with one 
type of insurance (b = -.14, p = .05), and consistent with the work of family sociologists 
(Waite and Gallagher, 2001) pALS who are unmarried also report more time between the 
onset of weakness and diagnosis than those who are married (b = -.30, p < .001). Both 
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marriage and insurance could be signs of social resources, allowing for another person or 
healthcare provider to notice weakness earlier than the pALS themselves. 
 Time between cramping and diagnosis. Gender shapes the experience of 
cramping as an ALS symptom. The constant value shows that the exemplar pALS report 
developing cramping about two years prior to diagnosis on average (b = -2.29, p < .001). 
Women report less time between developing cramping and diagnosis (b = .33 p < .05 or -
2.29+.33 or -1.96), compared to men. The time between experiencing cramping and 
diagnosis may be due to the differences in onset type, as bulbar onset develops more 
often in women (Table 3.3). In addition, those with the lowest level of education report 
less time between the development of cramping and diagnosis than those with at least a 
tech or trade degree or some college, similar to the pattern for weakness (b = .43, p < 
.05). Further, there is less time between the development of cramping and diagnosis for 
pALS who are younger (the ages of 18 and 39 (b = 1.19, p < .001), and more time 
between cramping and diagnosis among those who are older (60-69 (b = -.35, p < .01)) 
and over 80 years old (b = -6.32, p < .001) compared to pALS who are between the ages 
of 50 and 59. pALS who report bulbar onset also report less time between the  
development of  cramping and diagnosis. The findings for bulbar onset reflect the 
findings for women, the group who are most often diagnosed with bulbar onset (b = .90, 
p < .001). pALS who previously attended a multidisciplinary ALS clinic (MDC) but have 
discontinued attendance report more time between the onset of cramping symptoms and 
diagnosis (b = -1.29, p < .001). Finally, pALS who are unmarried have, on average, more 
time between the onset of cramping and diagnosis (b = -.37, p < .01). 
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 Time between trouble swallowing and diagnosis. Table 3.4 reports the results 
of the regression analysis of the time between trouble swallowing and diagnosis. 
Exemplar pALS report developing trouble swallowing one year before diagnosis on 
average (b = -1,00 p < .01). In the final model, none of the social position variables are 
associated with the time between the trouble swallowing symptom onset and diagnosis, 
however, prior to the addition of onset location and proximate risk factors into the model 
(Model 2), women reported less time between developing trouble swallowing and 
diagnosis than men (b = .27, p < .05). Women are more likely to have bulbar onset of 
ALS, and those with bulbar onset report less time between the development of trouble 
swallowing and diagnosis (b = .37, p < .05), thus adding the indicator for bulbar onset 
may have explained the association between the onset of trouble swallowing and the 
diagnosis of ALS. Age shapes the time between the experience of trouble swallowing 
symptoms and diagnosis, with those who are between the ages of 40-49 (b = -.64, p < 
.01), 60-69 (b = -1.23, p < .001), 70-79 (b = -1.09, p < .001), and over 80 (b = -1.61, p < 
.01) reporting more time between swallowing symptoms and diagnosis than those who 
are ages 50-59. Civilians report less time between the development of trouble swallowing 
and diagnosis than veterans (b = .37, p < .05), consistent with the findings in chapter 2 
that civilians are more likely to develop bulbar onset ALS.  
Proximate risk factors are related to symptoms of trouble swallowing as well, 
with those who report lower occupational risk experiencing less time between 
swallowing symptoms and diagnosis than those with high occupational risk (b = .67, p < 
.01), and those with a history of alcohol use (b = -56, p < .01) reporting more time 
between developing swallowing symptoms and diagnosis. pALS with two forms of health 
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insurance (b = .51, p < .01) and three forms of health insurance (b = 1.22, p < .001) 
report less time between developing trouble swallowing and diagnosis, and those with 
three forms of insurance reporting swallowing symptoms after diagnosis. Finally, 
resources in the form of MDC attendance, also shape the time when pALS notice trouble 
swallowing. pALS who do not attend an MDC clinic (b = .62, p < .001) and have 
attended but since discontinued MDC use (b = .96, p < .01) report less time between the  
development of trouble swallowing and diagnosis.  
 Time between twitching and diagnosis. Table 3.5 reports the results of the 
regression models for the time between twitching symptoms and diagnosis. The constant 
for this model shows the exemplar pALS report developing twitching at the same time as 
diagnosis  (b = .31, p >.05). The only social position variable that is associated with the 
time between twitching and diagnosis is education, with those with a high school 
education or less reporting less time between developing twitching and diagnosis, 
following the patterns of weakness and cramping (b = .53, p < .01). pALS with bulbar 
onset of ALS report less time between twitching and diagnosis, following the patterns of 
other symptoms as well (b = .69, p < .001). For both woman and pALS with bulbar onset, 
twitching is reported as developing after diagnosis. Civilians report developing twitching 
earlier than veterans (b = -.28, p < .05). pALS who have a history of smoking report more 
time between developing twitching and diagnosis  (b = -.26, p < .01). Resources, such as 
insurance coverage, MDC attendance, and marriage are also associated with the time 
between cramping and diagnosis. pALS with two forms of insurance (b = -.70 p < .001) 
and three types of insurance (b = -1.40, p < .001) report recognizing twitching longer 
before diagnosis than those with one form of insurance. pALS who do not attend an 
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MDC clinic (b = -.30, p < .01) and who are not married (b = -.25, p < .05) report more 
time between the development of twitching and diagnosis than those who do attend an 
MDC and who are married.  
 Time between trouble with bowels and diagnosis. For the constant value 
representing the exemplar pALS, trouble with bowels is reported as developing at the 
same time as diagnosis (b = .44, p >.05) on average. Similar to the time between 
swallowing and diagnosis, of the social position indicators, only gender (not 
race/ethnicity nor education)  is associated with the time between trouble with bowels 
and diagnosis (Table 3.6). Women report more time between having trouble with bowels 
and diagnosis than men (b = -1.50, p < .001). This association could reflect that women 
are more willing to seek medical help, or the association could be spurious because 
women are also more likely to have bulbar onset, and bulbar onset has a strong 
association with trouble with bowels.  Age does shape the experience of trouble with 
bowels, with those who are in between the ages of 40 and 49 reporting less time between 
developing trouble with bowels and diagnosis (b = 2.16, p < .001) with bowel symptoms 
reported as developed post diagnosis by 1.7 years. pALS who are 60-69 (b = -1.22, p < 
.01), 70-79 (b = -1.61, p < .01), and over the age of 80 (b = -3.18, p < .05) report more 
time between bowel issues and diagnosis, with bowel issues developing prior to 
diagnosis. Age may play a role here due to the salience of these symptoms for older 
adults but may often be disregarded as a potential consequence of aging.  
 Proximate risk factors also influence time to trouble with bowels. pALS who 
report low occupational risk (b = 1.39, p < .01) and who report a history of smoking (b = 
1.95, p < .01) experience more time between bowel trouble and diagnosis, with bowl 
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trouble developing post diagnosis, while those who report alcohol use report more time 
between the development of bowel issues and diagnosis (b = -2.23, p < .001). Social 
resources also shape the experience of  bowel issues. pALS who do not use an MDC 
report more time between bowel issues and diagnosis than those who do (b = -1.22, p < 
.001). Unmarried pALS report more time between the development of bowel trouble and 
diagnosis than married pALS, with trouble with being noticed post diagnosis (b = 1.01, p 
< .01; solving the equation indicates -.44 + 1.01 = .59), or about half a year after 
diagnosis. 
Discussion 
 
Four of the symptoms included in the analysis presented here—weakness, trouble 
swallowing, twitching, and trouble with bowels—are on average reported by pALS in the 
National ALS Registry as appearing prior to diagnosis. The appearance of faster 
progression for some pALS may be, in part, due to the length of time between when 
pALS notice and/or experience symptoms and the diagnosis of ALS. Therefore, 
understanding how social position shapes when symptoms first occur and are noticed is 
important to understanding the experience of progression of ALS. Time is of the essence 
when it comes to a diagnosis of ALS, as the median survival time from diagnosis is 
between 20 and 48 months (Chiò et al., 2009) 
Whilst the analysis presented here includes proximate risk factors which are often 
the focus of ALS progression research, proximate risks are not the sole factor in the 
timing of the development of symptoms. Education, gender, and age all have a role over 
and above the proximate risks included in the models, either through their relationship 
62 
 
   
 
with the biological processes underlying ALS or through the perception and reporting of 
symptoms.  
Education level shapes when symptoms occur, with pALS who have a high 
school or less education reporting the development of weakness, cramping, and twitching 
as developing closer to the date of diagnosis than those with higher levels of education. 
Weakness and twitching are often the very earliest signs of ALS, therefore the reporting 
by people with higher levels of education of these symptoms earlier than their peers with 
lower education is potentially a concern as pALS with lower levels of education may be 
missing earlier signs of weakness. Reporting of these symptoms closer to the date of 
diagnosis for those pALS with lower levels of education may be due to the speed of the 
biological development of the disease, however, it may be due to the type of work people 
with lower levels of education engage in, as well as access and utilization of healthcare 
services. As one example, people who work in highly physical jobs may think early 
weakness is due to aging, a higher than normal workload, or being overly tired. Earliest 
experiences of twitching may be disregarded as a consequence of overtired and 
overworked muscles. Therefore, these symptoms may be dismissed as normal 
consequences of daily activities, and the date reported to the registry may be when the 
symptoms became salient as something outside of the norm. In addition, fundamental 
cause theory often posits education (as well as its connection to socioeconomic status) as 
a cause of health disparities, with access to and utilization of health care being a part of 
these inequalities. pALS with lower education levels are more likely to not have been 
able to access medical care due to cost (e.g. copays, lost time at work) to ask questions 
about these symptoms until they become too hard to ignore, therefore delaying diagnosis. 
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Women report cramping and trouble swallowing later in the disease course and 
trouble with bowels earlier in the disease course, perhaps due to the higher prevalence of 
bulbar onset in this population. pALS often do not recognize bulbar dysfunction if the 
rate of progression is slow, therefore pALS unknowingly adapt to swallowing issues until 
the symptoms become hard to ignore (Onesti et al., 2017). The delay in recognizing 
swallowing difficulties may lead to a delay in diagnosis (Onesti et al., 2017). Moreover, 
the gradual adaptation to difficulty swallowing may result in changes in the diet, leading 
to constipation and other difficulties with the bowels. Therefore, as noted in chapter two, 
it is important to better understand why women disproportionately develop bulbar 
symptoms. 
Age at diagnosis also has some bearing on when pALS report symptoms 
occurring. Older pALS report symptoms occurring earlier in the disease course than 
younger pALS. As noted in chapter two, one reason for this difference might be that ALS 
onset is influenced by the aging of the central nervous system, and extant research also 
implicates aging of the central nervous system in symptom development and the rate of 
disease progression. The timing of diagnosis in the life course, however, would also be 
related to the perception of symptoms as outside the norm. For pALS who are older, as 
well as their spouses, caregivers, and physicians, early symptoms of ALS may be 
considered as signs of aging and not as potential signs of a fatal disease.  
Social and material resources, including marriage, insurance coverage, and MDC 
use, also shape the experience of symptoms of ALS. Compared to those who are married, 
unmarried pALS report earlier development of twitching and later development of 
weakness. Changes in strength or ability are something that is potentially noticed by a 
64 
 
   
 
partner or spouse as unusual, therefore may be recognized by married pALS earlier. 
Twitching, on the other hand, is often visible throughout the muscles, and for unmarried 
pALS may be one of the first signs that something is amiss that cannot be reasonably 
explained away. Moreover, pALS who are single may attempt to solve issues on their 
own for a longer period of time before realizing that symptoms are not due to a lack of 
self-care, whereas the inability to solve a health issue with self-care may be pointed out 
earlier by a partner or spouse leading to earlier help-seeking behavior.  
Insurance and MDC use are difficult to parse out, however, as these may change 
after diagnosis. It may be that an increase in the number of insurances policies may mean 
that the pALS is further into disease progression, as Medicare coverage is not available 
until five months post diagnosis and the determination of permanent disability. Insurance 
coverage may also be an indicator of socioeconomic status. Reporting discontinuation of 
using an MDC may be due to progression of the disease, as many pALS find it is difficult 
to travel the distance to these providers once they are no longer able to move (Radunovic 
et al, 2007; Hodgen et al., 2012; Obermann & Lyon, 2015; Stephens et al., 2016; Horton 
et al., 2018). In addition, never using or discontinuing MDCs may be an indicator of 
socioeconomic status or geographical location, as many MDCs are located in highly 
populated cities rather than rural areas (Radunovic et al, 2007; Hodgen et al., 2012; 
Obermann & Lyon, 2015; Stephens et al., 2016; Horton et al., 2018).  
There are several limitations to the research presented here. Designed for 
biomedical and epidemiological research, the National ALS Registry has limited 
measures of social status and social experiences. In addition, the registry limits access to 
survey data due to reidentification risks, therefore limiting the analysis. For example, it 
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would be ideal to have measures of parental status to assess if the demands of parenting 
make some symptoms more salient earlier in disease progression. Further, not all of the 
registry participants reported symptom development, either due to slowly progressing 
ALS, or perhaps due to not recognizing the symptom as described in the module. In 
addition, while the sample size overall is robust, smaller numbers of specific populations 
such as non-white patients, impedes intersectional analysis. Being able to assess the 
combined effects of gender, race/ethnicity and education is often important for 
understanding health (Warner and Brown, 2011) to better understand the relationship of 
social position and ALS. Doing intersectional analysis could help to parse out if social 
location (e.g. the intersection of several social positions) explains the association between 
social position and ALS symptoms.  
The ALS Registry is reliant on patient self-reporting data and may be subject to 
recall bias and bias due to self-identification. In addition, patients can complete the 
registry survey only online, which may limit access and cause the registry to reflect a 
younger, mostly white, and more educated patient sample. The registry sample provided 
by the CDC is less racially diverse than the overall registry which includes Medicare and 
Veteran’s Association claims data. There are several potential reasons for this, including 
access to computers that are required for self-registration; reduced awareness of the 
registry; and reduced participation in areas with substantial nonwhite populations (Kaye 
et al., 2018). Further, the registry is a large non-random sample that is opt-in and 
therefore results are not generalizable to the ALS population as a whole. Even with these 
limitations, the National ALS Registry is the most comprehensive, geographically diverse 
sample of people diagnosed with ALS. 
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Fundamental cause theory provides important guidance for exploring the social 
structural dimensions of ALS symptom development and diagnosis, yet the findings 
suggest limited support for the theory, as those with limited resources often have less 
time between symptom onset and diagnosis. In the case of ALS, however, it may be that 
a shorter time between symptoms and diagnosis is not evidence of greater resources, but 
of less opportunity to acknowledge symptoms as something out of the ordinary and less 
opportunity to seek medical care for what might seem to be a minor complaint. In 
addition, using fundamental cause theory in the design of the research presented here 
further suggests the need for a sociology of disease, as well as an adjustment in 
sociologists’ conceptualization of existing sociological theories to use them within this 
framework. Future research on ALS should consider the implications of social position in 
the development of symptoms, especially in the early in the diagnostic process. For 
example, including education level in the design of future research projects would help to 
distinguish if education level is causally related to symptom development and 
progression, or if it influences the perception of symptoms. 
Many of the earliest symptoms of ALS develop, on average, more than a year 
prior to diagnosis. Therefore, social position may influence ALSFR-R progression 
estimates. This is of particular concern, as ALSFR-R scores are used extensively as part 
of the evaluation process for participation in clinical trials. If trial administrators assume 
that time from symptom development to diagnosis reflects only the disease and not social 
position factors, then inclusion criteria will be inconsistently applied. There is the 
potential for symptoms to progress to a point prior to diagnosis that pALS are excluded 
from participating in these trials. As noted in chapter 2, trial participants are often young, 
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white, male, and mostly with limb onset (Chiò et al., 2011; Mitsumoto et al., 2014). 
Ensuring the inclusion of those who occupy different social positions, even with lower 
ALSFR-R scores, may help to bring more effective treatments that work for a broader 
spectrum of those experiencing ALS. 
Symptom development and progression can influence the effectiveness of 
approved treatments. The medications Riluzole and Edaravone slow progression only in 
certain subgroups of people with initial stages of ALS (Rothstein, 2017; Jaiswal, 2019). 
Social position shapes when symptoms develop and are reported, which may delay 
diagnosis and prevent access to these medications when they are most effective. In 
addition, the results presented in chapter two and here indicate that social position should 
be included in future analysis of ALS subgroups in order to better understand who 
benefits from new treatments and technologies.  
Similarly, it is important to understand how social position interacts with 
biological processes, as noted in the previous chapter. For example, women are more 
likely to develop bulbar onset ALS, which changes the nature of symptoms and the order 
in which they develop, as well as when symptoms become salient to the pALS. Being 
able to understand why women are more likely to develop bulbar onset ALS and the 
behaviors they engage in when symptoms begin to develop, may improve diagnosis and 
treatment for women with bulbar onset ALS. Moreover, these connections may help to 
clarify if there is a biological (e.g. hormones), a social exposure (e.g. stress), or a 
combination of the two implicated in the onset location and development of symptoms 
for women. 
Conclusion 
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 The analyses of the timing of symptoms relative to diagnosis contributes to the 
knowledge of both sociology of disease and research, specifically on ALS. First, for 
several symptoms, the timing of symptoms relative to diagnosis is shaped by social 
position, as suggested by fundamental cause theory and the social determinants of health. 
These theories guided the exploration of social position and disease experience, but the 
patterns for ALS are not all consistent with predictions by the theories. In the case of a 
specific disease, it may be that the ways in which sociologists understand fundamental 
cause theory and the social determinants of health need to be adjusted in order to be used 
in a sociology of disease (Pescosolido, 2006; Link, 2008; Timmermans and Haas, 2008). 
In the case of ALS, people with limited resources often have less time between symptom 
onset and diagnosis. Rather than an indicator of greater access to resources, a diagnosis 
closer to the reported appearance of symptoms may be a sign of having less opportunity 
to acknowledge the signs of a disease that may at first seem to be a minor complaint 
related to people’s circumstances. The results from this work reaffirms the need for a 
sociology of disease, as dealing with a disease just prior to and after diagnosis is different 
from understanding how disease can be prevented altogether. Additionally, age, as an 
indicator of life course theory, shapes the experience of ALS symptoms. Future research 
should address if these differences are due to the perception and salience of symptom 
development, or if the differences may be due to the interaction of the biological and 
social aspects of ALS.
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Table 3.1 Descriptive Statistics and Bivariate Association Results for Time between the development of Symptoms and Diagnosis 
 Weakness n =  9787 Cramping n = 5675 Swallowing n = 2170 Twitching n = 5140 Bowels n = 1138 
 Sample 
Proportion 
P Value 
Mean 
(SD) 
Proportion Yes P Value 
Mean 
(SD) 
Proportion  
Yes 
P Value 
Mean 
(SD) 
Proportion Yes P Value 
Mean 
(SD) 
Proportion Yes P Value 
Mean (SD) 
Race/Ethnicity          * 
White (0) .97 -1.29 (.03) .58 -2.07 (.06) .22 -.62 (.25) .76 -1.33 (.05) .12 -.63 (.50) 
Racial/Ethnic Minority (1) .03 -1.39 (.12) .76 -1.99 (.23) .28 -.62 (.07) .55 -1.13 (.19) .21 -2.19 (.14) 
Gender    **      *** 
Male (0) .60 1.27 (.04) .60 -2.20 (.08) .20 -.73 (.07) .59 -1.36 (.07) .09 -1.22 (.17) 
Female (1) .40 1.32 (.04) .55 -1.85 (.07) .26 -.50 (.11) .50 -1.25 (.05) .16 -2.82 (.22) 
Education  ***      ***  *** 
High School or Less (0) .14 -1.04 (.11) .64 -1.95 (.21) .29 -.73 (.16) .61 -.72 (.19) .16 -1.57 (.30) 
Tech/Trade/Some College (1) .21 -1.31 (.04) .62 -2.13 (.11) .21 -.64 (.10) .53 -1.30 (.09) .14 -1.13 (.25) 
College Degree or More (2) .65 -1.34 (.03) .56 -2.08 (.06) .21 -.59 (.09) .55 -1.47 (.05) .10 -2.73 (.21) 
Age at Diagnosis  ***      ***  *** 
18-39 (0) .04 -1.18 (.07) .66 -.92 (.15) .11 .85 (.35) .67 -1.05 (.14) .06 .38 (.48) 
40-49 (1) .14 -1.19 (.07) .62 -1.65 (.13) .20 -.73 (.23) .62 -1.27 (.11) .07 .26 (.33) 
50-59 (2) .30 -1.04 (.07) .62 -1.92 (.11) .20 -.07 (.18) .59 -1.14 (.11) .19 -2.14 (.28) 
60-69 (3) .36 -1.50 (.04) .57 -2.30 (.09) .25 -.96 (.06) .50 -1.50 (.07) .12 -2.58 (.26) 
70-79 (4) .14 -1.37 (.06) .50 -2.37 (.16) .24 -.73 (.14) .52 -1.48 (.13) .17 -2.22 (.31) 
80+ (5) 
.01 -1.93 (.22) .36 -8.29 (.96) .44 -1.15 (.39) .26 -1.30 (.64) .18 
-4.02 
(1.37) 
Onset Location  **      **  * 
Limb .74 -1.38 (.03) .62 -2.17 (.06) .13 -.74 (.09) .58 -1.42 (.06) .13 -2.24 (.18) 
Bulbar .21 -.92 (.07) .40 -1.42 (.21) .53 -.58 (.10) .44 -.77 (.10) .09 -1.85 (.30) 
Trunk/Global .05 -1.53 (.11) .69 -2.35 (.21) .32 -.26 (.20) .62 -1.49 (.18 .06 .20 (.93) 
Veteran Status  **  ***    **  * 
Civilian or Other (0) .76 -1.25 (.03) .57 -1.93 (.07) .22 -.56 (.08) .54 -1.25 (.05) .11 -2.32 (.19) 
Veteran (1) .24 -1.43 (.04) .61 -2.51 (.12) .25 -.79 (.08) .59 -1.53 (.10) .14 -1.58 (.20) 
Occupational Risk Category      ***  **  ** 
Low Risk (0) .62 -1.31 (.03) .57 -2.16 (.09) .22 -.34 (.09) .53 -1.45 (.05) .11 -1.45 (.21) 
High Risk (1) .38 -1.26 (.06) .60 -1.93 (.15) .23 -1.08 (.13) .60 -1.13 (.10) .13 -3.05 (.38) 
Ever Smoked Cigarettes    ***    **  *** 
No .54 -1.27 (.04) .56 -1.88 (.08) .22 -.54 (.11) .54 -1.21 (.07) .10 -3.04 (.25) 
Yes .46 1.32 (.03) .60 -2.28 (.08) .23 -.71 (.07) .57 -1.44 (.06) .14 -1.30 (.15) 
Ever Drank Alcohol      ***  *  * 
No .19 -1.23 (.07) .55 -2.14 (.14) .28 -.57 (.17) .52 -1.07 (.10) .13 -1.40 (.32) 
Yes .81 -1.31 (.03) .59 -2.06 (.06) .21 -.18 (.15) .56 -1.37 (.05) .12 -2.29 (.16) 
Insurance  ***  ***    ***   
One .49 -1.16 (.04) .59 -1.79 (.10) .21 -.75 (.08) .54 -.92 (.08) .12 -2.62 (.34) 
Two .44 -1.42 (.04) .57 -2.32 (.09) .23 -.54 (.12) .56 -1.62 (.06) .12 -1.59 (.40) 
Three .07 -1.43 (.11) .62 -2.49 (.25) .25 -.35 (.20) .61 -2.15 .11 -1.51 (.65) 
Marital Status  ***  *  ***     
Married or Cohabitating (0) .82 -1.24 (.03) .58 -2.00 (.07) .21 -.62 (.08) .55 -1.29 (.06) .10 -2.28 (.18) 
Divorced, Single, Widowed .18 -1.52 (.05) .60 -2.39 (.13) .28 -.62 (.09) .57 -1.46 (.08) .19 -1.71 (.22) 
Attend Multidisciplinary 
Clinic  *    ***    *** 
Yes .25 -1.20 (.06) .60 -2.03 (.10) .26 -.34 (.16) .57 -1.43 (.09) .13 -3.34 (.27) 
Yes, but no longer attend .05 -1.18 (.14) .67 -3.49 (.37) .28 .19 (.24) .52 -.97 (.18) .13 -.62 (.64) 
No .70 -1.33 (.03) .57 -1.98 (.08) .20 -.83 (.07) .55 -1.30 (.06) .11 -1.73 (.18) 
Table 3.1 reports the proportion of people with different characteristics overall, the proportion in each category with a symptom, and the mean time 
between each symptom and ALS diagnosis for each category of each variable 
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Table 3.2 Multivariate Regression of Time between the development of Weakness and Diagnosis by Social 
Position, Age, Onset Location, Proximal Risk Factors, and Resources (n = 9787) 
 Model 1: 
Distal Factors 
 
Model 2: Distal 
Factors, Age, and 
Onset Location 
 
Model 3: Distal 
Factors, Age, Onset 
Location, and Proximal 
Risk Factors 
 
Model 4: Distal Factors, 
Age, Onset Location, 
Proximal Risk Factors, 
and Resources 
 
Dependent Variable β  SE β β  SE β β  SE β β  SE β 
Racial/Ethnic Minority -.14  .16 -.21  .16 -.22  .16 -.20  .16 
Female -.06  .05 -.09  .05 -.14 * .06 -.10  .06 
Education (ref = 
Tech/Trade/Some College) 
            
High School or Less .27 ** .09 .31 *** .09 .30 *** .09 .31 *** .09 
College or More -.03  .07 -.04  .07 -.05  .07 -.04  .07 
Age at Diagnosis (ref=50-59)             
18-39    -.03  .14 -.06  .14 -.04  .14 
40-49    -.14  .09 -.15  .09 -.14  .09 
60-69    -.50 *** .07 -.49 *** .07 -.46 *** .07 
70-79    -.38 *** .08 -.35 *** .09 -.32 *** .09 
80+    -1.06 *** .26 -1.02 *** .26 -.96 *** .27 
Onset Location (ref = Limb)             
Bulbar       .53 *** .07 .53 *** .07 
Trunk/Global       -.15  .12 -.13  .12 
Civilian        .12  .06 .10  .08 
Low Occupational Risk       .01  .07 .01  .08 
History of Smoking       -.02  .06 -.01  .06 
History of Drinking       -.06  .08 -.04  .08 
Insurance (ref = 1 type)             
Two Types          -.14 * .07 
Three Types          -.03  .16 
Multidisciplinary Clinic Use (ref 
= Currently Attend) 
            
Do not Attend          .12  .07 
Previously Attended but 
Discontinued 
         .19  .15 
Never Married, Separated, 
Divorced, Widowed 
         -.30 *** .07 
Constant -1.28 *** .06 -1.10 *** .08 -1.12 *** .12 -1.13  *** .13 
+ p < .10, *p < .05, **p < .01, ***p < .001 
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Table 3.3 Multivariate Regression of Time between the development Cramping and Diagnosis by Social 
Position, Age, Onset Location, Proximal Risk Factors, and Resources (n = 5675) 
 Model 1: Distal 
Factors 
 
Model 2: Distal Factors, 
Age, and Onset Location 
 
Model 3: Distal Factors, 
Age, Onset Location, 
and Proximal Risk 
Factors 
 
Model 4: Distal Factors, 
Age, Onset Location, 
Proximal Risk Factors, and 
Resources 
 
Dependent Variable β  SE β β  SE β β  SE β β  SE β 
Racial/Ethnic Minority .11  .29 -.04  .29 -.04  .29 .005  .29 
Female .36 ** .13 .34 ** .12 .31 * .13 .33 * .14 
Education (ref = 
Tech/Trade/Some College) 
            
High School or Less .16  .18 .41 * .18 .42 * .18 .43 * .18 
College or More .08  .14 .01  .14 -.01  .15 .03  .15 
Age at Diagnosis (ref=50-59)             
18-39    1.09 *** .27 1.16 *** .27 1.19 *** .27 
40-49    .25  .17 .23  .18 .23  .18 
60-69    -.47 *** .13 -.38 ** .13 -.35 ** .13 
70-79    -.48 ** .19 .29  .20 -.27  .21 
80+    -6.84 *** .87 -6.66 *** .89 -6.32 *** .91 
Onset Location (ref = Limb)             
Bulbar    .87 *** .22 .85 *** .22 .90 *** .22 
Trunk/Global    -.08  .24 -.16  .24 -.15  .24 
Civilian        .28  .17 .25  .20 
Low Occupational Risk       -.20  .21 -.17  .20 
History of Smoking       -.29 * .12 -.21  .12 
History of Drinking       .38 * .17 .31  .18 
Insurance (ref = 1 type)             
Two Types          -.19  .18 
Three Types          -.03  .35 
Multidisciplinary Clinic Use 
(ref = Currently Attend) 
            
Do not Attend          -.06  .15 
Previously Attended but 
Discontinued 
         -1.29 *** .29 
Never Married, Separated, 
Divorced, Widowed 
         -.37 ** .17 
Constant -2.28 *** .14 -2.20 *** .15 -2.49 *** .27 -2.29 *** .31 
+ p < .10, *p < .05, **p < .01, ***p < .001 
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Table 3.4 Multivariate Regression of Time between the development of Trouble Swallowing and Diagnosis by 
Social Position, Age, Onset Location, Proximal Risk Factors, and Resources  (n = 2170) 
 Model 1: 
Distal Factors 
 
Model 2: Distal 
Factors, Age, and 
Onset Location 
 
Model 3: Distal Factors, 
Age, Onset Location, and 
Proximal Risk Factors 
 
Model 4: Distal Factors, 
Age, Onset Location, 
Proximal Risk Factors, and 
Resources 
 
Dependent Variable β  SE 
β 
β  SE β β  SE β β  SE β 
Racial/Ethnic Minority -.02  .36 .06  .36 -.05  .36 -.49  .38 
Female .26 * .13 .27 * .13 .15  .14 .23  .15 
Education (ref = Tech/Trade/Some 
College) 
            
High School or Less -.09  .22 -.03  .23 -.14  .23 -.15  .23 
College or More .10  .18 .20  .17 .07  .18 .08  .18 
Age at Diagnosis (ref=50-59)             
18-39    1.00 * .48 .73  .48 .61  .47 
40-49    -.63 ** .24 -.49 * .24 -.64 ** .24 
60-69    -.95 *** .16 -1.00 *** .16 -1.23 *** .16 
70-79    -.65 *** .20 -.82 *** .21 -1.09 *** .22 
80+    -1.09 * .50 -1.14 * .49 -1.61 ** .53 
Onset Location (ref = Limb)             
Bulbar    .29  .15 .30 * .15 .37 * .15 
Trunk/Global    .62 * .25 .67 ** .25 .68 ** .25 
Civilian        -.06  .17 .23  .18 
Low Occupational Risk       .74 *** .17 .67 *** .18 
History of Smoking       .15  .14 .06  .14 
History of Drinking       -.60 *** .18 -.56 ** .18 
Insurance (ref = 1 type)             
Two Types          .51 ** .17 
Three Types          1.22 *** .33 
Multidisciplinary Clinic Use (ref = 
Currently Attend) 
            
Do not Attend          .62 *** .15 
Previously Attended but Discontinued          .96 ** .32 
Never Married, Separated, 
Divorced, Widowed 
         .15  .17 
Constant -.79 *** .17 -.49 * .21 -.32  .32 -1.00 ** .32 
+ p < .10, *p < .05, **p < .01, ***p < .001 
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Table 3.5 Multivariate Regression of Time between the development of Twitching and Diagnosis by Social 
Position, Age, Onset Location, Proximal Risk Factors, and Resources (n = 5410) 
 Model 1: Distal 
Factors 
  
Model 2: Distal 
Factors, Age, and 
Onset Location 
 
Model 3: Distal Factors, 
Age, Onset Location, and 
Proximal Risk Factors 
 
Model 4: Distal Factors, 
Age, Onset Location, 
Proximal Risk Factors, and 
Resources 
 
Dependent Variable β SE 
β 
β SE β β  SE β β  SE β 
Racial/Ethnic Minority .08  .24 .06  .24 .07  .24 .16  .24 
Female .06  .10 .03  .10 .006  .11 .02  .11 
Education (ref = Tech/Trade/Some 
College) 
            
High School or Less .58 *** .17 .61 *** .17 .54 ** .17 .53 ** .17 
College or More -.17  .12 -.17  .12 -.20  .12 -.19  .13 
Age at Diagnosis (ref=50-59)             
18-39    .23  .21 .16  .22 .22  .22 
40-49    -.14  .14 -.19  .14 -.17  .14 
60-69    -.45 *** .12 -.43  .12 -.23  .12 
70-79    -.43 ** .17 -.38 *** .17 .03  .19 
80+    -.67  .71 -.59 * .72 .07  .71 
Onset Location (ref = Limb)             
Bulbar    .70 *** .13 .70 *** .13 .69 *** .13 
Trunk/Global    -.07  .19 -.05  .19 .01  .19 
Civilian        .07  .12 -.28 * .13 
Low Occupational Risk       -.24 * .12 -.19  .12 
History of Smoking       -.26 ** .10 -.26 ** .10 
History of Drinking       -.17  .15 -.06  .15 
Insurance (ref = 1 type)             
Two Types          -.70 *** .12 
Three Types          -1.40 *** .23 
Multidisciplinary Clinic Use (ref = 
Currently Attend) 
            
Do not Attend          -.30 ** .12 
Previously Attended but 
Discontinued 
         .48  .27 
Never Married, Separated, 
Divorced, Widowed 
         -.25 * .13 
Constant -1.33 *** .12 -1.22 *** .14 -.82 *** .23 -.31  .24 
+ p < .10, *p < .05, **p < .01, ***p < .001 
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Table 3.6 Multivariate Regression of Time between the development of Trouble with Bowels and Diagnosis by 
Social Position, Age, Onset Location, Proximal Risk Factors, and Resources (n = 1138) 
 Model 1: 
Distal Factors 
  
Model 2: Distal 
Factors, Age, and 
Onset Location 
 
Model 3: Distal 
Factors, Age, Onset 
Location, and Proximal 
Risk Factors 
 
Model 4: Distal Factors, 
Age, Onset Location, 
Proximal Risk Factors, 
and Resources 
 
Dependent Variable β  SE 
β 
β  SE β β  SE β β  SE β 
Racial/Ethnic Minority .78  .73 .43  .73 .49  .71 .12  .38 
Female -1.54 *** .30 -1.86 *** .30 -.78 *** .30 -1.50 *** .30 
Education (ref = 
Tech/Trade/Some College) 
            
High School or Less -.32  .48 .13  .48 -.05  .49 .01  .47 
College or More -1.49 *** .37 -1.32 *** .34 -.67  .34 -.66  .35 
Age at Diagnosis (ref=50-59)             
18-39    3.09 *** .91 1.45  .87 1.16  .86 
40-49    2.18 *** .55 2.24 *** .53 2.16 *** .51 
60-69    -.70  .40 -1.05 ** .39 -1.22 ** .46 
70-79    -.74  .41 -1.38 *** .40 -1.61 ** .57 
80+    -2.31  1.23 -2.98 * 1.14 -3.18 * 1.31 
Onset Location (ref = Limb)             
Bulbar    .63  .38 .38  .38 .38  .39 
Trunk/Global    1.83  1.08 1.89  1.03 1.65  1.00 
Civilian        -.55  .35 -.30  .50 
Low Occupational Risk       1.53 ** .35 1.39 ** .48 
History of Smoking       2.13 *** .31 1.95 *** .35 
History of Drinking       -2.16 *** .44 -2.23 *** .44 
Insurance (ref = 1 type)             
Two Types          .93  .84 
Three Types          .52  1.32 
Multidisciplinary Clinic Use 
(ref = Currently Attend) 
            
Do not Attend          -1.22 *** .28 
Previously Attended but 
Discontinued 
         .10  .80 
Never Married, Separated, 
Divorced, Widowed 
         1.01 ** .32 
Constant -.39  .31 -.31  .43 -.26  .73 -.44  .72 
+ p < .10, *p < .05, **p < .01, ***p < .001 
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CHAPTER FOUR: DOES POSITION IN THE LIFE COURSE SHAPE MEDICAL 
CARE FOR PEOPLE WITH ALS? 
Introduction 
Research has made clear the need to address gaps and shortcomings in treatment 
and care provision for ALS (Goutman & Simmons, 2018). Although calls for additional 
research are more general in nature, sociologists are well positioned to understand the 
disparities in care for people diagnosed with ALS. Therefore, this paper asks the 
question: Does position in the life course and social position shape medical and 
supportive care reported by people with ALS?  Guided by life course theory and 
fundamental cause theory, I posit the timing in the life course of an ALS diagnosis and 
social position (e.g. race/ethnicity, gender, education level) shapes medical and 
supportive care accessed by people who are diagnosed with ALS.  
Medical Care and ALS 
Treatment of ALS is complex for all involved (Radunovic et al, 2007). 
Multidisciplinary ALS clinics (MDCs) are the option of choice of ALS experts 
(Radunovic et al, 2007; Obermann and Lyon, 2015). MDCs have teams of ALS 
specialists, allowing for care and needed devices and supplies to be coordinated from one 
center (Mitsumoto and Del Bene, 2000). Not all patients, however, choose to use or have 
access to multidisciplinary ALS clinics without facing a long journey or needing to 
overcome the financial constraints of travel (Radunovic et al, 2007; Hodgen et al., 2012; 
Obermann & Lyon, 2015; Stephens et al., 2016; Horton et al., 2018).  
For pALS who are not referred by a medical provider or are otherwise unable to 
attend an MDC (e.g. cost, distance), other barriers to adequate care include a lack of pre-
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existing knowledge of ALS (Stephens et al., 2015). Moreover, pALS often face lack of 
time to research ALS and to consider potential treatment options (Stephens et al., 2015). 
Each stage of ALS comes with new levels of care, which require difficult conversations 
and decisions. Medications, such as Riluzole, are often prescribed at diagnosis even 
before attending an MDC (if one is available) (Dorst et al., 2018). As patients lose the 
ability to walk, wheelchairs and scooters become necessary. As difficulties with speaking 
and swallowing become more frequent, people with ALS may need an assistive 
communication device in order to communicate with caregivers, a percutaneous 
gastrostomy (PEG) tube for nutrition, and may need to decide on non-invasive ventilation 
support (e.g. C-PAP or Bi-PAP) (Dorst et al., 2018). As the disease progresses and 
breathing becomes more difficult, people with ALS need to make the decision to accept 
or decline invasive mechanical ventilation (e.g. tracheotomy), which is accompanied by 
the need to complete advanced directives (Dorst et al., 2018). When ALS enters into the 
final stages, people are faced with making decisions about entering in-home or facility-
based hospice care and ending treatments. Many care decisions have to be made quickly, 
depending on the rate of progression, in order to ensure the timing of care meets the 
needs of the person with ALS (Radunovic et al, 2007; Obermann and Lyon, 2015; 
Stephens et al., 2016; Horton et al., 2018; Dorst et al., 2018; Andersen, 2018). 
Timing in the Life Course and Medical Care Decision Making 
pALS make care decisions within the context of their lives. The diagnosis of ALS 
and the likelihood of death within a few years is an off-time transition, given ALS often 
strikes in the years where people are in the prime of their careers, raising children, and 
caring for elderly parents (Elder & Rockwell, 1979). Research illustrates that people who 
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are over the age of 70 when diagnosed with ALS tend to be more accepting of the natural 
course of the disease than those in early-to-mid adulthood (Foley et al., 2014). Older 
adults with a diagnosis of ALS have completed many important milestones (e.g. raising 
children into adulthood) (Foley et al., 2014). Further, pALS who perceive that the end of 
life is near often adjust their choices regarding interventions, placing more value on the 
social relationships and the remaining time they have left, rather than the potential 
extension of a life with limited means of communication and more burdensome care 
(Kotter-Grühn et al., 2010; Foley et al., 2014). In addition, those people with ALS who 
have a partner and adult children, more common in late adulthood, may be less reliant on 
hiring in-home nursing or respite care, and in that context make different decisions 
regarding mechanical ventilation and other invasive treatments (Foley et al., 2014). Given 
these factors, I hypothesize: 
H1: People who are diagnosed later in the life course will be less likely to 
report accessing each type of care due to their acceptance of the natural 
disease course, with the exception of advanced directives and hospice care 
which reflect preparing for the end of life.  
H2: Marital status will shape the medical and supportive care received, with 
those who are married being more likely to report accessing each type of care 
because they have caregivers and a support system in place prior to decision-
making. 
Fundamental Cause Theory and Disparities in Medical Care for ALS 
Although many argue that healthcare is a right, the reality is that in the United 
States, healthcare is a commodity favoring those who can afford it (Pereira, 2003). Social 
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position, including race/ethnicity, gender, and socioeconomic status/education, have been 
considered social determinants of health and potentially fundamental causes of health 
disparities (Link & Phelan, 1995). Fundamental cause theory may be useful in 
understanding why there are variations in the medical and supportive care people with 
ALS access.  
Race/ethnicity, gender and socioeconomic status, are indicators of structural 
inequalities, and are associated with both health care access and utilization. Lower 
socioeconomic status can prevent access to healthcare in multiple ways, including by 
limiting affordable options, limiting the time available to explore and gain knowledge of 
potential treatment options, and the decision to postpone needed care due to cost 
(Pereiria, 2004). Structures of inequality, as indicated by gender and race/ethnicity, may 
also play a role in access due to bias in the healthcare system, as demonstrated in the case 
of cardiac care (McMurray et al., 1991; Menezes et al., 2014; Gay, 2018). Further, 
education is important to overall health; Mirowsky and Ross (2010) find that education 
affects the evaluation and use of health information plus the ability to enact health 
knowledge.  
Barriers due to social position may limit medical and supportive care used to 
improve quality of life for pALS. Therefore, fundamental cause theories suggests the 
following hypothesis: 
H3: Compared to those in more privileged positions, people who are 
racial/ethnic Minorities, women, and those with lower education will have 
lower odds of higher cost medical and supportive care for ALS (e.g. 
wheelchair or scooter use, invasive ventilation, assisted communication 
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devices, Riluzole, and MDC usage), due to potential bias in the medical 
system, cost, and level of knowledge and information provided.  
 Fundamental cause theory also suggests that race/ethnicity and gender are likely 
to play a role in the level of trust placed in genetic testing or in research studies. 
Historical evidence of research mistreatment and omissions of racial minorities and 
women shapes trust in research and providers. Clinical trials have illustrated that a lack of 
information on and access to clinical trials may influence the rate of racial/ethnic 
minority groups and women participating in clinical trials (Roberson, 1994; Shavers et 
al., 2001; Murthy et al., 2004; Suther and Kiros, 2012; Coakley et al., 2012). Results of 
clinical trials that have not included women have led to consequences for women and 
their children (e.g. thalidomide disaster, tetracycline in pregnancy), which may dissuade 
women from participating in clinical trials (Ridings, 2013; Vennila et al., 2014). Further, 
a history of abuse of Black-Americans in the name of research (e.g. Tuskegee Syphilis 
Study, the case of Henrietta Lacks) has created fear and distrust of the medical 
community in this population (Harris et al., 1996; Murthy et al., 2004). Therefore, I 
hypothesize: 
H3a: Women and minorities will be less likely to report genetic testing and 
participating in clinical trials.  
Although prior research has not studied the use of hospice by racial and ethnic 
minorities diagnosed with ALS, studies regarding cancer mortality have shown 
race/ethnicity shapes the use of hospice care in the United States with minorities entering 
hospice less often than Whites (Virnig et al., 2002; Connor et al., 2008; Turkman et al., 
2019). Several factors seem to contribute to the underuse of hospice services by members 
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of the Black-American community in particular. For Black-Americans, personal or 
cultural values often conflict with hospice philosophy, which requires giving up 
lifesaving or life-extending measures for comfort care alone (Washington et al., 2008). In 
addition, Black-Americans often cite a lack of awareness of hospice services, as well as 
concerns of burdening family in terms of emotional burden and time/economic burden 
(Washington et al., 2008). Similar to research on clinical trials, there is a mistrust of the 
health care system which may limit the acceptance of hospice care (Washington et al., 
2008). Finally, for racial and ethnic minorities, there is a fear that there will be little 
diversity among hospice workers, which may limit understanding of cultural and personal 
preferences (Washington et al., 2008).   
Therefore, I postulate: 
H3b: Minorities will be less likely to report being enrolled in hospice.  
 
Data and Methods 
Data 
 The National ALS Registry, created in October 2010, is a voluntary web-based 
registry for people who have been diagnosed with ALS. The registry collects data on 
demographic characteristics, clinical data such as phenotype, and outcome data. Due to 
the potential physical, mental, and emotional limitations of pALS, the risk factor survey 
utilizes smaller modules to facilitate completion (Bryan et al., 2016). The analysis covers 
from 19 October 2010 to 31 December 2016 and includes 9789 people diagnosed with 
ALS.  
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Measures 
 Dependent Variable: Medical Services and Supportive Care. The National 
ALS Registry gathers data on ten medical or supportive care options, including (1) 
wheelchair or scooter use, (2) non-invasive ventilation, (3) invasive ventilation 
(tracheostomy), (4) assisted communicative device, (5) research study participation, (6) 
genetic testing, (7) advanced directives, (8) hospice care, (9) Riluzole use, and (10) 
multidisciplinary clinic use (MDC). Riluzole and MDC usage are each a categorical 
variable with values of currently use (ref), used but discontinued (=1), and never used 
(=2). All other variables are dichotomous, with the categories of have not used (=0) and 
have used (=1). 
 Independent Variables. The independent variables include: (1) age at diagnosis, 
(2) onset location as an indicator of the disease process, (3) social position, with 
education as a dichotomous variable of less than or more than a bachelor’s degree (4) 
veteran status, and (5) social resources, including insurance coverage and marital status. 
The independent variables, with the exception of the recoding of education, have been 
detailed in chapter 2 and chapter 3. I was unable to include proximal risk factors into the 
analysis due to the inability of the imputation model to converge. The large amount of 
missing data for some variables (e.g. health insurance), as well as the small number of 
pALS who reported accessing some types of medical and supportive care (e.g. invasive 
ventilation), required the omission of these variables used in chapters 2 and 3. 
Analysis 
 Multiple Imputation using Chained Equations was used to impute missing data 
(Enders, 2006). I use logistic regression with odds ratios to examine odds of reporting 
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each dependent variable, with the exception of Riluzole and MDC use, which use 
multinomial logistic regression with relative risk ratios. Each model is created in steps; 
(1) age at diagnosis, (2) age at diagnosis and onset location, (3) age at diagnosis, onset 
location, and social position (4) age at diagnosis, onset location, social position, and 
social resources. Models are built to reflect the timing of the ALS diagnosis in the life 
course as the variable of interest, include the control for the disease process (e.g. global 
onset indicates a quicker timeline to deciding on invasive ventilation), social position, 
and finally the addition of social resources to determine if these factors change the 
relationship between life course and medical and supportive care decisions. Results are 
reported for the full models, and statistical significance was determined at the p < .05 
level. 
Results 
Demographics 
As indicated by Table 4.1, the sample is a majority White (97.18%), and nearly 
60% male. Over 60% of the respondents reported having at least a bachelor’s degree. 
Veterans make up nearly 24% of the sample. The majority of the sample is married or 
cohabitating (82%). Most of the respondents are between the ages of 50-59 and 60-69 
(29.79% and 35.99 % respectively). Although all of the respondents reported health 
insurance coverage, the majority of the respondents reported either one type of insurance 
coverage (50.17%) or two types of insurance coverage (43.72%).  
Most pALS use some kind of medical and/or supportive care. The most common 
kind is wheelchair or scooter use (72%), followed by non-invasive ventilation (29%). 
Fewer pALS use invasive ventilation (tracheotomy) (2%). Nearly 13% of respondents 
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reported assistive communication device use. About a fifth of respondents reported 
participating in a research study or having genetic testing done (22% and 20% 
respectively). Over two-thirds (68.89%) of respondents report having advanced directives 
in place, however, only 4% have reported enrolling in hospice care. Fifty percent report 
using Riluzole currently, and nearly 70% report currently attending an MDC.  
Regression Models of Medical and Supportive Care 
Life course and medical or supportive care. Age at diagnosis is associated with 
reported medical and/or supportive care for pALS, with many categories of care less 
likely to be reported by older pALS. There is, however, an exception with the reporting 
of non-invasive ventilation, with groups who have less privileged having higher odds of 
accessing non-invasive ventilation. In addition, end of life care, including advanced 
directives and hospice enrollment, were more likely to be reported by pALS diagnosed at 
younger ages. Therefore, Hypothesis 1 is partially supported. 
In Table 4.2, the results show that pALS who are diagnosed between the ages of 
60-69 (OR = .74, CI [.65, .83]), 70-79 (OR = .45, CI [.38, .53]), and who are diagnosed at 
80+ (OR = .56, CI [.36, .86]) are less likely to report using a wheelchair or scooter than 
pALS who are between the ages of 50-59. The predicted probability of wheelchair or 
scooter use decreases as pALS age (Figure 4.1).  
The association of age with non-invasive ventilation, reported in Table 4.3, was 
contrary to hypothesis one. pALS who are diagnosed between the age of 18 and 49 are 
42% less likely to use non-invasive ventilation (OR = .58, CI [.44, .78]), whereas those 
who are diagnosed between the ages of 60 and 69 are 18% more likely to use non-
invasive ventilation (OR = 1.18, CI [1.00, 1.38]) than those who are between the ages of 
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50 and 59. Age at diagnosis does not appear to shape the use of non-invasive ventilation, 
however, non-invasive ventilation is a standard of care for pALS who are having 
shortness of breath or other difficulties breathing which may mean all pALS are more 
likely to be accepting of this type of care. 
Age is associated with invasive ventilator use (Table 4.4). pALS who are 
diagnosed between the ages of 40 and 49 are 114% more likely to report the use of 
invasive ventilator use compared to those who are diagnosed between the ages of 50-59 
(OR = 2.14, CI [1.44, 3.16]). pALS who were diagnosed between the ages of 60 and 69 
were 48% less likely (OR = .52, CI [.33, .82]) and 70 and 79 were 92% less likely (OR = 
.08, [.02, .27]) to report invasive ventilator use. For invasive ventilation, 4% of pALS 
between 40-49, 2% of pALS between 18-39 and between 50-59, and 1% of pALS 
between 60-69 are predicted to opt into invasive ventilation (Figure 4.2).  
Age is also associated with the use of assistive communication devices among 
pALS (see Table 4.5). pALS who are diagnosed between the ages of 60 and 69 (OR = 
.52, CI [.43, .62]), 70 and 79 (OR = .39, CI [.31, .50]), or 80 and older (OR = .57, CI [.33, 
.98]) they are less likely to report the use of an assistive communication device than those 
who are diagnosed between the ages of 50 and 59. There is no statistically significant 
difference for assistive communication device use for pALS who are diagnosed between 
the ages of 18-49 and 40-49 when compared to pALS who are diagnosed between the 
ages of 50-59. The predicted probability of opting into assistive communication device 
use decreases for those who are diagnosed after age 50 (Figure 4.3).   
Age at diagnosis also shapes participation in research studies, as well as genetic 
testing (Table 4.6 and 4.7). pALS who are younger at the time of an ALS diagnosis are 
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more likely to report participating in a research study, and pALS who are older at 
diagnosis are less likely to have participated (see Table 4.6 for full results). The 
probability of reporting participation in a research study decreases with older age, from 
40% of pALS diagnosed between ages 18-19, to 2% diagnosed at ages 80 and older 
(Figure 4.4). For genetic testing, pALS who are diagnosed between the ages of 18-39 are 
117% more likely (OR = 2.17, CI [1.71, 2.74]) and those diagnosed between 40 and 49 
are 49% more likely (OR = 1.49, CI [1.26, 1.76]) to report using genetic testing 
performed than those who are between the ages of 50-59. pALS who were diagnosed 
between the ages of 70-79 were 47% less likely to report having genetic testing done than 
pALS between diagnosed between 50-59 (OR = .53, CI [.43, 1.19]). The predicted 
probability of reporting having genetic testing done were lowest (12%) for pALS 
diagnosed between ages 70-79, and highest (36%) between the ages for pALS diagnosed 
between 18-39 (Figure 4.5). For genetic testing, some of the differences in age may be 
due to familial (genetically linked) ALS developing earlier in the life course, leading to a 
higher likelihood of testing, although it is offered to all patients. The lower levels of 
reporting genetic testing in older pALS does support hypothesis one.  
Table 4.10 reports the results of the multinomial logistic regression for Riluzole 
use. Riluzole is one of two medication options for pALS and is thought to extend survival 
by two to three months (Dorst et al., 2018). pALS who are over the age of 80 are 141% 
more likely to report never having used Riluzole (RR = 2.41, CI [1.62, 3.58] than pALS 
who are between the ages of 50 and 59. pALS between the ages of 60 and 69 are 40% 
less likely to report having discontinued the use of Riluzole (RR = .60, CI [.51, .86]), and 
pALS between the ages of 70 and 79 are 32% less likely to report discontinued the use of 
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Riluzole (RR = .68, CI [.54, .86]) than pALS between the ages of 50 and 59. The fact that 
older adults are less likely to report discontinuing Riluzole use may be due to these pALS 
never starting Riluzole, supporting hypothesis one. 
Finally, age at the time of diagnosis also shapes who has never used a 
Multidisciplinary ALS clinic. When compared to attending an MDC, pALS who are in 
the older age groups (between the ages of 60 and 69 (RR = 1.15, CI [1.02, 1.32]), 70 and 
79 (RR = 1.51, CI [1.28, 1.78]), and who are over 80 years of age (RR = 2.12, CI [1.38, 
3.25]) are more likely to report never attending an MDC compared to pALS between the 
ages of 50 and 59. Age is not associated with discontinued MDC use compared to 
currently attending an MDC (Table 4.11). Again, this may be because older adults do not 
access MDCs in the first place. 
Planning for end of life care, as well as accepting that the end of life is near, is 
also shaped by the pALS age at diagnosis in expected ways. Consistent with the idea that 
a diagnosis of ALS and the likelihood that death will happen in the future, which may be 
an on-time or off-time transition depending on the position in the life course, pALS who 
are between the ages of 18 and 39 at diagnosis are 57% less likely (OR = .43, CI [.34, 
.54]) and those who are diagnosed between the ages of 40 and 49 are 36% less likely (OR 
= .64, CI [.56, .73]) to have reported being having advanced directives in place than those 
diagnosed between the ages of 50 and 59 (Table 4.8). pALS who are 60 and older at 
diagnosis are more likely to report having advanced directives in place. The predicted 
probabilities of reporting having completed advanced directives increase with age, from 
45% for pALS diagnosed between the ages of 18-49, to 99% for pALS diagnosed at ages 
80 and older (Figure 4.6). 
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Further, as hypothesized, those who are older at diagnosis are more likely to 
report being enrolled in hospice care (Table 4.9). pALS diagnosed between the ages of 60 
and 69 are 188% more likely to report being enrolled in hospice (OR = 2.88, CI [2.10, 
3.96]), and those who are diagnosed between the ages of 70 and 79 are 183% more likely 
to report hospice enrollment (OR = 2.83, CI [1.86, 4.30]) than those who are diagnosed 
between the ages of 50 and 59. pALS diagnosed over the age of 80 are more likely report 
enrollment in hospice care as well (OR = 7.21, CI [3.35, 15.51]).  
Marital status and medical or supportive care. Hypothesis 2 states that pALS 
who are unmarried compared to those who are married will be less likely to report all 
types of medical or supportive care except for advanced directives and enrollment in 
hospice care. Given the results, Hypothesis 2 is partially supported. Tables 4.6 and 4.7 
illustrate that pALS who are unmarried are 26% less likely to report participating in a 
research study (OR = .74, CI [.64, .86]), and 27% less likely to report genetic testing (OR 
= .73, [.63, .85]).  
In regard to Riluzole use, which may extend survival by a few months (Dorst et 
al., 2018), unmarried pALS were 38% more likely than married pALS to report never 
taking Riluzole compared to currently taking Riluzole (RR = 1.38, CI [1.24, 1.55]) (Table 
4.10). Unmarried pALS are 135% more likely to report having discontinued attending an 
MDC versus currently attending compared to married pALS (RR = 2.35, CI [1.88, 2.93]) 
(Table 4.11).  
Several types of medical care or supportive care were just as likely to be reported 
by unmarried and married pALS. There was no difference in wheelchair or scooter use 
(OR = .98, CI [.87, 1.10]), non-invasive ventilator use (OR = .98, CI [.87, 1.11]), or 
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assistive communication device (OR = 1.04, CI [.88, 1.23]) by marital status (Tables 4.2, 
4.3, and 4.5). In addition, unmarried pALS are no more or less likely to report never 
attending an MDC versus currently attending when compared to their married peers (RR 
= .99, CI [.67, .99]) (Table 4.11). Surprisingly, Table 4.8 demonstrates that unmarried 
pALS are no more or less likely to report having advanced directives in place than their 
married peers, as there is a greater need for advanced directives in the case of unmarried 
pALS who are unable to communicate and do not have a spouse or next of kin to do so 
for them (OR = 1.10, CI [.97, 1.25]). 
Finally, pALS who are single are 122% more likely to report invasive ventilator 
use (OR = 2.22, CI [1.53, 3.20]) (Table 4.4). The predicted probability of unmarried 
pALS to report invasive ventilator use is 2.9%, whereas the predicted probability for 
married pALS is 1.4% (Figure 4.7). The increased odds of invasive ventilation use being 
reported by unmarried pALS is unexpected, given the high-level of care required with a 
tracheostomy and mechanical ventilation and the need for in-home care cannot be met by 
a spouse or partner. pALS who are unmarried are 141% more likely to report having 
enrolled in hospice care in comparison to their married peers (OR = 2.41, CI [1.92, 3.02]) 
(Table 4.9). The probability of unmarried pALS reporting hospice enrollment is 7%, 
compared to 3% for married pALS (Figure 4.8). 
Social position and medical or supportive care. Social position is associated 
with some of the medical and supportive care reported by pALS. Table 4.2 reports the 
results for wheelchair or scooter use. Women are 22% more likely than men to report 
wheelchair or scooter use (OR = 1.22, CI [1.10, 1.35]). This finding is surprising, as 
women are more likely to develop bulbar onset ALS, and pALS with bulbar onset are less 
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likely to report wheelchair or scooter use (OR = .45, CI [.39, .51]). The finding may be 
due to women socialized to being more dependent on others for their needs, in this case, 
movement. Alternatively, men may feel that using assistive devices, such as a wheelchair, 
may be a threat to their masculinity and do not want to be seen as impaired. pALS with a 
college degree or higher are 18% more likely to report wheelchair or scooter use than 
those without a college degree (OR = 1.18, CI [1.04, 1.35]). There is no difference in 
wheelchair or scooter use by race/ethnicity (OR = .85, [.64, 1.14]) or by marital status 
(OR = .98, CI [.87, 1.10]). 
Social position was associated with reported non-invasive ventilation, although in 
unexpected ways (Table 4.3). Racial/ethnic minorities are 76% more likely to report non-
invasive ventilator use compared to Whites (OR = 1.76, CI [1.36, 2.27]). Women were 
20% less likely to use non-invasive ventilation compared to men with ALS (OR = .80, CI 
= .72, .89]). Those with a college education or more were 13% more likely to report non-
invasive ventilator use (OR = 1.13, CI [1.02, 1.24]). Social position, again, seems to 
shape invasive ventilation in unexpected ways (Table 4.4). Minorities were 509% more 
likely to report invasive ventilator use than Whites (OR = 6.09, CI [3.76, 9.84]), which is 
unexpected due to the previous literature on health disparities that suggests minorities 
would be less likely to access this type of care. The population of racial/ethnic minorities 
in the National ALS Registry is small and logistic regression does not handle small cell 
counts well. Therefore, to substantiate the results of the logistic regression I performed a 
sensitivity analysis using a complementary log-log regression which returned a similar 
odds ratio and confidence interval to the logistic regression (OR = 5.55, CI [3.56, 8.63]). 
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The predicted probability for reporting invasive ventilation for racial/ethnic minorities is 
7.5%, compared to the predicted probability for whites of 1.5% (Figure 4.9). 
Women were 51% less likely to report invasive ventilator use than men (OR = 
.49, CI [.33, .73]). The findings for both non-invasive and invasive ventilation use means 
that the associations for social position are perhaps more about personal and cultural 
expectations and less about social power at the time of the decision-making.  
As expected, racial/ethnic minorities are 45% less likely than Whites to report the 
use of an assistive communication device (OR = .55, [.35, .87]), however, women were 
99% more likely to report using an assistive communication device than men (OR = 1.99, 
CI [1.72, 2.31]) (Table 4.5). pALS with a college education or more were more likely to 
report the use of an assistive communication device (OR = 1.18, CI [1.03, 1.36]).  
pALS with higher education also have a higher likelihood of reporting 
participation in a research study or genetic testing. pALS with a higher level of education 
were 69% more likely to report participating in a research study (OR = 1.69, CI [1.51, 
1.90]) and 13% more likely to report having genetic testing done (OR = 1.13, [1.00, 
1.27]) (Table 4.6 and 4.7). As previously described in chapters 1 and 2, this may mean 
that clinical trials suffer from issues of representation, which may lead to promising 
treatments failing when introduced into the larger population.  
Women are 25% less likely than men to report having advanced directives in 
place than men (OR = .75, CI [.68, .83]). This finding is interesting, as women are often 
socialized to worry about their family, and advanced directives are often thought to lessen 
the burden on the family members at the end of life. pALS with higher levels of 
education are 57% more likely than those with lower levels of education to report having 
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advanced directives in place (OR = 1.57, CI [1.42, 1.73]) (Table 4.8). Women are 30% 
less likely than men to report enrollment in hospice care (OR = .70, CI [.55, .89]) (Table 
4.9). pALS with higher levels of education are just as likely to report being enrolled in 
hospice as pALS with lower education levels (OR = 1.17, CI [.94, 1.45]). This finding 
may illustrate that hospice care, as it is often free and/or covered by Medicare, may not 
reflect the same disparities by education level. 
The use of Riluzole varies by social position (Table 4.10). There are three 
categories of Riluzole use in the ALS Registry; currently using, discontinued using, and 
have never used. Racial/ethnic minorities are 49% less likely to report never taking 
Riluzole than Whites (RR = .51, CI [.38, .68]), however, are no more or less likely to 
report having discontinued its use (RR = 1.05, CI [.73, 1.52]). Women are more likely 
than men to report having never taken Riluzole (RR = 1.28, CI [1.16, 1.41]) and to have 
discontinued the use of Riluzole (OR = 1.33, CI [1.15, 1.54]) versus reporting the current 
use of Riluzole. pALS with higher levels of education are 21% less likely to report 
having never taken Riluzole than pALS with lower levels of education (RR = .79, CI = 
[.72, .86]), and are 29% more likely to report having discontinued the use of Riluzole 
(RR = 1.29, CI = [1.11, 1.50]). There is debate over the actual effectiveness of Riluzole, 
and those who choose not to take it may find it cost prohibitive, or potentially have 
reasoned it is not effective enough in slowing their symptoms to justify the continued 
cost. 
Social position further shapes who attends an MDC (Table 4.11). Minorities are 
81% more likely to report having never attending an MDC compared to currently 
attending an MDC, in contrast to their White peers (RR = 1.81, CI [1.38, 2.37]). Women, 
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when compared to men, are 24% more likely to report never attending an MDC clinic 
versus currently attending (RR = 1.24, CI [1.11, 1.39]), and are 21% less likely to report 
discontinued attendance at an MDC compared to currently attending (RR = .79, [.63, 
.99]. pALS with higher levels of education, in contrast to pALS with lower levels of 
education, are 35% less likely to report never attending an MDC (RR = .65, CI [.50, 
.66]), however, they are no more or less likely to report having discontinued attendance at 
an MDC (RR = .93, CI [.75, 1.14]), when compared to pALS currently attending an 
MDC. The results indicate that social position is associated with accessing what 
physicians regard as the ‘gold standard’ of care and may be indicative of barriers to 
attendance such as cost or travel distance.  
Participation in research studies and genetic testing by gender and 
race/ethnicity. Social position is associated with the report of participation in a research 
study yet is not associated with genetic testing (Tables 4.6 and 4.7). Racial/ethnic 
minorities are 39% less likely to have participated in a research study than Whites (OR = 
.61, CI [.44, .86]), with the predicted probability of participating in a research study of 
15% for racial/ethnic minorities compared to 22% for whites (Figure 4.10). There was no 
association with race/ethnicity and genetic testing. Women were 21% less likely to report 
participating in a research study (OR = .79, CI [.70, .88]) and 34% less likely to report 
having genetic testing done (OR = .66, CI [.58, .74]) than men. The predicted probability 
for participating in a research study is 20%, and the predicted probability of genetic 
testing is 16% for women, compared to 24% and 23% respectively for men (Figures 4.11 
and 4.12).  
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Race/ethnicity and hospice care. Contrary to Hypothesis 3a, racial/ethnic 
minority status is not associated with enrollment in hospice. Racial/Ethnic minorities are 
no more or less likely to report being enrolled in hospice than Whites (OR = 1.26, CI 
[.71, 2.26]). 
Discussion 
Life Course Theory and the Shaping of Medical and Supportive Care 
Addressing the gaps in care provision for ALS is an important part of improving 
the quality of life for people with ALS (Goutman & Simmons, 2018). As part of 
understanding the gaps in care for those with ALS it is important to determine where, as 
well as why, gaps in care exist. Using life course theory and fundamental cause theory as 
a framework for model creation, I explored how the timing of an ALS diagnosis, as well 
as social position, shapes the medical care reported by people diagnosed with ALS in the 
National ALS Registry. Although it is difficult to fully grasp why gaps in care exist and if 
these gaps are problematic in every case, the results do show where there are differences 
by both position in the life course and social position.  
The timing of an ALS diagnosis in the life course does shape the types of care 
people with ALS chose to obtain. pALS who are older than 59 are less likely to report 
engaging in most types of medical and supportive care. These findings are expected when 
viewed through a life course lens. Qualitative research has demonstrated that people who 
are age 70 or over when diagnosed with ALS tend to be more accepting of the natural 
course of the disease than those in early-to-mid adulthood (Foley et al., 2014). Death, in 
the form of the diagnosis of a disease such as ALS, in later adulthood and old age may be 
more expected as part of the life course after reaching many previous life transition 
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milestones (Elder & Rockwell, 1979; Foley et al., 2014). When death is already expected 
in the short(er) term, the addition of an ALS diagnosis may cause people to adjust their 
goals for care, placing a higher value on spending time with family and limiting 
interventions to prevent the inevitable outcome (Kotter-Grühn et al., 2010; Foley et al., 
2014). Therefore, it was not surprising that older adults were more likely to report 
enrollment in hospice care as well as having advanced directives in place, as these are 
often acknowledgements of an anticipated death.  
The diagnosis of ALS and the likelihood of a fatal outcome within a few years, 
however, would be considered an off-time transition in young adulthood or middle ages, 
as they are often in the prime of their careers, raising young children, and potentially 
caring for elderly parents (Elder & Rockwell, 1979). The prospect of death leaves young 
people feeling cheated of a full life and robbed of their remaining years, and leaves those 
in middle age anxious regarding unfinished plans and responsibilities (Kalish, 1985). Just 
as older adults who expect death and thus make decisions to not forestall death, those 
earlier in the life course opt to do everything and anything to prevent death. Therefore, 
the higher likelihood of pALS in the early part of the life course to pursue every type of 
medical or supportive care is expected. In contrast, care for older adults is often 
conceptualized as dependent on the value placed on their lives and a differential in the 
availability of resources, however, these findings illustrate it may be more dependent the 
sense of the on-time versus off-time nature of a diagnosis. Therefore, what appears to be 
gaps in care for older pALS may be more of an intentional decision-making process 
among older pALS. 
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The one exception to the expected findings was for non-invasive ventilation. Age 
at diagnosis is not associated overall with non-invasive ventilation (e.g. Bi-PAP or C-
PAP machine). Only pALS diagnosed between the ages of 18 and 49 showed a lower use 
of non-invasive ventilation, and those who were between the ages of 60 and 69 were 
more likely to report the use of non-invasive ventilation. One reason for this may be that 
non-invasive ventilation is the standard of care for pALS who are beginning to have 
difficulty breathing. In addition, the use of a Bi-PAP or C-PAP machine has been 
normalized as a supportive therapy for those with sleep apnea, which may suggest to 
pALS that non-invasive ventilation is perhaps within the realm of normal behavior rather 
than supportive care and is a potential area for future research. The widespread, non-age 
dependent, use of non-invasive ventilation is an important finding, as those who use non-
invasive ventilation have longer survival times than those who do not (Lechtzin et al., 
2007). 
Marital status is associated with use of medical and supportive care. Unmarried 
pALS are less likely to report participating in a research study and genetic testing and are 
more likely to report discontinuing Riluzole use and having never attended an MDC. 
Several explanations for this exist. Unmarried pALS do not have a supportive partner to 
ensure they are able to be transported to clinical trial visits or MDC appointments, 
meaning unmarried pALS do not opt into research studies as often, as well as discontinue 
their MDC attendance once they are no longer able to drive or travel unassisted (Spataro 
et al., 2017). In addition, without a partner encouraging the continued use of Riluzole for 
its perceived benefits of extending life, unmarried pALS might be more apt to stop its use 
(Spataro et al., 2017). Finally, genetic testing is often seen as a tool to warn children of a 
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potentially genetic disease, and if unmarried pALS do not have children or are not close 
with their children, they may forgo such testing (Crook et al., 2017; van Es et al., 2017).  
From the perspective of life course theory, it is surprising that unmarried pALS 
are much more likely to report invasive ventilation than their married peers. Invasive 
ventilation is less often adopted overall by pALS in the United States, which is reflected 
in the National ALS Registry, because of the prohibitive cost of round-the-clock care. In 
addition, many pALS are concerned over the potential burden placed on informal 
caregivers, both in providing an extraordinarily complex level of care and the financial 
cost that must be assumed. For unmarried pALS, it may be that when the costs can be 
managed and professional care can be brought into the home, then the perception of 
burden is lessened, and invasive ventilation is viewed as a reasonable choice. A second 
explanation also exists, as many pALS are placed on invasive ventilation as a result of 
complications of ALS, including pneumonia and other infections. Without having a 
partner as the next of kin to verbalize pALS wishes or to ensure advanced directives and 
DNR orders are communicated, unmarried pALS may be more likely to be placed on 
invasive ventilation. For some pALS, invasive ventilation can be discontinued once the 
crisis has passed, however, at least some remain on invasive ventilation indefinitely 
(Cazzolli and Oppenheimer, 1996; Benditt, 2002). To fully understand the patterns from 
the survey data, adding a qualitative study would be ideal. 
Social Position and the Shaping of Medical and Supportive Care 
 Social position does shape some of the medical and supportive care reported by 
pALS, although not always in ways that are consistent with the research on health 
disparities using a fundamental cause and the social determinants of health framework.  
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 Women, in comparison to men, are less likely to report using non-invasive and 
invasive ventilation, completing advanced directives or enrolling in hospice care, and are 
more likely to report never using or discontinuing the use of Riluzole. Women are also 
more likely to report never attending an MDC. Women, however, are more likely to 
report the use of a wheelchair or scooter and are less likely to report discontinuing 
attendance at an MDC. These differences may be in part due to differences in the disease 
course for men and women, which I attempt to control for with the inclusion of onset 
location; however, there are several other potential explanations. For example, previous 
research in gender differences in medical decision-making about stroke care demonstrates 
men and women do not differ in preference for interventions, although women were more 
dissatisfied with the provision of information on interventions (Crawford et al., 2000; 
Kapral et al., 2006; Saposnik et al., 2009). Women may need additional information from 
their providers to understand the risks and benefits of interventions with ALS and may 
avoid the intervention if their questions go unanswered. Further, many studies have 
shown that women are neglected in medical research and treated differently by the 
healthcare system. For example, cardiac care has been researched as a disease of men, 
men’s symptoms are taken more seriously, and men are treated more aggressively than 
women (McMurray et al., 1991; Gay, 2018). As ALS is viewed as a disease of men, it 
may be that women are subject to the same types of biases from researchers and 
providers as are found in cardiac care and suggests a need for additional qualitative 
research with women diagnosed with ALS and their healthcare providers. Overall, the 
differences in care are concerning, especially within the context of bias. 
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 Differences in education, which may be thought of as a proxy of socioeconomic 
status, also shaped the care reported by pALS. pALS with higher levels of education were 
more likely to report wheelchair or scooter use, the use of a non-invasive ventilator, using 
an assistive communication device, and of having advanced directives in place. 
Education also influenced the use of Riluzole, with fewer pALS with higher levels of 
education reporting having never taken Riluzole, and more stating that they have 
discontinued its use. pALS with higher levels of education are less likely to report having 
never attended an MDC than their peers with lower levels of education. Moreover, pALS 
with higher levels of education were more likely to participate in research studies and to 
have had genetic testing performed. The potential reason for the differences in care 
reported by education level are threefold. The first is that ALS onset is different for those 
with lower levels of education, as noted in chapter one and two, therefore care needs are 
different and are not completely captured in the registry data. Second, education acts as a 
proxy of socioeconomic status, and those with higher levels of education are more able to 
afford and access medical and supportive care. Finally, it may be that higher levels of 
education allow pALS to acquire, evaluate, and use information regarding their diagnosis 
in a way that informs their choices in care differently and allows pALS with higher levels 
of education to advocate for the care they need (Mirowsky and Ross, 2010). In any case, 
it is important to consider education in the development of interventions and the 
provision of care for pALS as this appears to be one source of the gaps in care.  
The pALS identified as belonging to a racial/ethnic minority group in the National 
ALS Registry are less likely to report using an assistive communication device and are 
more likely to report having never attended an MDC clinic, both of which can be 
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expensive and difficult to access. There were no differences by race/ethnicity for the use 
of a wheelchair or scooter, however, this may be affected by other findings including the 
use of non-invasive and invasive ventilation. 
pALS identified as racial/minorities in the sample were much more likely to 
report non-invasive and invasive ventilation. Given the potential for care disparities to 
exist in ALS, the two forms of ventilation are areas one would expect to see disparities 
given the issues of cost and/or access. Smaller clinic-based studies have also noted an 
increase in use of both types of ventilation for Black American pALS, with invasive 
ventilation being up to eight times more likely compared to White-American pALS 
(Quadri et al., 2019; Gungogdu et al., 2013). Although other studies have found 
comparable results, few studies have attempted to understand these differences. One 
reason for the difference could be that racial and ethnic minority populations present with 
far more advanced ALS or progress to later stages of the disease more quickly, or for 
complications for ALS to arise more often, leading to a higher than expected number of 
racial and ethnic minorities using invasive ventilation (Ceriana et al., 2017; Rodriguez et 
al., 2018).  
Previous work in understanding why pALS choose to use invasive ventilation has 
focused on the idea that invasive ventilation is ‘life-saving’, meaning pALS who opt to 
pursue invasive ventilation believe they will live significantly longer with it than without 
and allowing them to live when they might otherwise die (Lemoignan and Ells, 2010). 
Given the difference in life expectancy for racial minorities in the United States, Black 
Americans are more likely to experience the death of a parent, a child, a sibling, or other 
loved ones (Umberson et al., 2017). In light of the higher numbers of deaths witnessed, 
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Black Americans may be more likely to opt into invasive ventilation to stay alive—
preventing the loss of another family member—not only for their own desire to live but 
in order to protect their families. Developing an understanding of how the differences in 
the adoption of invasive ventilation may be rooted in a deeper history of racism in the 
United States is a critical area for future research.  
Gender and race/ethnicity in research participation and genetic testing. 
Social position, in the form of gender and race/ethnicity, is associated with participation 
in a research study, but is not associated with genetic testing. Women were less likely to 
report participating in research studies and in genetic testing, yet minorities were less 
likely to participate in research studies. As discussed in both chapters one and two, 
clinical trials for ALS treatments suffer from widespread failure (e.g. treatments are 
ineffective), and the majority of trial participants are young, white, and male, with limb 
onset (Chiò et al., 2011; Mitsumoto et al., 2014). As discussed in the section of 
differences between the types of care reported by men and women, it is important to 
include women and racial/ethnic minority groups in clinical trials to ensure the trials and 
resulting treatments are not solely geared to white men, over and above increasing the 
potential for successful clinical trials. 
Race/ethnicity and hospice care. Race and ethnicity are not associated with 
enrollment in hospice. Minorities are no more or less likely to report being enrolled in 
hospice than whites. Although studies examining the use of hospice for cancer diagnosis 
have previously shown minorities enter hospice less often than whites which may be due 
to barriers such as access to and knowledge of hospice care and cultural concerns (Virnig 
et al., 2002; Connor et al., 2008; Turkman et al., 2019), ALS diagnosis does not reflect 
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the same disparities. ALS is a fatal diagnosis and has no cure and little in the way of 
treatment, however, whereas cancer diagnoses are less certain and may present more 
options for a potential cure and the option to attempt to extend life. Additionally, the lack 
of association between race/ethnicity and hospice care may be due to the increase in use 
of invasive ventilation in racial/ethnic minority groups.  
Limitations  
There are a number of limitations to consider with this study. The first is the 
nature of the National ALS Registry. The National ALS Registry has been designed for 
biomedical and epidemiological research, and therefore limits the work of the social 
scientist, however, many of the needed components to understand where disparities in 
care exist are available. The ALS Registry is reliant on patient self-reporting data and 
may be subject to recall bias and bias due to self-identification. Further, the registry is a 
large non-random sample that is opt-in and is therefore not generalizable to the ALS 
population.  
Another limitation is the issue of missing data. Unlike previous studies in the 
dissertation, I was unable to include proximal risk factors into the analysis of medical and 
supportive care due to the inability of the imputation model to converge. The large 
amount of missing data for some variables (e.g. health insurance), as well as the small 
number of pALS who reported accessing some types of medical and supportive care (e.g. 
invasive ventilation), required the omission of these variables. Future studies should 
attempt to account for proximal risk factors to better understand how they may influence 
the decision to access certain types of medical and supportive care. 
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In addition, the registry is available in an online format only, which may limit 
access and cause the registry to reflect a younger, white, and a more educated patient 
sample. The registry sample provided by the CDC is less racially diverse than the overall 
registry which includes Medicare and Veteran’s Association claims data. There are 
several potential reasons for this, including access to computers that are required for self-
registration; reduced awareness of the registry; and reduced participation in areas with 
substantial nonwhite populations (Kaye et al., 2018). In addition, while the sample size 
overall is robust, smaller numbers of specific populations, such as non-white patients, 
limits the ability to do intersectional analysis to better understand the relationship of 
social position and ALS. Finally, the limited access to data due to reidentification risks 
limit the analysis to a small number of survey modules, which prevents a fuller picture of 
the experience of ALS. Even with these limitations, the National ALS Registry is the 
most comprehensive, geographically diverse sample of people diagnosed with ALS.  
Conclusion 
  
 The analyses of disparities in medical care contributes to the knowledge of both 
sociology and ALS. Position in the life course also shapes the experience care reported 
by pALS, although not always in ways theory would posit. There are many potential 
reasons for these findings, including a sense of burden, access and knowledge, and a fear 
or acceptance of death. 
Medical care is shaped by social position, as suggested by fundamental cause 
theory. These theories do highlight the differences in medical and supportive care, 
however, some of the findings actually run counter to the theories’ predictions. 
Therefore, although fundamental cause theory works fairly well in the case of a specific 
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disease, sociological theories created for the more general social experiences (e.g. who 
will get a disease and who will not) may need to be adjusted to reflect the differences in 
experiencing specific diseases. Further, adjustment of current theories in the sociology of 
health and illness allow for their use in exploring the connection between the social world 
and the experience and care for those diagnosed with the specific disease in question 
(Pescosolido, 2006; Link, 2008; Timmermans and Haas, 2008). In addition, the results 
from this work again reaffirm the need for a sociology of disease, as dealing with the care 
needs for a specific disease, such as ALS, is different from many other diseases. Future 
research should address the potential reasons why life course theory and fundamental 
cause theory drive findings that are different among people already diagnosed with ALS 
compared to the bigger picture of general illness, in order to better adjust the theories in a 
sociology of disease framework.
104 
 
   
 
 Table 4.1 Descriptive Statistics for Medical and Supportive Care  (N = 9789) 
 Pre-Imputation Post-Imputation Percentage 
Variable Frequency Percent  
Powerchair/Scooter    
No  6961 71.11 72.12 
Yes 2680 27.38 27.88 
Missing 148 1.51 0 
Total 9789 100.00 100.00 
Non-Invasive Ventilation    
No 6837 69.84 71.31 
Yes 2760 28.19 28.69 
Missing 192 1.96 0 
Total 9789 100.00 100.00 
Invasive Ventilation    
No 9402 96.05 98.34 
Yes 160 1.63 1.66 
Missing 227 2.32 0 
Total 100.00 100.00 100.00 
Assistive Communication Device    
No 8381 85.62 87.31 
Yes 1221 12.47 12.69 
Missing 187 1.91 0 
Total 9789 100.00 100.00 
Genetic Testing Done    
No 7115 72.68 79.76 
Yes 1774 18.12 20.24 
Missing 900 9.19 0 
Total 9789 100.00 100.00 
Participate in Research Study    
No 7460 76.21 77.86 
Yes 2123 21.72 22.14 
Missing 203 2.07 0 
Total 9789 100.00 100.00 
Advanced Directives in Place    
No 2985 30.49 31.11 
Yes 6604 67.46 68.89 
Missing 200 2.04 0 
Total 9789 100.00 100.00 
Hospice    
No 9232 94.31 95.77 
Yes 407 4.16 4.23 
Missing 150 1.53 0 
Total 9789 100.00 100.00 
Riluzole Use    
Never Used 3656 37.35 37.88 
Used to Take 1110 11.34 11.48 
Currently Use 4894 49.99 50.64 
Missing 129 1.32 0 
Total 9789 100.00 100.00 
Multidisciplinary Clinic    
Never Attended 2342 23.92 24.61 
Previously Attended but No Longer 430 4.39 4..49 
Currently Attend 6790 69.36 70.90 
Missing 227 2.32 0 
Total 9789 100.00 100.00 
Age at Diagnosis    
18-39 (0) 427 4.36 4.36 
40-49 (1) 1382 14.12 14.12 
50-59 (2) 2916 29.79 29.79 
60-69 (3) 3522 35.99 35.99 
70-79 (4) 1406 14.37 14.36 
80+ (5) 134 1.37 1.37 
Missing 2 .02 0 
Total 9789 100.00 100.00 
Onset Location    
Limb (0) 7169 73.24 73.61 
Speech/Swallowing (1) 2003 20.46 20.59 
Trunk/Global (2) 564 5.76 5.80 
Missing 53 .54 0 
Total 9789 100.00 100.00 
Race/Ethnicity    
White (0) 9513 97.18 97.18 
Racial/Ethnic Minority (1) 276 2.82 2.82 
Missing 0 0 0 
Total 9789 100.00 100.00 
Gender    
Male (0) 5861 59.87 59.87 
Female (1) 3928 40.13 40.13 
Missing 0 0 0 
Total 9789 100.00 100.00 
Education    
Less than a College Degree (0) 3426 35.00 35.00 
College Degree or More (1) 6363 65.00 65.00 
Missing 0 0 0 
Total 9789 100.00 100.00 
Veteran Status    
Civilian or Other (0) 7473 76.34 76.40 
Veteran (1) 2309 23.59 23.60 
Missing 7 .07 0 
Insurance    
One 1976 20.19 50.17 
Two 1823 18.62 43.72 
Three  259 2.65 6.11 
Missing 5731 58.55 0 
Total 9789 100.00 100.00 
Marital Status    
Married or Cohabitating (0) 7998 81.70 81.80 
Never Married, Separated, Divorced, Widowed (1) 1779 18.17 18.20 
Missing 12 .12 0 
Total 9789 100.00 100.00 
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Table 4.2 Logistic Regression Predicting Odds of Reporting Wheelchair or Power Scooter Use (N=9789) 
 Model 1: Age Only Model 2: Age and 
Onset Location 
Model 3: Age, Onset 
Location, and Social 
Position 
Model 4: Age, Onset 
Location, Social 
Position, and Veteran 
Status 
Model 5: Age, Onset 
Location, Social Position, 
Veteran Status, and 
Resources 
Dependent 
Variable 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence  
Interval 
Age at 
Diagnosis (ref= 
50-59) 
               
18-39 1.36 ** 1.09, 1.69 1.25 * 1.00, 1.55 1.22  .98, 1.53 1.23  .99, 1.53 1.20  (.96, 1.50) 
40-49 1.11  .97, 1.27 1.11  .97, 1.28 1.12  .97, 1.29 1.12  .98, 1.29 1.13  (.98, 1.30) 
60-69 .86 ** .77, .95 .90  .81, 1.01 .90  .81, 1.00 .89 * .80, 1.00 .74 *** (.65, .83) 
70-79 .57 *** .49, .67 .60 *** .51, .70 .61 *** .52, .71 .60 *** .51, .70 .45 *** (.38, .53) 
80+ .79  .53, 1.17 .88  .59, 1.32 .90  .60, 1.36 .88  .59, 1.33 .56 ** (.36, .86) 
                
Onset Location 
(ref=Limb) 
               
Bulbar    .47 *** .42, .54 .47 *** .41, .53 .47 *** .41, .53 .45 *** (.39, .51) 
Trunk/Global    1.05  .87, 1.28 1.07  .89, 1.30 1.08  .90, 1.31 1.01  (.83, 1.23) 
                
Racial/Ethnic 
Minority 
      .90  .68, 1.19 .90 ** .68, 1.19 .85  (.64, 1.14) 
                
Female       1.12 * 1.02, 1.23 1.15 ** 1.04, 1.27 1.22 *** (1.10, 1.35) 
                
College Degree 
or More 
      1.18 *** 1.07, 1.29 1.17 *** 1.06, 1.29 1.11 * (1.01, 1.23) 
                
Civilian          .93  .83, 1.05 1.18 ** (1.04, 1.35) 
                
Number of 
Types of 
Insurance (ref= 
One type) 
               
Two Types             1.92 *** (1.63, 2.26) 
Three Types             2.90 *** (2.21, 3.80) 
                
Never Married, 
Separated, 
Divorced 
            .98  (.87, 1.10) 
                
Constant .43 *** .39, .46    .41 *** .37, .46 .43 *** .37, .50 .29 *** (.24, .34) 
+ p < .10, *p < .05, **p < .01, ***p < .001 
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Table 4.3 Logistic Regression Predicting Odds of Reporting Non-Invasive Ventilation (N=9789) 
 Model 1: Age Only Model 2: Age and 
Onset Location 
Model 3: Age, Onset 
Location, and Social 
Position 
Model 4: Age, Onset 
Location, Social Position 
and Veteran Status 
Model 5: Age, Onset 
Location, Social Position, 
Veteran Status, and 
Resources 
Dependent 
Variable 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence  
Interval 
Age at 
Diagnosis (ref= 
50-59) 
               
18-39 .52 *** (.39, .69) .58 *** (.44, .78) .60 *** (.45, .79) .60 *** (.45, .80) .58 *** (.44, .78) 
40-49 1.13  (.98, 1.30) 1.15  (1.00, 1.33) 1.12  (.97, 1.30) 1.12  (.97, 1.30) 1.12  (.97, 1.30) 
60-69 1.15 * (1.03, 1.28) 1.11  (.99, 1.24) 1.12 * (1.00, 1.26) 1.12  (1.00, 1.25) 1.01  (.89, 1.13) 
70-79 1.50 *** (1.31, 1.72) 1.37 *** (1.19, 1.58) 1.39 *** (.53, 1.31) 1.37 *** (1.19, 1.59) 1.18 * (1.00, 1.38) 
80+ .87  (.56, 1.34) .80  (.51, 1.24) .83   .82  (.52, 1.28) .64  (.41, 1.03) 
                
Onset Location 
(ref=Limb) 
               
Bulbar    1.51 *** (1.35, 1.68) 1.55 *** (1.39, 1.73) 1.56 *** (1.40, 2.31) 1.54 *** (1.38, 1.72) 
Trunk/Global    3.93 *** (3.29, 4.70) 3.87 *** (3.23, 4.63) 3.90 *** (3.26, 4.67) 3.78 *** (3.15, 4.54) 
                
Racial/Ethnic 
Minority 
      1.80 *** (1.40, 2.31) 1.80 *** (1.40, 2.31) 1.76 *** (1.36, 2.27) 
                
Female       .76 *** (.69, .83) .77 *** (.70, .85) .80 *** (.72, .89) 
                
College Degree 
or More 
      1.17 ** (1.06, 1.29) 1.17 ** (1.06, 1.28) 1.13 * (1.02, 1.24) 
                
Veteran          .95  (.84, 1.06) 1.09  (.93, 1.23) 
                
Number of 
Types of 
Insurance (ref= 
One type) 
               
Two Types             1.49 *** (1.27, 1.74) 
Three Types             1.70 ** (1.19, 2.44) 
                
Never Married, 
Separated, 
Divorced 
            .98  (.87, 1.11) 
                
Constant .36 *** (.33, .39) .31 *** (.28, .34) .30 *** (.27, .34) .31 *** (.27, .36) .25 *** (.21, .30) 
+ p < .10, *p < .05, **p < .01, ***p < .001 
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Table 4.4 Logistic Regression Predicting Odds of Reporting  Invasive Ventilation (N=9789) 
 Model 1: Age Only Model 2: Age and 
Onset Location 
Model 3: Age, Onset 
Location, and Social 
Position 
Model 4: Age, Onset 
Location, Social 
Position, and Veteran 
Status 
Model 5: Age, Onset 
Location, Social Position, 
Veteran Status, and 
Resources 
Dependent 
Variable 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence  
Interval 
Age at 
Diagnosis (ref= 
50-59) 
               
18-39 .85  (.38, 1.88) 1.14  (.51, 2.53) 1.23  (.55, 2.75) 1.29  (.58, 2.88) 1.31  (.58, 2.95) 
40-49 2.00 *** (1.37, 2.92) 2.14 *** (1.46, 3.14) 2.05 *** (1.39, 3.01) 2.10 *** (1.43, 3.09) 2.14 *** (1.44, 3.16) 
60-69 .53 ** (.35, .81) .50 *** (.33, .76) .51 ** (.34, .78) .45 *** (.30, .70) .52 ** (.33, .82) 
70-79 .10 *** (.03, .33) .08 *** (.03, .26) .08 *** (.03, .27) .07 *** (.02, .22) .08 *** (.02, .27) 
80+ .42  (.06, 3.03) .37  (.05, 2.65) .39  (.05, 2.83) .28  (.04, 2.09) .43  (.05, 3.49) 
                
Onset Location 
(ref=Limb) 
               
Bulbar    1.97 *** (1.33, 2.90) 2.01 *** (1.36, 2.98) 2.03 *** (1.37, 3.01) 2.19 *** (1.47, 3.26) 
Trunk/Global    7.56 *** (4.99, 
11.44) 
7.59 *** (4.96, 11.61) 8.34 *** (5.41, 12.85) 8.46 *** (5.44, 13.14) 
                
Racial/Ethnic 
Minority 
      5.84 *** (3.67, 9.30) 5.90 *** (3.70, 9.40) 6.09 *** (3.76, 9.84) 
                
Female       .53 *** (.37, .76) .60 ** (.41, .88) .49 *** (.33, .73) 
                
College Degree 
or More 
      .95  (.68, 1.34) .92  (.65, 1.29) .97  (.68, 1.37) 
                
Civilian          .54 ** (.36, .79) .45 *** (.29, .70) 
                
Number of 
Types of 
Insurance (ref= 
One type) 
               
Two Types             .82  (.49, 1.39) 
Three Types             .28  (.06, 1.32) 
                
Never Married, 
Separated, 
Divorced 
               
             2.22 *** (1.53, 3.20) 
Constant .02 *** (.02, .03) .01 *** (.01, .02) .02 *** (.01, .02) .02 *** (.02, .04) .02 *** (.01, .04) 
 
+ p < .10, *p < .05, **p < .01, ***p < .001 
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Table 4.5 Logistic Regression Predicting Odds of Reporting using an Assistive Communication Device (N=9789) 
 Model 1: Age Only Model 2: Age and 
Onset Location 
Model 3: Age, Onset 
Location, and Social 
Position 
Model 4: Age, Onset 
Location, Social Position, 
and Veteran Status 
Model 5: Age, Onset 
Location, Social Position, 
Veteran Status, and 
Resources 
Dependent 
Variable 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds Ratio Confidence  
Interval 
Age at Diagnosis 
(ref 50-59) 
               
18-39 .54 *** (.37, .78) .78  (.84, 1.16) .74  (.50, 1.08) .76  (.52, 1.11) .71  (.48, 1.06) 
40-49 1.09  (.91, 1.31) 1.10  (.91, 1.34) 1.14  (.94, 1.38) 1.16  (.95, 1.41) 1.17  (.96, 1.42) 
60-69 .82 ** (.71, .95) .65 *** (.56, .76) .62 *** (.53, .73) .61 *** (.51, .71) .52 *** (.43, .62) 
70-79 .69 *** (.56, .85) .55 *** (.44, .68) .53 *** (.43, .66) .51 *** (.41, .63) .39 *** (.31, .50) 
80+ 1.28  (.80, 2.02) .87  (.53, 1.42) .87  (.53, 1.43) .81  (.49, 1.33) .57 * (.33, .98) 
                
Onset Location 
(ref=Limb) 
               
Bulbar    6.33 *** (5.54, 7.23) 6.20 *** (5.42, 7.09) 6.28 *** (5.48, 7.18) 6.30 *** (5.50, 7.23) 
Trunk/Global    1.36 * (1.01, 1.85) 1.49 * (1.07, 1.98) 1.51 ** (1.11, 2.05) 1.46 * (1.07, 1.99) 
                
Racial/Ethnic 
Minority 
      .56 ** (.36, .88) .56 ** (.36, .87) .55 ** (.35, .87) 
                
Female       1.70 *** (1.50, 1.94) 1.87 *** (1.62, 2.15) 1.99 *** (1.72, 2.31) 
                
College Degree or 
More 
      1.26 *** (1.10, 1.44) 1.25 ** (1.09, 1.43) 1.18 * (1.03, 1.36) 
                
Civilian          .74 *** (.62, .87) .86  (.71, 1.04) 
                
Number of Types 
of Insurance (ref= 
One type) 
               
Two Types             2.07 *** (1.64, 2.63) 
Three Types             1.81 * (1.05, 3.11) 
                
Never Married, 
Separated, 
Divorced 
            1.04  (.88, 1.23) 
                
Constant .16 *** (.15, .18) .10 *** (.09, .11) .07 *** (.06, .08) .08 *** (.07, .10) .06 *** (.04, .07) 
+ p < .10, *p < .05, **p < .01, ***p < .001 
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Table 4.6 Logistic Regression Predicting Odds of Reporting Participating in a Research Study (N=9789) 
 Model 1: Age Only Model 2: Age and 
Onset Location 
Model 3: Age, Onset 
Location, and Social 
Position 
Model 4: Age, Onset 
Location, Social Position, 
and Veteran Status 
Model 5: Age, Onset 
Location, Social Position, 
Veteran Status, and 
Resources 
Dependent 
Variable 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds Ratio Confidence  
Interval 
Age at Diagnosis 
(ref 50-59) 
               
18-39 1.85 *** (1.49, 2.30) 1.83 *** (1.47, 2.28) 1.88 *** (1.51, 2.35) 1.87 *** (1.50, 2.34) 1.85 *** (1.47, 2.33) 
40-49 1.37 *** (1.19, 1.58) 1.36 *** (1.18, 1.57) 1.34 *** (1.16, 1.55) 1.34 *** (1.15, 1.54) 1.35 *** (1.17, 1.57) 
60-69 .77 *** (.68, .86) .76 *** (.67, .85) .75 *** (.67, .85) .76 *** (.67, .86) .63 *** (.55, .72) 
70-79 .37 *** (.31, .45) .38 *** (.32, .46) .40 *** (.33, .48) .41 *** (.33, .49) .30 *** (.25, .37) 
80+ .13 *** (.05, .33) .13 *** (.05, .32) .14 *** (.06, .34) .15 *** (.06, .36) .09 *** (.04, .23) 
                
Onset Location 
(ref=Limb) 
               
Bulbar    1.15 * (1.02, 1.30) 1.19 ** (1.05, 1.35) 1.19 ** (1.05, 1.35) 1.16 * (1.02, 1.32) 
Trunk/Global    .31 *** (.23, .43) .31 *** (.23, .43) .31 *** (.22, .42) .28 *** (.20, .39) 
                
Racial/Ethnic 
Minority 
      .65 ** (.47, .91) .65 ** (.47, .91) .61 ** (.44, .86) 
                
Female       .74 *** (.67, .82) .72 *** (.65, .81) .79 *** (.70, .88) 
                
College Degree or 
More 
      1.79 *** (1.60, 2.01) 1.80 *** (1.61, 2.01) 1.69 *** (1.51, 1.90) 
                
Civilian          1.11  (.97, 1.26) 1.41 *** (1.22, 1.63) 
                
Number of Types 
of Insurance (ref= 
One type) 
               
Two Types             1.88 *** (1.59, 2.23) 
Three Types             3.02 *** (2.13, 4.28) 
                
Never Married, 
Separated, 
Divorced 
            .74 *** (.64, .86) 
Constant .33 *** (.30, .36) .33 *** (.30, .36) .25 *** (.22, .28) .23 *** (.20, .27) .16 *** (.13, .19) 
+ p < .10, *p < .05, **p < .01, ***p < .001 
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Table 4.7 Logistic Regression Predicting Odds of Reporting Genetic Testing (N=9789) 
 Model 1: Age Only Model 2: Age and 
Onset Location 
Model 3: Age, Onset 
Location, and Social 
Position 
Model 4: Age, Onset 
Location, Social Position, 
and Veteran Status 
Model 5: Age, Onset 
Location, Social Position, 
Veteran Status, and 
Resources 
Dependent 
Variable 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds Ratio Confidence  
Interval 
Age at Diagnosis 
(ref 50-59) 
               
18-39 2.05 *** (1.63, 2.58) 1.99 *** (1.58, 2.51) 2.12 *** (1.67, 2.67) 2.12 *** (1.68, 2.68) 2.17 *** (1.71, 2.74) 
40-49 1.47 *** (1.25, 1.72) 1.47 *** (1.25, 1.72) 1.45 *** (1.24, 1.71) 1.46 *** (1.24, 1.72) 1.49 *** (1.26, 1.76) 
60-69 .85 ** (.74, .97) .86 * (.75, 1.72) .87 * (.78, .99) .86 * (.75, .99) .89  (.77, 1.03) 
70-79 .50 *** (.41, .61) .51 *** (.42, .62) .51 *** (.42, .62) .51 *** (.42, .62) .53 *** (.43, .66) 
80+ .50 ** (.28, .87) .51 * (.29, .90) .53 * (.30, .94) .53 * (.30, .93) .64  (.34, 1.19) 
                
Onset Location 
(ref=Limb) 
               
Bulbar    .85 * (.75, .98) .89  (.78, 1.02) .89  (.78, 1.02) .90  (.78, 1.03) 
Trunk/Global    .79  (.60, 1.02) .76 * (.58, .99) .77 * (.59, 1.00) .79  (.60, 1.04) 
                
Racial/Ethnic 
Minority 
      .67 * (.46, .97) .67 * (.46, .97) .71  (.49, 1.01) 
                
Female       .63 *** (.56, .70) .63 ** (.56, .71) .66 *** (.58, .74) 
                
College Degree or 
More 
      1.15 ** (1.03, 1.29) 1.15 * (1.03, 1.29) 1.13 * (1.00, 1.27) 
                
Civilian          .96  (.84, 1.10) .88  (.75, 1.03) 
                
Number of Types 
of Insurance (ref= 
One type) 
               
Two Types             .98  (.79, 1.22) 
Three Types             .57 * (.34, .97) 
               (.63, .85) 
Never Married, 
Separated, 
Divorced 
            .73 ***  
Constant .27 *** (.24, .29) .28 *** (.26, .31) .30 *** (.26, .34) .31 *** (.26, .36) .35 *** (.29, .43) 
+ p < .10, *p < .05, **p < .01, ***p < .001 
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Table 4.8 Logistic Regression Predicting Odds of Reporting Having Advanced Directives (N=9789) 
 Model 1: Age Only Model 2: Age and 
Onset Location 
Model 3: Age, Onset 
Location, and Social 
Position 
Model 4: Age, Onset 
Location, Social Position, 
and Veteran Status 
Model 5: Age, Onset 
Location, Social Position, 
Veteran Status, and 
Resources 
Dependent 
Variable 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds Ratio Confidence  
Interval 
Age at Diagnosis 
(ref 50-59) 
               
18-39 .42 *** (.34, .53) .44 *** (.36, .55) .45 *** (.36, .55) .45 *** (.36, .56) .43 *** (.34, .54) 
40-49 .65 *** (.57, .74) .66 *** (.58, .75) .65 *** (.57, .74) .65 *** (.57, .75) .64 *** (.56, .74) 
60-69 2.15 *** (1.93, 2.40) 2.13 *** (1.91, 2.38) 2.18 *** (1.95, 2.43) 2.14 *** (1.91, 2.39) 1.83 *** (1.61, 2.08) 
70-79 4.05 *** (3.41, 4.81) 3.92 *** (3.30, 4.66) 4.25 *** (3.58, 4.07) 4.09 *** (3.43, 4.89) 3.25 *** (2.68, 3.94) 
80+ 83.53 *** (11.66, 
598.25) 
82.41 *** (11.50, 
590.3) 
97.56 *** (13.60, 
699.84) 
93.97 *** (13.10, 674, 
40) 
61.18 *** (8.43, 444.05) 
                
Onset Location 
(ref=Limb) 
               
Bulbar    1.11  (.99, 1.25) 1.16 ** (1.03, 1.30) 1.17 ** (1.04, 1.31) 1.14 * (1.01, 1.29) 
Trunk/Global    2.15 *** (1.70, 2.72) 2.20 *** (1.73, 2.81) 2.25 *** (1.77, 2.87) 2.13 * (1.68, 2.73) 
                
Racial/Ethnic 
Minority 
      .41 *** (.31, .53) .41 *** (.31, .53) .37 *** (.29, .49) 
                
Female       .69 *** (.63, .76) .73 *** (.66, .80) .75 *** (.68, .83) 
                
College Degree or 
More 
      1.64 *** (1.49, 1.80) 1.62 *** (1.48, 1.79) 1.57 *** (1.42, 1.73) 
                
Civilian          .83 ** (.73, .95) 1.04  (.91, 1.20) 
                
Number of Types 
of Insurance 
(ref= One type) 
               
Two Types             1.83 *** (1.52, 2.22) 
Three Types             2.73 *** (1.62, 4.60) 
                
Never Married, 
Separated, 
Divorced 
            1.10  (.97, 1.25) 
Constant 1.60 *** (1.48, 1.72) 1.51 *** (1.39, 1.63) 1.64 ***  1.48 *** (1.28, 1.71) 1.01  (.84, 1.22) 
+ p < .10, *p < .05, **p < .01, ***p < .001 
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Table 4.9 Logistic Regression Predicting Odds of Reporting Hospice Care (N=9789) 
 Model 1: Age Only Model 2: Age and 
Onset Location 
Model 3: Age, Onset 
Location, and Social 
Position 
Model 4: Age, Onset 
Location, Social Position, 
and Veteran Status 
Model 5: Age, Onset 
Location, Social Position, 
Veteran Status, and 
Resources 
Dependent 
Variable 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds 
Ratio 
Confidence 
Interval 
Odds Ratio Confidence  
Interval 
Age at Diagnosis 
(ref= 50-59) 
               
18-39 1.42  (.79, 2.54) 1.51  (.84, 2.72) 1.51  (.84, 2.72) 1.47  (.82, 2.65) 1.47  (.81, 2.66) 
40-49 1.07  (.71, 1.62) 1.08  (.72, 1.63) 1.07  (.71, 1.62) 1.05  (.69, 1.59) 1.02  (.67, 1.55) 
60-69 2.55 *** (1.93, 3.38) 2.49 *** (1.89, 3.30) 2.50 *** (1.89, 3.31) 2.63 *** (1.98, 3.48) 2.88 *** (2.10, 3.96) 
70-79 2.82 *** (1.63, 3.19) 2.17 *** (1.55, 3.05) 2.19 *** (1.56, 3.07) 2.40 *** (1.70, 3.38) 2.83 *** (1.86, 4.30) 
80+ 5.34 *** (2.97, 9.61) 5.09 *** (2.82, 9.17) 5.18 *** (2.87, 9.35) 5.92 *** (3.26, 10.77) 7.21 *** (3.35, 15.51) 
                
Onset Location 
(ref=Limb) 
               
Bulbar    1.32 * (1.04, 1.66) 1.31 * (1.04, 1.66) 1.29 * (1.02, 1.64) 1.29 * (1.02, 1.64) 
Trunk/Global    1.70 ** (1.18, 2.44) 1.71 ** (1.19, 2.45) 1.62 ** (1.13, 2.34) 1.65 ** (1.13, 2.40) 
                
Racial/Ethnic 
Minority 
      1.30  (.73, 2.30) 1.32  (.75, 2.34) 1.26  (.71, 2.26) 
                
Female       1.01  (.82, 1.24) .87  (.69, 1.09) .70 ** (.55, .89) 
                
College Degree or 
More 
      1.07  (.86, 1.32) 1.08  (.87, 1.33) 1.17  (.94, 1.45) 
                
Civilian          1.53 *** (1.16, 2.01) 1.33  (.94, 1.87) 
                
Number of Types 
of Insurance (ref= 
One type) 
               
Two Types             .75  (.40, 1.43) 
Three Types             .38  (.10, 1.38) 
                
Never Married, 
Separated, 
Divorced 
            2.41 *** (1.92, 3.02) 
                
Constant .02 *** (.02, .03)    .02 *** (.02, .03) .02 *** .01, .02 .02 *** (.01, .03) 
+ p < .10, *p < .05, **p < .01, ***p < .001 
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Table 4.10 Multinomial Logistic Regression Predicting Odds of Riluzole Use (n = 9789) 
Base Outcome = Currently Use Riluzole 
 Model 1: Age Only Model 2: Age and  
Onset Location 
Model 3: Age, Onset Location,  
and Social Position 
Model 4: Age, Onset Location,  
Social Position, and Veteran 
Status 
Model 5: Age, Onset Location,  
Social Position, Veteran Status,  
and Resources 
 Never Used Discontinued Never Used Discontinued Never Used Discontinued Never Used Discontinued Never Used Discontinued 
Age at Diagnosis (ref 
50-59) 
OR  CI OR 
 
 
 
CI OR  CI OR  CI OR  CI OR  CI OR  CI OR  CI OR  CI OR  CI 
18-39 .83  (.66, 
1.05) 
1.01  (.75, 
1.36) 
.88  (.69, 
1.10) 
.98  (.73, 
1.32) 
.83  (.65, 
1.05) 
.94  (.70, 
1.27) 
.81  (.64, 
1.03) 
.93  (.69, 
1.25) 
.81  (.64, 
1.02) 
.93  (.69, 
1.26) 
40-49 .99  (.86, 
1.14) 
.85  (.69, 
1.03) 
1.00  (.87, 
1.15) 
.85  (.69, 
1.03) 
1.03  (.90, 
1.19) 
.86  (.70, 
1.05) 
1.02  (.88, 
1.17) 
.85  (.70, 
1.04) 
1.00  (.87, 
1.16) 
.86  (.70, 
1.05) 
60-69 1.06  (.95, 
1.18) 
.87 *** (.49, 
.67) 
1.05  (.94, 
1.17) 
.89 *** (.50, 
.69) 
1.03  (.93, 
1.15) 
.58 *** (.50, 
.69) 
1.07  (.96, 
1.19) 
.60 *** (.51, 
.70) 
1.09  (.97, 
1.22) 
.60 *** (.51, 
.72) 
70-79 1.05  (.91, 
1.21) 
.62 *** (.50, 
.77) 
1.01  (.88, 
1.16) 
.62 *** (.50, 
.77) 
.99  (.86, 
1.14) 
.64 *** (.51, 
.79) 
1.06  (.92, 
1.22) 
.68 *** (.54, 
.83) 
1.10  (.93, 
1.30) 
.68 *** (.54, 
.86) 
80+ 2.20 *** (1.53, 
3.18) 
.34 * (.13, 
.85) 
2.17 *** (1.50, 
3.12) 
.36 * (1.62, 
2.36) 
2.01 *** (1.39, 
2.92) 
.37 * (.15, 
.95) 
2.23 *** (1.54, 
3.25) 
.40 * (.16, 
1.01) 
2.41 *** (1.62, 
3.58) 
.44  (.17, 
1.12) 
Onset Location 
(ref=Limb) 
                              
Bulbar       1.10  (.99, 
1.23) 
.64 *** (.53, 
.78) 
1.06  (.96, 
1.18) 
.62  (.52, 
.75) 
1.05  (.94, 
1.17) 
.62 *** (.51. 
.75) 
1.06  (.95, 
1.18) 
.62 *** (.51, 
.75) 
Trunk/Global       1.96 *** (1.62, 
2.36) 
1.80 *** (1.37, 
2.35) 
2.05 *** (1.69, 
2.48) 
1.88 *** (1.44, 
2.47) 
1.97 *** (1.63, 
2.39) 
1.84 *** (1.40, 
2.41) 
1.98 *** (1.63, 
2.40) 
1.89 *** (1.43, 
2.48) 
Racial/Ethnic 
Minority 
            .52 *** (.39, 
.69) 
1.02  (.71, 
1.47) 
.52 *** (.39, 
.69) 
1.02  (.71, 
1.47) 
.51 *** (.38, 
.68) 
1.05  (.73, 
1.52) 
Female             1.51 *** (1.38, 
1.65) 
1.40 *** (1.22, 
1.61) 
1.36 *** (1.23, 
1.50) 
1.32 *** (1.14, 
1.52) 
1.28 *** (1.16, 
1.41) 
1.33 *** (1.15, 
1.54) 
College Degree or 
More 
            .76 *** (.70, 
.84) 
1.30 *** (1.12, 
1.51) 
.77 *** (.71, 
.85) 
1.31 *** (1.13, 
1.52) 
.79 *** (.72, 
.86) 
1.29 *** (1.11, 
1.50) 
Civilian                   1.39 *** (1.24, 
1.56) 
1.22 * (1.02, 
1.45) 
1.33 *** (1.16, 
1.52) 
1.16  (.96, 
1.41) 
Number of Types of 
Insurance (ref= One 
type) 
                              
Two Types                         1.00  (.85, 
1.19) 
1.01  (.80, 
1.29) 
Three Types                         .71  (.50, 
1.01) 
.76  (.48, 
1.19) 
Never Married, 
Separated, Divorced 
                        1.38 *** (1.24, 
1.55) 
.87  (.72, 
1.05) 
Constant .72 *** (.68, 
.78) 
.30 *** (.27, 
.33) 
.67 *** (.63, 
.75) 
.31 *** (.28, 
.35) 
.71 *** (.64, 
.79) 
.23 *** (.19, 
.27) 
.56 *** (.49, 
.65) 
.20 *** (.16, 
.24) 
.56 *** (.47, 
.66) 
.21 *** (.16, 
.27) 
+ p < .10, *p < .05, **p < .01, ***p < .001 
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Table 4.11 Multinomial Logistic Regression Predicting Odds of Attending a Multidisciplinary Clinic (n = 9789) 
Base Outcome = Currently Attend a Multidisciplinary Clinic 
 Model 1: Age Only Model 2: Age and Onset 
Location 
Model 3: Age, Onset Location, 
and Social Position 
Model 4: Age, Onset Location,  
Social Position, and Veteran 
Status 
Model 5: Age, Onset Location, 
Social Position,  
Veteran Status, and Resources 
 Never Attended Discontinued Never Attended Discontinued Never Attended Discontinued Never Attended Discontinued Never Attended Discontinued 
 OR  CI OR  CI OR  CI OR  CI OR  CI OR  CI OR  CI OR  CI OR  CI OR  CI 
Age at Diagnosis 
(ref 50-59) 
                              
18-39 .95  (.74, 
1.22) 
1.48  (.95, 
2.30) 
.94  (.73, 
1.21) 
1.46  (.94, 
2.28) 
.93  (.72, 
1.20) 
1.48  (.95, 
2.30) 
.95  (.73, 
1.22) 
1.47  (.94, 
2.29) 
.99  (.77, 
1.28) 
1.44  (.92, 
2.26) 
40-49 1.00  (.86, 
1.16) 
.81  (.58, 
1.14) 
1.00  (.86, 
1.16) 
.81  (.57, 
1.13) 
1.00  (.85, 
1.16) 
.80  (.57, 
1.13) 
1.01  (.87, 
1.18) 
.80  (.57, 
1.12) 
1.01  (.87, 
1.18) 
.77  (.54, 
1.08) 
60-69 .96  (.86, 
1.08) 
1.05  (.83, 
1.34) 
.97  (.86, 
1.09) 
1.05  (.83, 
1.34) 
.97  (.86, 
1.09) 
1.06  (.83, 
1.34) 
.94  (.84, 
1.06) 
1.06  (.83, 
1.36) 
1.15 * (1.02, 
1.32) 
.99  (.76, 
1.28) 
70-79 1.21 ** (1.04, 
1.40) 
1.02  (.74, 
1.40) 
1.21 ** (1.04, 
1.40) 
1.03  (.74, 
1.42) 
1.16  (1.00, 
1.34) 
1.02  (.74, 
1.41) 
1.09  (.94, 
1.27) 
1.04  (.75, 
1.44) 
1.51 *** (1.28, 
1.78) 
.97  (.68, 
1.39) 
80+ 1.42  (.96, 
2.09) 
2.11 * (1.07, 
4.13) 
1.44  (.98, 
2.13) 
2.11 * (1.07, 
4.14) 
1.31  (.89, 
1.94) 
2.08 * (1.05, 
4.08) 
1.21  (.82, 
1.79) 
2.12 * (1.07, 
4.20) 
2.12 *** (1.38, 
3.25) 
1.79  (.87, 
3.68) 
Onset Location 
(ref=Limb) 
                              
Bulbar       .90  (.80, 
1.02) 
1.01  (.80, 
1.29) 
.88 * (.78, 
1.00) 
1.02  (.80, 
1.29) 
.89  (.79, 
1.01) 
1.01  (.80, 
1.29) 
.91  (.81, 
1.03) 
1.01  (.79, 
1.29) 
Trunk/Global       1.13  (.93, 
1.38) 
.65  (.39, 
1.08) 
1.13  (.94, 
1.39) 
.64  (.38, 
1.07) 
1.18  (.96, 
1.43) 
.63  (.38, 
1.06) 
1.29 * (1.06, 
1.60) 
.59 * (.35, 
1.00) 
Racial/Ethnic 
Minority 
            1.66 *** (1.28, 
2.17) 
1.15  (.62, 
2.12) 
1.67 *** (1.28, 
2.17) 
1.15  (.62, 
2.12) 
1.81 *** (1.38, 
2.37) 
1.06  (.57, 
1.96) 
Female             1.20 *** (1.09, 
1.33) 
.95  (.77, 
1.17) 
1.32 *** (1.19, 
1.47) 
.93  (.75, 
1.16) 
1.24 *** (1.11, 
1.39) 
.79 * (.63, 
.99) 
College Degree or 
More 
            .63 *** (.57, 
.69) 
.90  (.73, 
1.10) 
.62 *** (.56, 
.68) 
.90  (.73, 
1.11) 
.65 *** (.50, 
.66) 
.93  (.75, 
1.14) 
Civilian                   .78 *** (.67, 
.86) 
1.08  (.83, 
1.39) 
.57 *** (.38, 
.56) 
1.12  (.83, 
1.52) 
Number of Types of 
Insurance (ref= One 
type) 
                              
Two Types                         .46 *** (.38, 
.56) 
1.55 * (1.07, 
2.23) 
Three Types                         .30 *** (.22, 
.40) 
.80  (.32, 
1.98) 
Never Married, 
Separated, Divorced 
                        .99  (.67, 
.97) 
2.35 *** (1.88, 
2.93) 
Constant .34 *** (.31, 
.37) 
.06 *** (.05, 
.07) 
.34 *** (.31, 
.38) 
.06 *** (.05, 
.08) 
.43 *** (.57, 
.69) 
.07 *** (.05, 
.09) 
.51 *** (.45, 
.60) 
.06 *** (.05, 
.09) 
.81 * (.67, 
.97) 
.05 *** .03, 
.07 
+ p < .10, *p < .05, **p < .01, ***p < .001 
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Figure 4.1 Predicted Probability of Wheelchair/Scooter Use by Age at Diagnosis 
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Figure 4.2 Predicted Probability of Invasive Ventilation by Age at Diagnosis 
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Figure 4.3 Predicted Probability of Assistive Communication Device Use by Age at 
Diagnosis 
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Figure 4.4 Predicted Probability of Participating in a Research Study by Age at 
Diagnosis 
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Figure 4.5 Predicted Probability of Genetic Testing by Age at Diagnosis 
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Figure 4.6 Predicted Probability of Completing Advanced Directives by Age at 
Diagnosis 
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Figure 4.7 Predicted Probability of Invasive Ventilation by Marital Status 
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Figure 4.8 Predicted Probability of Enrolling in Hospice by Marital Status 
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Figure 4.9 Predicted Probability of Invasive Ventilation by Race/Ethnicity 
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Figure 4.10 Predicted Probability of Participating in a Research Study by 
Race/Ethnicity 
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Figure 4.11 Predicted Probability of Participating in a Research Study by Gender 
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Figure 4.12 Predicted Probability of Genetic Testing by Gender 
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CHAPTER FIVE: SUMMARY OF RESULTS, CONCLUSION, AND FUTURE 
WORK 
Summary of Results and Conclusion 
 
For the dissertation, I looked at how social position and position in the life course 
shapes the experience of ALS. Currently, ALS is not well understood by either the 
biological or the social sciences. Although research to understand the biological basis of 
ALS is well underway, less social science research has focused on the experience of 
ALS. There is a need, however, to explore how sociological perspectives can advance 
knowledge even of diseases that are little understood, rare, and deadly. In the case of 
ALS, the results of the dissertation show how a sociological perspective and sociological 
theories (e.g. fundamental cause, life course) help develop a better understanding of the 
disease process and experience of the disease by pALS, albeit with some adjustment. 
Further, the findings presented here illustrate the need for a sociology of disease, in order 
to better understand how the social world affects the experience of a particular disease, 
rather than the general overview provided by the sociology of health and illness. 
Overall, the dissertation shows that social position and position in the life course 
are relevant to both the disease process and the lived experiences of pALS. The results 
are useful to rethink the enrollment process for potential clinical trials and to understand a 
potential reason why trials fail, and to begin improving access and communication of 
ALS treatments to prevent health disparities among pALS. The dissertation further 
contributes to the efforts to improve the quality of life for people with ALS. Finally, the 
results from these studies supplies a potential opening for sociologists, epidemiologists, 
biomedical researchers, and medical providers to engage in conversation across 
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disciplines in developing new ways to understand ALS as a disease process and as a lived 
experience. 
The second chapter of the dissertation explored how social position shaped the 
reported onset location at the time of an ALS diagnosis. Although there are still many 
unanswered questions regarding who will eventually develop ALS, I use sociological 
theories to understand the social dimensions of a disease that is often conceptualized as 
purely biological. The results show that social position does shape the onset location of 
ALS symptoms and that the mechanisms behind the onset of ALS are more complicated 
than just accounting for exposures to proximate risk factors and biological differences. 
Several potential explanations exist for these findings. Social position and position in the 
life course could influence the perception of symptoms of ALS and where they begin. 
Moreover, social position could be the trigger for a gene by environment interaction 
which influences the biological development of symptoms and where they begin. Finally, 
social position has been shown in previous work to influence access to healthcare 
resources, allowing the symptoms to spread throughout the body before a diagnosis can 
be made.  
The goal of a sociology of disease in the case of ALS is to take the themes and 
theories from the sociology of health and illness and focus attention on specific health 
outcomes such as onset location. The goal of chapter two is not to point out collective 
risk factors but to account for the multiple pathways in which the experience of the social 
world may influence ALS onset location directly (Pescosolido, 2006; Timmermans and 
Haas, 2008). For example, the onset location of ALS is determined through diagnostic 
testing to determine the involvement of the nerves. The unrelenting progression that is 
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characteristic of ALS, however, may mean that pALS who go through diagnostic testing 
later in the disease course (e.g. due to the dismissal of symptoms as a sign of aging or of 
a hard life) appear to have greater involvement of the nerves, leading to a distorted 
clinical picture. A sociology of disease allows sociologists to think about how clinical 
endpoints may appear to differ due to social stratification, such as race/ethnicity, gender, 
and social class.  
The third chapter examined how social position shapes the experience of 
symptoms of ALS. Overall, the results show the importance of social position in 
understanding symptom development and progression of ALS. Even though proximate 
risks are often the sole factor considered in biomedical research on ALS symptom 
development and disease progression, the results show education, gender, and age all 
have a role over and above the proximate risks included in the models. As sociologists 
have documented in earlier studies, many diseases consist of more than just exposure to 
proximate risks, and ALS has many of the same tendencies. Moreover, the use of 
fundamental cause theory, life course theory, and the social determinants of health help to 
highlight where differences occur, although refinements are needed to use theories in the 
sociology of health and illness in a disease to understand disparities. For example, guided 
by fundamental cause theory, one would expect that those in less advantaged social 
positions (e.g. minorities, women, lower levels of education) will report more time 
between the development of ALS symptoms than their more advantaged peers. Results 
indicate, however, that pALS with limited resources often have less time between 
symptom onset and diagnosis than their more advantaged peers. Rather than an indicator 
of greater access to resources, a diagnosis closer to the reported appearance of symptoms 
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may be a sign of having less opportunity and resources to acknowledge the signs of a 
disease that may at first seem to be a minor complaint. In the case of ALS, it may not be 
that fundamental cause theory is not supported, but that sociologists need to adjust the 
way they think about applying the theory. The results from this work reaffirms the need 
for a sociology of disease, as dealing with a disease just prior to and after diagnosis is 
different from understanding how disease can be prevented altogether.  
Chapter four tested how position in the life course and social position has shaped 
medical care decisions reported by people with ALS. Disparities in medical and 
supportive care for pALS are clear in the National ALS Registry data, both by the timing 
in the life course of diagnosis and by social position. Although the disparities by age at 
diagnosis may be explained by the acceptance or refusal of death as the next stage of life, 
disparities by social position are much more difficult to explain.  
Medical care is shaped by social position, as suggested by fundamental cause 
theory. Fundamental cause theory does highlight the differences in medical and 
supportive care, however, some of the findings actually run counter to the theories’ 
predictions. Therefore, although fundamental cause theory works fairly well in the case 
of a specific disease, sociological theories created for the more general social experiences 
(e.g. who will get a disease and who will not) may need to be adjusted to reflect the 
differences in experiencing specific diseases. Further, adjustment of current theories in 
the sociology of health and illness allow for their use in exploring the connection between 
the social world and the experience and care for those diagnosed with the specific disease 
in question (Pescosolido, 2006; Link, 2008; Timmermans and Haas, 2008). Moreover, the 
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results from this work again reaffirm the need for a sociology of disease, as dealing with 
the care needs for a specific disease, such as ALS, is different from many other diseases. 
Theories such as fundamental cause are often focused on the final outcomes of 
disease (e.g. mortality) and the influence of social factors (e.g. socioeconomic status) on 
those outcomes (Phelen et al., 2004). The focus on potential outcomes, such as the 
development of disease or the risk of death from a disease, is a weakness of the sociology 
of health and illness. Given the focus on the larger picture of outcomes, it is 
understandable why sociologists often do not focus on diseases such as ALS with no 
known cause or cure. Although ALS is universally fatal for those who are diagnosed, the 
results presented in the dissertation demonstrate the lived experience of ALS (and 
perhaps the disease itself) is influenced by the social position.  
Given these findings, approaching ALS from a sociology of health and illness 
perspective misses important connections between social position and the experience of 
the disease itself. Therefore, the findings of the dissertation allow me to strongly echo 
Timmermans and Haas’ (2008) call for a ‘sociology of disease,’ in which sociologists 
explore the connection between the social world and disease. As a medical sociologist 
who often focuses on one disease (e.g. ALS) and on clinical endpoints (e.g. onset 
location, symptom development, medical and supportive care), the further development 
of a sociology of disease allows for a better understanding of multiple pathways in which 
the experience of the social world may influence disease directly (Pescosolido, 2006; 
Timmermans and Haas, 2008). Moreover, testing the themes and theories from the 
sociology of health and illness and focusing on the clinical endpoints for a specific 
disease, such as I have done here with ALS, allows sociologists to understand when and 
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how general overarching theories may need to be adjusted or conceptualized differently 
to understand micro-level disease specific populations.  
Although the current conceptualization of the theories may have their limitations 
in the research and in the interpretation of the results, a larger limitation was the data 
itself. Without the quest to understand the social context of ALS, as well a testing the 
need for a sociology of disease, many of the limitations of the National ALS Registry 
may not have been discovered. The limitations of the National ALS Registry reaffirm the 
need to understand the specific social context of a disease, rather than a general overview 
of illness on the macro-level. 
The Limitations and Promise of the National ALS Registry 
Limitations of the National ALS Registry 
The National ALS Registry is one of several ALS registries in the United States, 
including the Veterans Administration National Registry, the Argeo Paul Cellucci ALS 
Registry of Massachusetts, and the Northeast ALS Consortium (NEALS) Upper Motor 
Neuron Disease (UMND) Registry (Allen et al., 2008; Murphy et al., 2014; Abille and 
Fraser, 2017). The National ALS Registry, however, is the most geographically diverse 
ALS registry in the United States. In addition, the National ALS Registry is attached to 
the national biobank repository, which allows individual data from the registry to be 
matched with data from the biobank, allowing for detailed biomedical research into the 
biological causes of ALS.  
It is difficult, however, to define the ALS population in the United States. Coming 
to a final diagnosis of ALS is a process of elimination, the cost of which can be in the 
tens of thousands of dollars prior to insurance. (Kiernan et al., 2011; Obermann & Lyon, 
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2015). The variability of the earliest symptoms can lead to incorrect diagnoses and 
unnecessary medical procedures, culminating in a delayed diagnosis (Belsh and 
Schiffman, 1996; Srinivasan et al., 2006). Further, the understanding of ALS as a disease 
has changed to include frontotemporal dementia as a type of onset. Therefore, there is the 
potential that pALS are missed due to misdiagnosis or diagnosis prior to new findings. 
Moreover, if pALS are further into the progression of the disease, they may not take part 
in the registry due to physical and psychological limitations or pALS may die before 
completing the registration process. These limitations mean the National ALS Registry is 
the best-case scenario and where researchers should see the fewest disparities, however, 
disparities have been found across the three studies presented here. 
With several potential registries to join, and limited time to do so given the nature 
of ALS, and the potential for misdiagnosis or uncertainty of the diagnosis, not every case 
may be counted in the National ALS Registry. For example, the latest CDC report 
estimates there were 16,583 cases of definite ALS in the United States in 2015 and 
(Mehta et al., 2018), however, the ALS Association estimates that up to 30,000 people 
may be affected by ALS each year (ALSA, 2020), meaning that the National ALS 
Registry may be missing up to 45% of the population of pALS. The incongruence of the 
estimates from the CDC and ALSA highlights the difficulties in defining the true 
population of pALS in the United States.  
The National ALS Registry is available in an online format only, which may limit 
access and cause the registry to reflect a younger, white, and educated patient sample. 
The registry sample provided by the CDC is less racially diverse than the overall registry 
which includes Medicare and Veteran’s Association claims data (Kaye et al., 2018). 
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There are several potential reasons for this, including access to computers that are needed 
for self-registration, reduced awareness of the registry, and reduced participation in areas 
with substantial nonwhite populations.  
The nature of the design of the National ALS Registry, with individual modules 
the participant can complete at home on a schedule that works for their situation and their 
physical and psychological limitations, is one that makes sense for a disease like ALS. 
Although convenient and easier to use for the pALS, it does lead to issues with missing 
data. With the exception of the first module about demographic information (e.g. 
race/ethnicity, gender, education level), many of the questions in the dataset had at least 
some missing data. The highest amounts of missing data were in the insurance module 
and the clinical data module, which were added to the registry at a later date. At that time, 
pALS were notified of a new module to complete via email. Given the short survival time 
after a diagnosis of ALS, however, pALS may have been deceased at the time of the 
notification. pALS may choose to do some modules with the intent of returning to finish 
the others (e.g. with a caregiver or after retrieving information needed), but have their 
health deteriorate to a point where they are unable to do so. Further, pALS may find the 
modules to be too complex given their health situation and may forgo completing all the 
individual modules.  
An important feature of the National ALS Registry is that it was designed with 
biomedical and epidemiological research in mind. Therefore, the registry is not ideal for 
research from a social science perspective. For example, chapter one of the dissertation 
supports earlier studies that show women are more likely to develop bulbar onset of ALS 
even when accounting for proximate risk factors. Without more information on other 
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types of exposures, including stress exposure and adverse childhood events, it is difficult 
to parse out the full picture of why there is a statistically significant difference in the 
onset location for women compare to men. Differences in onset location may be due to 
both biological and social factors, and without access to both types of information in 
registry data, both fields will suffer from incomplete analysis of the factors involved in 
ALS development and progression. 
Concerns about deductive identification severely limited the amount of 
information available for the analyses. As ALS is rare, and participation in the registry is 
voluntary, reidentification is a serious concern. Therefore, the CDC limits access to a 
small number of survey modules. Although not ideal, the issue of reidentification does 
limit the work that can be done with registry data. For example, the analysis presented in 
chapter four may have benefited from more information on whether the pALS had 
children or not. To access the information on the number of children, however, I would 
have needed to relinquish access to other data important to answering the research 
questions in the dissertation. Further, although the sample size overall is robust, smaller 
numbers of specific populations, such as non-white patients, limits the ability to do 
intersectional analysis. The inclusion of an intersectional approach may have further 
clarified how social position shapes the onset location and symptom development for 
pALS. Additionally, the non-random sample opt-in nature of the survey means the results 
may not be generalizable to the ALS population as a whole.   
The Potential Promise of the National ALS Registry 
Although the National ALS Registry does pose some difficulties for researchers, 
it is one of the few sources of information existing on pALS in the United States. The 
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promise of the National ALS Registry in discovering treatments and cures for ALS is 
clear, although with improvements it could be even more promising for social science 
research. I present some possibilities for overcoming current barriers in the sections 
below. Although only a brief outline of potential suggestions to enhance social science 
research such as that done for the dissertation, the overall goal is to begin a conversation 
on potential improvements to the registry. 
Implementing mandatory reporting. Only Massachusetts requires the 
mandatory reporting of ALS cases, which are then included in the Argeo Paul Cellucci 
ALS Registry of Massachusetts. To fully define the ALS population in the United States, 
the National ALS Registry needs to ensure every case is counted, which would require 
mandatory reporting. Further, mandatory reporting would allow physicians and other 
healthcare personnel to report protected health information including onset location, 
ALSFR-R scores, symptom development, and clinical data to the registry, potentially 
allowing for pALS to answer additional modules related to social and environmental risk 
factors and reducing some respondent burden. Creating a mandatory reporting system 
would help the registry increase its reach to pALS who are unable to access the current 
registry, as well as ensuring more complete and accurate information for research. 
Moreover, turning to a mandatory reporting system could increase sample sizes enough 
to allow for intersectional analysis of social position.  
Increase awareness of and aid for registry completion among pALS. One of 
the flaws of the ALS Registry is the limited population from which data is collected. In 
addition to a lack of access to the internet, caregivers and patients have limited time to 
carry out an optional task such as a registry module due to the pressures of everyday 
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medical care needs. One potential solution is to offer access to completing the survey in 
clinics, as well as through organizations such as the ALS Association, Paralyzed Veterans 
of America, and the Muscular Dystrophy Association, all of which are involved in 
supporting the ALS community. Improving access, along with having a knowledgeable 
person available to help navigate the registry and answer questions, would increase the 
number of people taking part in the registry. 
Including social factors in data collection. The results of the dissertation show 
that social position shapes both the disease process and the lived experiences of ALS. 
The inclusion of social factors, such as childhood adverse event scales, early life 
socioeconomic status, and reporting of life event and chronic stressors in adulthood, 
would  provide additional valuable information on the potential interaction of the social 
world and biological processes over the course of pALS lives. Further, including social 
factors may help to determine where and why pALS may be facing disparities in 
healthcare.  
Future Work 
 The dissertation has posed new questions about the role of social position in the 
disease course and lived experience of ALS. There  are several potential avenues of 
inquiry. The first, from a quantitative perspective, is the inclusion of early life 
experiences, childhood exposure to proximate risk factors, and the experience of stress in 
future research on ALS. Previous research has examined the effects of stress in ALS 
through pathways related to hormones (e.g. cortisol) and damage to the nervous system 
(e.g. oxidative stress) (Fidler et al, 2011; Bozzo et al., 2017), and stress exposure can 
vary by social position and early life experiences.  To study stress effects would require 
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recruiting pALS to complete a survey asking comparable questions to the registry’s 
clinical questions, demographic information, as well as measures such as the childhood 
adverse events scale, childhood environmental exposures, and life events and chronic 
stressors across the life course. Collecting data of this nature could help to further clarify 
the interaction between the social and the biological in the development of ALS. Further, 
researchers might consider an analysis of ALS subgroups using data from the National 
ALS Registry. Exploring the potential subgroups using clinical data and data on social 
position may help to clarify why some pALS respond to new treatments and adopt the 
latest technologies, while others do not. In addition, gaining a better understanding of the 
potential variation in experiences and responses among subgroups of pALS may be one 
way to better understand what exposures and experiences may influence ALS 
development and progression.   
There is a need for qualitative research to understand the association between 
social position and perceptions of ALS onset and symptom development. The meaning 
and salience of biological symptoms are likely to differ for people with more or less 
physically demanding jobs, regular medical care, and expectations for aging. For 
example, many of the social position results, such as those for education, could be due to 
a difference in exposures to proximate risks. The findings that social position matters 
over and above proximate risk exposure, however, may be due to when symptoms are 
perceived and become salient. People with lower levels of education usually have 
different types of work demands than people with higher education. Jobs requiring more 
physical labor could lead to pALS attributing symptoms to work-related exhaustion or as 
the consequence of a hard life, whereas people with more education might find the 
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symptoms harder to explain away. pALS with lower education could also attribute 
symptoms to the expected effects of getting older or might not have access to affordable 
medical care and thus ignore symptoms as long as possible in contrast to higher educated 
people who are more likely to have insurance and regular medical visits. To better 
understand how pALS make sense of symptoms prior to diagnosis, it will be valuable to 
conduct interviews with pALS about how they understood the changes in their bodies 
associated with ALS.  
There is an important gap in the knowledge about how patient social position 
affects medical decision making for people with ALS. A few of the most interesting 
findings in chapter five are opposite of the hypothesized direction. One specific example 
is the higher number of unmarried pALS and pALS who are racial or ethnic minorities 
reporting adoption of invasive ventilation. Much of the research on health disparities runs 
counter to these findings and poses an interesting question of why these pALS are 
choosing this extremely expensive and care intensive treatment option. Qualitative work, 
including interviews with pALS and their caregivers, would provide valuable information 
to best interpret these results. Further, work to determine if the differences in the adoption 
of invasive ventilation among racial and ethnic minorities are potentially rooted in a 
deeper history of racism and its consequences is a critical area for future consideration. 
Finally, the results of the studies presented in the dissertation support the need for 
a sociology of disease. Future work should include adapting existing theories used in the 
sociology of health and illness to better understand experiences of populations of people 
who have developed a specific disease. As the results presented here show, the 
experience of a disease like ALS differs from other diseases like cancer, and to 
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understand differences in outcomes for patients requires a new and different perspective, 
one offered by a sociology of disease.  
  
141 
 
   
 
REFERENCES 
 
Adler, N. E., Boyce, T., Chesney, M. A., Cohen, S., Folkman, S., Kahn, R. L., & Syme, S. L. 
(1994). Socioeconomic status and health: the challenge of the gradient. American 
Psychologist, 49(1), 15. 
Abille, V., Fraser, A., & Knorr, R. (2017). ALS Surveillance in Massachusetts: A one-of-a-kind 
registry for tracking an elusive disease. 
Al-Chalabi, A., Hardiman, O., Kiernan, M. C., Chiò, A., Rix-Brooks, B., & van den Berg, L. H. 
(2016). Amyotrophic lateral sclerosis: Moving towards a new classification system. The 
Lancet Neurology, 15(11), 1182–1194. https://doi.org/10.1016/S1474-4422(16)30199-5 
Allen, K. D., Kasarskis, E. J., Bedlack, R. S., Rozear, M. P., Morgenlander, J. C., Sabet, A., ... & 
Oddone, E. Z. (2008). The National Registry of Veterans with amyotrophic lateral 
sclerosis. Neuroepidemiology, 30(3), 180-190. 
Andersen, J. A. (2018). Amyotrophic Lateral Sclerosis and a" Death With Dignity". Omega, 
30222818788254. 
Appel, V., Stewart, S. S., Smith, G., & Appel, S. H. (1987). A rating scale for amyotrophic 
lateral sclerosis: description and preliminary experience. Annals of Neurology: Official 
Journal of the American Neurological Association and the Child Neurology 
Society, 22(3), 328-333. 
Arthur, K. C., Calvo, A., Price, T. R., Geiger, J. T., Chiò, A., & Traynor, B. J. (2016). Projected 
increase in amyotrophic lateral sclerosis from 2015 to 2040. Nature Communications, 7, 
12408. 
Aschbacher, K., O’Donovan, A., Wolkowitz, O. M., Dhabhar, F. S., Su, Y., & Epel, E. (2013). 
Good stress, bad stress and oxidative stress: insights from anticipatory cortisol 
reactivity. Psychoneuroendocrinology, 38(9), 1698-1708. 
Atsuta, N., Watanabe, H., Ito, M., Tanaka, F., Tamakoshi, A., Nakano, I., Aoki, M., Tsuji, S., 
Yuasa, T., Takano, H., Hayashi, H., Kuzuhara, S., & Sobue, G. (2009). Age at onset 
influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis. 
Journal of the Neurological Sciences, 276(1), 163–169. 
https://doi.org/10.1016/j.jns.2008.09.024 
Belsh, J. M., & Schiffman, P. L. (1996). The amyotrophic lateral sclerosis (ALS) patient 
perspective on misdiagnosis and its repercussions. Journal of the Neurological 
Sciences, 139, 110-116. 
Benditt, J. O. (2002). Respiratory complications of amyotrophic lateral sclerosis. In Seminars in 
respiratory and critical care medicine (Vol. 23, No. 03, pp. 239-247). Copyright© 2002 
by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.  
142 
 
   
 
Bodner, T. E. (2008). What improves with increased missing data imputations?. Structural 
Equation Modeling: A Multidisciplinary Journal, 15(4), 651-675. 
Bozzo, F., Mirra, A., & Carrì, M. T. (2017). Oxidative stress and mitochondrial damage in the 
pathogenesis of ALS: New perspectives. Neuroscience Letters, 636, 3–8. 
https://doi.org/10.1016/j.neulet.2016.04.065 
Braveman, P. A., Cubbin, C., Egerter, S., Chideya, S., Marchi, K. S., Metzler, M., & Posner, S. 
(2005). Socioeconomic status in health research: one size does not fit all. JAMA, 294(22), 
2879-2888. 
Braveman, P., Egerter, S., & Williams, D. R. (2011). The social determinants of health: coming 
of age. Annual Review of Public Health, 32, 381-398. 
Brown, R. C., Lockwood, A. H., & Sonawane, B. R. (2005). Neurodegenerative diseases: an 
overview of environmental risk factors. Environmental Health Perspectives, 113(9), 
1250-1256. 
Brown, R. H., & Al-Chalabi, A. (2017). Amyotrophic lateral sclerosis. New England Journal of 
Medicine, 377(2), 162-172. 
Bryan, L., Kaye, W., Antao, V., Mehta, P., Muravov, O., & Horton, D. K. (2016). Preliminary 
Results of National Amyotrophic Lateral Sclerosis (ALS) Registry Risk Factor Survey 
Data. PLoS ONE, 11(4). https://doi.org/10.1371/journal.pone.0153683 
Caller, T. A., Field, N. C., Chipman, J. W., Shi, X., Harris, B. T., & Stommel, E. W. (2012). 
Spatial clustering of amyotrophic lateral sclerosis and the potential role of 
BMAA. Amyotrophic Lateral Sclerosis, 13(1), 25-32. 
Caller, T., Henegan, P., & Stommel, E. (2018). The Potential Role of BMAA in 
Neurodegeneration. Neurotoxicity Research, 33(1), 222–226. 
https://doi.org/10.1007/s12640-017-9752-7 
Carr, D., Freedman, V. A., Cornman, J. C., & Schwarz, N. (2014). Happy Marriage, Happy Life? 
Marital Quality and Subjective Well-being in Later Life. Journal of Marriage and 
Family, 76(5), 930–948. https://doi.org/10.1111/jomf.12133 
Carter, Chelsey. 2019.“‘It’s a White Disease!’” Anthropology News website, February 11, 2019. 
DOI: 10.1111/AN.1091 
Cassileth, B. R., Lusk, E. J., Miller, D. S., Brown, L. L., & Miller, C. (1985). Psychosocial 
correlates of survival in advanced malignant disease?. New England Journal of 
Medicine, 312(24), 1551-1555. 
Cazzolli, P. A., & Oppenheimer, E. A. (1996). Home mechanical ventilation for amyotrophic 
lateral sclerosis: nasal compared to tracheostomy-intermittent positive pressure 
ventilation. Journal of the Neurological Sciences, 139, 123-128. 
143 
 
   
 
Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. 
(1999). The ALSFRS-R: a revised ALS functional rating scale that incorporates 
assessments of respiratory function. Journal of the Neurological Sciences, 169(1), 13–21. 
https://doi.org/10.1016/S0022-510X(99)00210-5 
Ceriana, P., Surbone, S., Segagni, D., Schreiber, A., & Carlucci, A. (2017). Decision-making for 
tracheostomy in amyotrophic lateral sclerosis (ALS): a retrospective study. Amyotrophic 
Lateral Sclerosis and Frontotemporal Degeneration, 18(7-8), 492-497. 
Chiò, A., Benzi, G., Dossena, M., Mutani, R., & Mora, G. (2005). Severely increased risk of 
amyotrophic lateral sclerosis among Italian professional football players. Brain, 128(3), 
472–476. https://doi.org/10.1093/brain/awh373 
Chiò, A., Logroscino, G., Hardiman, O., Swingler, R., Mitchell, D., Beghi, E., ... & Eurals 
Consortium. (2009). Prognostic factors in ALS: a critical review. Amyotrophic Lateral 
Sclerosis, 10(5-6), 310-323. 
Chiò, A., Canosa, A., Gallo, S., Cammarosano, S., Moglia, C., Fuda, G., ... & Gabriele, M. 
(2011). ALS clinical trials: do enrolled patients accurately represent the ALS 
population?. Neurology, 77(15), 1432-1437. 
Coakley, M., Fadiran, E. O., Parrish, L. J., Griffith, R. A., Weiss, E., & Carter, C. (2012). 
Dialogues on diversifying clinical trials: successful strategies for engaging women and 
minorities in clinical trials. Journal of Women's Health, 21(7), 713-716. 
Cohen, P., West, S. G., & Aiken, L. S. (2014). Applied Multiple Regression/Correlation Analysis 
for the Behavioral Sciences. Psychology Press. 
Collins, P. H. (1990). Black feminist thought in the matrix of domination. Black Feminist 
Thought: Knowledge, Consciousness, and the Politics of Empowerment, 138, 221-238. 
Connor, S. R. (2008). Development of hospice and palliative care in the United States. OMEGA-
Journal of Death and Dying, 56(1), 89-99. 
Crawford, B. M., Meana, M., Stewart, D., & Cheung, A. M. (2000). Treatment decision making 
in mature adults: gender differences. Health Care for Women International, 21(2), 91-
104. 
Crook, A., Williams, K., Adams, L., Blair, I., & Rowe, D. B. (2017). Predictive genetic testing 
for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counselling 
considerations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18(7-
8), 475-485. 
de Jong, S. W., Huisman, M. H. B., Sutedja, N. A., van der Kooi, A. J., de Visser, M., Schelhaas, 
H. J., Fischer, K., Veldink, J. H., & van den Berg, L. H. (2012). Smoking, Alcohol 
Consumption, and the Risk of Amyotrophic Lateral Sclerosis: A Population-based Study. 
American Journal of Epidemiology, 176(3), 233–239. https://doi.org/10.1093/aje/kws015 
144 
 
   
 
Del Aguila, M. A., Longstreth, W. T., McGuire, V., Koepsell, T. D., & Van Belle, G. (2003). 
Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology, 60(5), 
813-819. 
D’Amico, E., Factor-Litvak, P., Santella, R. M., & Mitsumoto, H. (2013). Clinical perspective on 
oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radical Biology and 
Medicine, 65, 509-527. 
Diez Roux, A. V. (2012). Conceptual approaches to the study of health disparities. Annual 
Review of Public Health, 33, 41-58. 
Dorst, J., Ludolph, A. C., & Huebers, A. (2018). Disease-modifying and symptomatic treatment 
of amyotrophic lateral sclerosis. Therapeutic Advances in Neurological Disorders, 11, 
1756285617734734. 
Dupuis, L., Pradat, P.-F., Ludolph, A. C., & Loeffler, J.-P. (2011). Energy metabolism in 
amyotrophic lateral sclerosis. The Lancet Neurology, 10(1), 75–82. 
https://doi.org/10.1016/S1474-4422(10)70224-6 
Elder Jr, G. H. (1994). Time, human agency, and social change: Perspectives on the life 
course. Social Psychology Quarterly, 4-15. 
Elder Jr, G. H., & Rockwell, R. C. (1979). The life-course and human development: An 
ecological perspective. International Journal of Behavioral Development, 2(1), 1-21. 
Elder, G. H. (1998). The Life Course as Developmental Theory. Child Development, 69(1), 1–
12. https://doi.org/10.1111/j.1467-8624.1998.tb06128.x 
Enders, C. K. (2006). A primer on the use of modern missing-data methods in psychosomatic 
medicine research. Psychosomatic Medicine, 68(3), 427-436. 
Fang, F., Quinlan, P., Ye, W., Barber, M. K., Umbach, D. M., Sandler, D. P., & Kamel, F. 
(2009). Workplace exposures and the risk of amyotrophic lateral sclerosis. Environmental 
Health Perspectives, 117(9), 1387-1392. 
Ferraro, K. F., & Farmer, M. M. (1996). Double jeopardy, aging as leveler, or persistent health 
inequality? A longitudinal analysis of white and black Americans. The Journals of 
Gerontology Series B: Psychological Sciences and Social Sciences, 51(6), S319-S328. 
Ferraro, K. F., Shippee, T. P., & Schafer, M. H. (2009). Cumulative inequality theory for 
research on aging and the life course. 
Ferraro, K. F., Schafer, M. H., & Wilkinson, L. R. (2016). Childhood disadvantage and health 
problems in middle and later life: Early imprints on physical health?. American 
Sociological Review, 81(1), 107-133. 
Fidler, J. A., Treleaven, C. M., Frakes, A., Tamsett, T. J., McCrate, M., Cheng, S. H., 
Shihabuddin, L. S., Kaspar, B. K., & Dodge, J. C. (2011). Disease progression in a mouse 
145 
 
   
 
model of amyotrophic lateral sclerosis: The influence of chronic stress and 
corticosterone. The FASEB Journal, 25(12), 4369–4377. https://doi.org/10.1096/fj.11-
190819 
Foley, G., Timonen, V., & Hardiman, O. (2014). Acceptance and Decision Making in 
Amyotrophic Lateral Sclerosis From a Life-Course Perspective. Qualitative Health 
Research, 24(1), 67–77. https://doi.org/10.1177/1049732313516545 
Freese, J., & Lutfey, K. (2011). Fundamental Causality: Challenges of an Animating Concept for 
Medical Sociology. In B. A. Pescosolido, J. K. Martin, J. D. McLeod, & A. Rogers 
(Eds.), Handbook of the Sociology of Health, Illness, and Healing: A Blueprint for the 
21st Century (pp. 67–81). Springer. https://doi.org/10.1007/978-1-4419-7261-3_4 
Gay, J. (2018). The Health of Women: A Global Perspective. Routledge. 
Georgoulopoulou, E., Fini, N., Vinceti, M., Monelli, M., Vacondio, P., Bianconi, G., ... & 
Mandrioli, J. (2013). The impact of clinical factors, riluzole and therapeutic interventions 
on ALS survival: a population based study in Modena, Italy. Amyotrophic Lateral 
Sclerosis and Frontotemporal Degeneration, 14(5-6), 338-345. 
Geronimus, A. T. (1992). The weathering hypothesis and the health of African-American women 
and infants: evidence and speculations. Ethnicity & Disease, 2(3), 207-221. 
Geronimus, A. T., Bound, J., Waidmann, T. A., Colen, C. G., & Steffick, D. (2001). Inequality in 
life expectancy, functional status, and active life expectancy across selected black and 
white populations in the United States. Demography, 38(2), 227-251. 
Gevitz, N. (1986). Sociology in Medicine. JAMA, 256(19), 2742-2742. 
Glass, T. A., & Mcatee, M. J. (2005). Extending Horizons, Envisioning The Future. 
Glass, T. A., & McAtee, M. J. (2006). Behavioral science at the crossroads in public health: 
extending horizons, envisioning the future. Social science & medicine, 62(7), 1650-1671. 
Goosby, B. J., & Heidbrink, C. (2013). The transgenerational consequences of discrimination on 
African‐American health outcomes. Sociology Compass, 7(8), 630-643. 
Goutman, S. A., & Simmons, Z. (2018). Symptom management in ALS: we can do better. 
Muscle & Nerve, 57(1), 1. 
Gundogdu, B., Al-Lahham, T., Kadlubar, F., Spencer, H., & Rudnicki, S. A. (2014). Racial 
differences in motor neuron disease. Amyotrophic Lateral Sclerosis & Frontotemporal 
Degeneration, 15(0), 114–118. https://doi.org/10.3109/21678421.2013.837930 
Harris, Y., Gorelick, P. B., Samuels, P., & Bempong, I. (1996). Why African Americans may not 
be participating in clinical trials. Journal of the National Medical Association, 88(10), 
630. 
146 
 
   
 
Haverkamp, L. J., Appel, V., & Appel, S. H. (1995). Natural history of amyotrophic lateral 
sclerosis in a database population Validation of a scoring system and a model for survival 
prediction. Brain, 118(3), 707-719. 
Horton, D. K., Graham, S., Punjani, R., Wilt, G., Kaye, W., Maginnis, K., … Mehta, P. (2018). 
A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and 
their proximity to multidisciplinary ALS clinics, 2013. Amyotrophic Lateral Sclerosis 
and Frontotemporal Degeneration, 19(1–2), 126–133. 
https://doi.org/10.1080/21678421.2017.1406953 
Househam, E., & Swash, M. (2000). Diagnostic delay in amyotrophic lateral sclerosis: what 
scope for improvement?. Journal of the Neurological Sciences, 180(1-2), 76-81. 
Howard, G., Anderson, R. T., Russell, G., Howard, V. J., & Burke, G. L. (2000). Race, 
socioeconomic status, and cause-specific mortality. Annals of epidemiology, 10(4), 214-
223. 
Ingre, C., Roos, P. M., Piehl, F., Kamel, F., & Fang, F. (2015). Risk factors for amyotrophic 
lateral sclerosis. Clinical Epidemiology, 7, 181–193. 
https://doi.org/10.2147/CLEP.S37505 
Iwasaki, Y., Ikeda, K., & Kinoshita, M. (2001). The diagnostic pathway in amyotrophic lateral 
sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2(3), 123-
126. 
Jaiswal, M. K. (2019). Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis 
drugs. Medicinal Research Reviews, 39(2), 733-748. 
Kalish, R. (1985). Coping with death. The Final Transition, 5, 11. 
Kapral, M. K., Devon, J., Winter, A. L., Wang, J., Peters, A., & Bondy, S. J. (2006). Gender 
differences in stroke care decision-making. Medical Care, 70-80. 
Kaye, W. E., Wagner, L., Wu, R., & Mehta, P. (2018). Evaluating the completeness of the 
national ALS registry, United States. Amyotrophic Lateral Sclerosis and Frontotemporal 
Degeneration, 19(1–2), 112–117. https://doi.org/10.1080/21678421.2017.1384021 
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., ... & Zoing, M. 
C. (2011). Amyotrophic lateral sclerosis. Lancet (London, England), 377(9769), 942. 
Kleykamp, M. A. (2006). College, jobs, or the military? Enlistment during a time of war. Social 
Science Quarterly, 87(2), 272-290. 
Kotter-Grühn, D., Grühn, D., & Smith, J. (2010). Predicting one’s own death: the relationship 
between subjective and objective nearness to death in very old age. European Journal of 
Ageing, 7(4), 293-300. 
147 
 
   
 
Kraemer, M., Buerger, M., & Berlit, P. (2010). Diagnostic problems and delay of diagnosis in 
amyotrophic lateral sclerosis. Clinical Neurology and Neurosurgery, 112(2), 103-105. 
Lechtzin, N., Scott, Y., Busse, A. M., Clawson, L. L., Kimball, R., & Wiener, C. M. (2007). 
Early use of non‐invasive ventilation prolongs survival in subjects with 
ALS. Amyotrophic Lateral Sclerosis, 8(3), 185-188. 
Lemoignan, J., & Ells, C. (2010). Amyotrophic lateral sclerosis and assisted ventilation: how 
patients decide. Palliative & Supportive Care, 8(2), 207-213. 
Levine, S. (1987). The changing terrains in medical sociology: emergent concern with quality of 
life. Journal of Health and Social Behavior, 1-6. 
Link, B. G. (2008). Epidemiological sociology and the social shaping of population 
health. Journal of Health and Social Behavior, 49(4), 367-384. 
Link, B. G., & Phelan, J. (1995). Social conditions as fundamental causes of disease. Journal of 
Health and Social Behavior, 80-94. 
Longstreth, W. T., McGuire, V., Koepsell, T. D., Wang, Y., & Belle, G. van. (1998). Risk of 
Amyotrophic Lateral Sclerosis and History of Physical Activity: A Population-Based 
Case-Control Study. Archives of Neurology, 55(2), 201–206. 
https://doi.org/10.1001/archneur.55.2.201 
Louwerse, E. S., Visser, C. E., Bossuyt, P. M. M., & Weverling, G. J. (1997). Amyotrophic 
lateral sclerosis: mortality risk during the course of the disease and prognostic factors. 
Journal of the Neurological Sciences, 152, s10–s17. https://doi.org/10.1016/S0022-
510X(97)00238-4 
Lutfey, K., & Freese, J. (2005). Toward some fundamentals of fundamental causality: 
Socioeconomic status and health in the routine clinic visit for diabetes. American Journal 
of Sociology, 110(5), 1326-1372. 
Lyman, K. A. (1989). Bringing the social back in: A critique of the biomedicalization of 
dementia. The Gerontologist, 29(5), 597-605. 
Magnus, T., Beck, M., Giess, R., Puls, I., Naumann, M., & Toyka, K. V. (2002). Disease 
progression in amyotrophic lateral sclerosis: Predictors of survival. Muscle & Nerve, 
25(5), 709–714. https://doi.org/10.1002/mus.10090 
Manjaly, Z. R., Scott, K. M., Abhinav, K., Wijesekera, L., Ganesalingam, J., Goldstein, L. H., ... 
& Turner, M. R. (2010). The sex ratio in amyotrophic lateral sclerosis: a population based 
study. Amyotrophic Lateral Sclerosis, 11(5), 439-442. 
Mara Gaudette, T. S., Makito Hirano. (2000). Current status of SOD1 mutations in familial 
amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron 
Disorders, 1(2), 83–89. https://doi.org/10.1080/14660820050515377 
148 
 
   
 
Masters, R. K., Link, B. G., & Phelan, J. C. (2015). Trends in education gradients of 
‘preventable’ mortality: a test of fundamental cause theory. Social Science & 
Medicine, 127, 19-28. 
McCombe, P. A., & Henderson, R. D. (2010). Effects of gender in amyotrophic lateral sclerosis. 
Gender Medicine, 7(6), 557–570. https://doi.org/10.1016/j.genm.2010.11.010 
McMurray, R. J., Clarke, O. W., Barrasso, J. A., Clohan, D. B., Epps, C. H., Glasson, J., ... & 
Halkola, K. A. (1991). Gender disparities in clinical decision making. JAMA, 266(4), 
559-562. 
Mehta, P., Kaye, W., Bryan, L., Larson, T., Copeland, T., Wu, J., ... & Horton, K. (2016). 
Prevalence of amyotrophic lateral sclerosis—United States, 2012–2013. Morbidity and 
Mortality Weekly Report: Surveillance Summaries, 65(8), 1-12. 
Mehta, P., Kaye, W., Raymond, J., Wu, R., Larson, T., Punjani, R., ... & Horton, K. (2018). 
Prevalence of amyotrophic lateral sclerosis—United States, 2014. Morbidity and 
Mortality Weekly Report, 67(7), 216. 
Menezes, A. R., Lavie, C. J., DeSchutter, A., & Milani, R. V. (2014). Gender, race and cardiac 
rehabilitation in the United States: is there a difference in care?. The American Journal of 
the Medical Sciences, 348(2), 146-152. 
Ross, C. E., & Mirowsky, J. (2010). Why education is the key to socioeconomic differentials in 
health. Handbook of Medical Sociology, 6, 33-51. 
Mitchell, John Douglas, Pauline Callagher, Joyce Gardham, Catriona Mitchell, Mandy Dixon, 
Robert Addison-Jones, Wendy Bennett, and Mary R. O'Brien. "Timelines in the 
diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor 
neuron disease (MND)–a 20-year review: can we do better?." Amyotrophic Lateral 
Sclerosis 11, no. 6 (2010): 537-541. 
Mitsumoto, H., & Bene, M. D. (2000). Improving the quality of life for people with ALS: the 
challenge ahead. Amyotrophic Lateral Sclerosis and Other Motor Neuron 
Disorders, 1(5), 329-336. 
Mitsumoto, H., Brooks, B. R., & Silani, V. (2014). Clinical trials in amyotrophic lateral 
sclerosis: Why so many negative trials and how can trials be improved? The Lancet 
Neurology, 13(11), 1127–1138. https://doi.org/10.1016/S1474-4422(14)70129-2 
Muddasir Qureshi, M., Hayden, D., Urbinelli, L., Ferrante, K., Newhall, K., Myers, D., ... & 
Cudkowicz, M. E. (2006). Analysis of factors that modify susceptibility and rate of 
progression in amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis, 7(3), 
173-182. 
Murphy, A., Loci, L., Mitsumoto, H., Lomen-Hoerth, C., Kisanuki, Y., Andrews, J., ... & Atassi, 
N. (2014). The Northeast ALS Consortium (NEALS) Upper Motor Neuron Disease 
(UMND) Registry (P5. 076). 
149 
 
   
 
Murthy, V. H., Krumholz, H. M., & Gross, C. P. (2004). Participation in cancer clinical trials: 
race-, sex-, and age-based disparities. JAMA, 291(22), 2720-2726. 
Nelson, L. M., McGuire, V., Longstreth, W. T., & Matkin, C. (2000). Population-Based Case-
Control Study of Amyotrophic Lateral Sclerosis in Western Washington State. I. 
Cigarette Smoking and Alcohol Consumption. American Journal of Epidemiology, 
151(2), 156–163. https://doi.org/10.1093/oxfordjournals.aje.a010183 
Nzwalo, H., de Abreu, D., Swash, M., Pinto, S., & de Carvalho, M. (2014). Delayed diagnosis in 
ALS: the problem continues. Journal of the Neurological Sciences, 343(1-2), 173-175. 
Obermann, M., & Lyon, M. (2015). Financial cost of amyotrophic lateral sclerosis: a case 
study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 16(1-2), 54-57. 
O'Brien, M. R., Whitehead, B., Jack, B. A., & Mitchell, J. D. (2011). From symptom onset to a 
diagnosis of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND): 
experiences of people with ALS/MND and family carers–a qualitative 
study. Amyotrophic Lateral Sclerosis, 12(2), 97-104. 
Oliver, D. J., & Turner, M. R. (2010). Some difficult decisions in ALS/MND. Amyotrophic 
Lateral Sclerosis, 11(4), 339-343. 
Onesti, E., Schettino, I., Gori, M. C., Frasca, V., Ceccanti, M., Cambieri, C., ... & Inghilleri, M. 
(2017). Dysphagia in amyotrophic lateral sclerosis: impact on patient behavior, diet 
adaptation, and riluzole management. Frontiers in Neurology, 8, 94. 
Paillisse, C., Lacomblez, L., Dib, M., Bensimon, G., Garcia‐Acosta, S., & Meininger, V. (2005). 
Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with 
riluzole. Amyotrophic Lateral Sclerosis, 6(1), 37–44. 
https://doi.org/10.1080/14660820510027035 
Pampel, F. C. (2009). The persistence of educational disparities in smoking. Social 
Problems, 56(3), 526-542. 
Pereira, A. (2003). “Live and Let Live: Healthcare Is a Fundamental Human Right.” Connecticut 
Public Interest Law Journal 3:481. 
Pescosolido, B. A. (2006). Of pride and prejudice: the role of sociology and social networks in 
integrating the health sciences. Journal of Health and Social Behavior, 47(3), 189-208. 
Phelan, J. C., & Link, B. G. (2013). Fundamental cause theory. In Medical Sociology on the 
Move (pp. 105-125). Springer, Dordrecht. 
Phelan, J. C., & Link, B. G. (2015). Is racism a fundamental cause of inequalities in 
health?. Annual Review of Sociology, 41, 311-330. 
150 
 
   
 
Phelan, J. C., Link, B. G., & Tehranifar, P. (2010). Social conditions as fundamental causes of 
health inequalities: theory, evidence, and policy implications. Journal of Health and 
Social Behavior, 51(1_suppl), S28-S40. 
Phelan, J. C., Link, B. G., Diez-Roux, A., Kawachi, I., & Levin, B. (2004). “Fundamental 
causes” of social inequalities in mortality: a test of the theory. Journal of Health and 
Social Behavior 45(3), 265-285. 
Phillips, K. A., Mayer, M. L., & Aday, L. A. (2000). Barriers To Care Among Racial/Ethnic 
Groups Under Managed Care: Ethnic minorities continue to encounter barriers to care in 
the current managed care–dominated US health care system. Health Affairs, 19(4), 65-75. 
Pulley, M. T., Brittain, R., Hodges, W., Frazier, C., Miller, L., Matyjasik‐Liggett, M., ... & 
Berger, A. R. (2019). Multidisciplinary amyotrophic lateral sclerosis telemedicine care: 
the store and forward method. Muscle & Nerve, 59(1), 34-39. 
Pupillo, E., Messina, P., Giussani, G., Logroscino, G., Zoccolella, S., Chiò, A., … Beghi, E. 
(2014). Physical activity and amyotrophic lateral sclerosis: A European population-based 
case–control study. Annals of Neurology, 75(5), 708–716. 
https://doi.org/10.1002/ana.24150 
Quick Facts About ALS & The ALS Association. (2020). Retrieved from 
http://www.alsa.org/news/media/quick-facts.html 
Radunović, A., Mitsumoto, H., & Leigh, P. N. (2007). Clinical care of patients with amyotrophic 
lateral sclerosis. The Lancet Neurology, 6(10), 913-925. 
Raymond, J., Oskarsson, B., Mehta, P., & Horton, K. (2019). Clinical characteristics of a large 
cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) 
Registry, 2010–2015. Amyotrophic Lateral Sclerosis and Frontotemporal 
Degeneration, 20(5-6), 413-420. 
Reisine, S., Mcquillan, J., & Fifield, J. (1995). Predictors of work disability in rheumatoid 
arthritis patients. Arthritis & Rheumatism: Official Journal of the American College of 
Rheumatology, 38(11), 1630-1637. 
Ridings, J. E. (2013). The thalidomide disaster, lessons from the past. In Teratogenicity 
Testing (pp. 575-586). Humana Press, Totowa, NJ. 
Rodriguez, J., Chopade, P., & Chen, I. H. A. (2018). Characterization of Amyotrophic Lateral 
Sclerosis (ALS) Seen in the Medical University of South Carolina ALS Multidisciplinary 
Clinic (P1. 342).Roberson, N. L. (1994). Clinical trial participation: viewpoints from 
racial/ethnic groups. Cancer, 74(S9), 2687-2691. 
Rothstein, J. D. (2017). Edaravone: a new drug approved for ALS. Cell, 171(4), 725. 
151 
 
   
 
Rubin, M. S., Clouston, S., & Link, B. G. (2014). A fundamental cause approach to the study of 
disparities in lung cancer and pancreatic cancer mortality in the United States. Social 
Science & Medicine, 100, 54-61. 
Saposnik, G., & Kapral, M. K. (2009). Understanding stroke in women: similar care, worse 
outcomes?. 
Schulz, A., Parker, E., Israel, B., & Fisher, T. (2001). Social context, stressors, and disparities in 
women's health. Journal-American Medical Womens Association, 56(4), 143-150. 
Shavers, V. L., Lynch, C. F., & Burmeister, L. F. (2001). Factors that influence African‐
Americans' willingness to participate in medical research studies. Cancer: 
Interdisciplinary International Journal of the American Cancer Society, 91(S1), 233-236. 
Shi, L., Lebrun, L. A., & Tsai, J. (2010). Access to medical care, dental care, and prescription 
drugs: the roles of race/ethnicity, health insurance, and income. Southern Medical 
Journal, 103(6), 509. 
Shi, L., Chen, C. C., Nie, X., Zhu, J., & Hu, R. (2014). Racial and socioeconomic disparities in 
access to primary care among people with chronic conditions. The Journal of the 
American Board of Family Medicine, 27(2), 189-198. 
Shneerson, J. M. (2011). Who will benefit from tracheostomy ventilation in motor neuron 
disease?. 
Slatcher, R. B. (2010). Marital Functioning and Physical Health: Implications for Social and 
Personality Psychology. Social and Personality Psychology Compass, 4(7), 455–469. 
https://doi.org/10.1111/j.1751-9004.2010.00273.x 
Spataro, R., Volanti, P., Lo Coco, D., & La Bella, V. (2017). Marital status is a prognostic factor 
in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 136(6), 624-630. 
Srinivasan, J., Scala, S., Jones, H. R., Saleh, F., & Russell, J. A. (2006). Inappropriate surgeries 
resulting from misdiagnosis of early amyotrophic lateral sclerosis. Muscle & Nerve: 
Official Journal of the American Association of Electrodiagnostic Medicine, 34(3), 359-
360. 
Stephens, H. E., Felgoise, S., Young, J., & Simmons, Z. (2015). Multidisciplinary ALS clinics in 
the USA: A comparison of those who attend and those who do not. Amyotrophic Lateral 
Sclerosis and Frontotemporal Degeneration, 16(3-4), 196-201. 
Stephens, H. E., Young, J., Felgoise, S. H., & Simmons, Z. (2016). A qualitative study of 
multidisciplinary ALS clinic use in the United States. Amyotrophic Lateral Sclerosis and 
Frontotemporal Degeneration, 17(1-2), 55-61. 
Stommel, E. W., Field, N. C., & Caller, T. A. (2013). Aerosolization of cyanobacteria as a risk 
factor for amyotrophic lateral sclerosis. Medical Hypotheses, 80(2), 142–145. 
https://doi.org/10.1016/j.mehy.2012.11.012 
152 
 
   
 
Straus, R. (1957). The nature and status of medical sociology. American sociological 
review, 22(2), 200-204. 
Sutedja, N. (2007). Risk Factors for Motor Neuron Diseases. 202. 
Sutedja, N. A., Veldink, J. H., Fischer, K., Kromhout, H., Wokke, J. H. J., Huisman, M. H. B., ... 
& Van den Berg, L. H. (2007). Lifetime occupation, education, smoking, and risk of 
ALS. Neurology, 69(15), 1508-1514. 
Suther, S., & Kiros, G. E. (2009). Barriers to the use of genetic testing: a study of racial and 
ethnic disparities. Genetics in Medicine, 11(9), 655-662. 
Swinnen, B., & Robberecht, W. (2014). The phenotypic variability of amyotrophic lateral 
sclerosis. Nature Reviews Neurology, 10(11), 661–670. 
https://doi.org/10.1038/nrneurol.2014.184 
Timmermans, S., & Haas, S. (2008). Towards a sociology of disease. Sociology of Health & 
Illness, 30(5), 659-676. 
Timmermans, S., & Buchbinder, M. (2010). Patients-in-waiting: living between sickness and 
health in the genomics era. Journal of Health and Social Behavior, 51(4), 408-423. 
Turkman, Y. E., Williams, C. P., Jackson, B. E., Dionne-Odom, J. N., Taylor, R., Ejem, D., ... & 
Rocque, G. B. (2019). Disparities in Hospice Utilization for Older Cancer Patients Living 
in the Deep South. Journal of Pain and Symptom Management, 58(1), 86-91. 
Turner, M. R., Hardiman, O., Benatar, M., Brooks, B. R., Chiò, A., De Carvalho, M., ... & 
Nicholson, G. (2013). Controversies and priorities in amyotrophic lateral sclerosis. The 
Lancet Neurology, 12(3), 310-322. 
Umberson, D., Thomeer, M. B., Reczek, C., & Donnelly, R. (2016). Physical illness in gay, 
lesbian, and heterosexual marriages: Gendered dyadic experiences. Journal of Health and 
Social Behavior, 57(4), 517-531. 
van Es, M. A., Hardiman, O., Chiò, A., Al-Chalabi, A., Pasterkamp, R. J., Veldink, J. H., & Van 
den Berg, L. H. (2017). Amyotrophic lateral sclerosis. The Lancet, 390(10107), 2084-
2098. 
Vennila, V., Madhu, V., Rajesh, R., Ealla, K. K. R., Velidandla, S. R., & Santoshi, S. (2014). 
Tetracycline-induced discoloration of deciduous teeth: case series. Journal of 
International Oral Health: JIOH, 6(3), 115. 
Virnig, Beth A., A. Marshall McBean, Sara Kind, and Rishi Dholakia. "Hospice use before 
death: variability across cancer diagnoses." Medical Care 40, no. 1 (2002): 73-78. 
Voustianiouk, A., Seidel, G., Panchal, J., Sivak, M., Czaplinski, A., Yen, A., ... & Lange, D. J. 
(2008). ALSFRS and appel ALS scores: discordance with disease progression. Muscle & 
153 
 
   
 
Nerve: Official Journal of the American Association of Electrodiagnostic 
Medicine, 37(5), 668-672. 
Waite, L. J., & Gallagher, M. (2001). The Case for Marriage: Why Married People are Happier, 
Healthier, and Better off Financially. Random House Digital, Inc.. 
Wang, M.-D., Little, J., Gomes, J., Cashman, N. R., & Krewski, D. (2017). Identification of risk 
factors associated with onset and progression of amyotrophic lateral sclerosis using 
systematic review and meta-analysis. NeuroToxicology, 61, 101–130. 
https://doi.org/10.1016/j.neuro.2016.06.015 
Warner, D. F., & Brown, T. H. (2011). Understanding how race/ethnicity and gender define age-
trajectories of disability: An intersectionality approach. Social Science & 
Medicine, 72(8), 1236-1248. 
Washington, K. T., Bickel-Swenson, D., & Stephens, N. (2008). Barriers to hospice use among 
African Americans: a systematic review. Health & Social Work, 33(4), 267-274. 
Watanabe, H., Atsuta, N., Nakamura, R., Hirakawa, A., Watanabe, H., Ito, M., … Sobue, G. 
(2015). Factors affecting longitudinal functional decline and survival in amyotrophic 
lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal 
Degeneration, 16(3–4), 230–236. https://doi.org/10.3109/21678421.2014.990036 
Weisskopf, M. G., Cudkowicz, M. E., & Johnson, N. (2015). Military Service and Amyotrophic 
Lateral Sclerosis in a Population-based Cohort. Epidemiology (Cambridge, Mass.), 26(6), 
831–838. https://doi.org/10.1097/EDE.0000000000000376 
Williams, D. R., & Collins, C. (2001). Racial Residential Segregation: A Fundamental Cause of 
Racial Disparities in Health. Public Health Reports, 116(5), 404–416. 
https://doi.org/10.1093/phr/116.5.404 
Williams, D. R., & Jackson, P. B. (2005). Social sources of racial disparities in health. Health 
Affairs, 24(2), 325-334. 
Yokoi, D., Atsuta, N., Watanabe, H., Nakamura, R., Hirakawa, A., Ito, M., Watanabe, H., 
Katsuno, M., Izumi, Y., Morita, M., Taniguchi, A., Oda, M., Abe, K., Mizoguchi, K., 
Kano, O., Kuwabara, S., Kaji, R., Sobue, G., & JaCALS. (2016). Age of onset 
differentially influences the progression of regional dysfunction in sporadic amyotrophic 
lateral sclerosis. Journal of Neurology, 263(6), 1129–1136. 
https://doi.org/10.1007/s00415-016-8109-0 
Yu, Y., Su, F.-C., Callaghan, B. C., Goutman, S. A., Batterman, S. A., & Feldman, E. L. (2014). 
Environmental Risk Factors and Amyotrophic Lateral Sclerosis (ALS): A Case-Control 
Study of ALS in Michigan. PLOS ONE, 9(6), e101186. 
https://doi.org/10.1371/journal.pone.0101186 
  
154 
 
   
 
APPENDIX A: SUPPLEMENTAL TABLES, CHAPTER ONE 
 
 
Table A1.1 Model 1: Multinomial Logistic Regression Predicting the Reporting of Onset Location, 
Distal Risk Factors, Relative Risk Ratios (N=9789) 
 
Base Category: Limb 
 Bulbar Global 
 Relative 
Risk Ratio 
Confidence 
Interval 
Relative 
Risk Ratio 
Confidence 
Interval 
Racial/Ethnic Minority 1.18  (.89, 1.58) .90  (.53, 1.54) 
Women 1.53 *** (1.39, 1.69) .57 *** (.47, .69) 
Education (ref= Tech, Trade, or 
Some College) 
      
High School or Less 1.23 * (1.04, 1.46) 1.10  (.84, 1.45) 
College or More 1.12  (.98, 1.27) .77 * (.63, .95) 
Constant .21 *** (.18, .24) .11 *** (.09, .13) 
 
*p < .05, **p < .01, ***p < .001 
 
  
155 
 
   
 
 
 
  
  
Table A1.2. Model 2: Multinomial Logistic Regression Predicting the Reporting of Onset Location, 
Distal Risk Factors, Veteran Status, Relative Risk Ratios (N=9789) 
Base Category: Limb 
 Bulbar Global 
 Relative Risk 
Ratio 
Confidence 
Interval 
Relative Risk 
Ratio 
Confidence 
Interval 
Racial/Ethnic Minority 1.18  (.89, 1.58) .89  (.52, 1.53) 
Women 1.52 *** (1.36, 1.69) .49 *** (.40, .60) 
Education (ref= Tech, Trade, or 
Some College) 
      
High School or Less 1.23 * (1.04, 1.46) 1.09  (.82, 1.52) 
College or More 1.12  (.98, 1.27) .77 * (.63, .96) 
Civilian 1.03  (.90, 1.18) 1.70 *** (1.36, 2.12) 
Constant .20 *** (.18, .24) .08 *** (.06, .10) 
 
*p < .05, **p < .01, ***p < .001 
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Table A1.3. Model 3: Multinomial Logistic Regression Predicting the Reporting of  Onset Location, 
Social Position, Veteran Status, Proximate Risk Factors, Relative Risk Ratios (N=9789) 
 
Base Category: Limb 
 Bulbar Global 
 Relative 
Risk Ratio 
Confidence 
Interval 
Relative 
Risk Ratio 
Confidence 
Interval 
       
Racial/Ethnic Minority 1.19  (.89, 1.59) .86  (.50, 1.47) 
Women 1.51 *** (1.35, 1.69) .47 *** (.39, .58) 
Education (ref= Tech, Trade, or 
Some College) 
      
High School or Less 1.22 * (1.03, 1.45) 1.14  (.86, 1.50) 
College or More 1.14 * (1.00, 1.30) .69 *** (.55, .86) 
Civilian 1.05  (.92, 1.20) 1.64 *** (1.31, 2.06) 
Low Occupational Risk  .97  (.83, 1.13) 1.56 ** (1.18, 2.07) 
Ever Smoked Cigarettes (ref=Never) 1.11  (1.00, 1.23) .89  (.74, 1.07) 
Ever Drank Alcohol (ref=Never) .95  (.83, 1.08) 1.10  (.86, 1.41) 
Constant .20 *** (.16, .25) .06 *** (.04, .09) 
 
*p < .05, **p < .01, ***p < .001 
